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G en e r a l  in t r o d u c t io n

Lower urinary tract symptoms (LUTS)
T he prevalence of voiding symptoms in the elderly male population is high and an 
increasing number o f those patients is seeking medical consultation for their com­
plaints. In former days these complaints were considered to be caused by an enlarged 
prostate and were therefore summarized in the term ‘prostatism’. These voiding symp­
toms, however, are not pathognomonic for benign prostatic hyperplasia (bph ). Other 
possible causes o f luts are detrusor instability, detrusor underactivity, urinary tract 
infection, and urolithiasis. Consequently, the term ‘prostatism’ was replaced by ‘lower 
urinary tract symptoms’.1 The majority o f complaints are caused by b ph . B ph is a his­
tologic diagnosis and has a prevalence that increases with age. B ph occurs in 88% o f 
men aged over 80.2
The pathophysiologic concept o f clinical bph  is a cascade o f events, starting with his­
tologic bph  that may cause benign prostatic enlargement (bpe). B pe may result in 
bladder outlet obstruction (boo) often leading to the development o f luts. Bph does 
not always result in boo and not all patients with boo have accompanying symptoms. 
Hald clearly illustrated the relation between luts, bph , and boo .3
Assessment of men with LUTS
Since luts are not specific to bph  or boo, complementary diagnostic tests are necessary 
to establish or reject the diagnosis o f boo in order to choose an appropriate treatment, 
to predict efficacy and durability o f a treatment and to evaluate treatment effect.
It is important for the urologist to know to what extent he may rely on a certain diag­
nostic test. Ideally, a test that provides 100% certainty about the presence o f a disease 
would be available; a so-called gold standard test. Unfortunately, in clinical practice 
such a test is hardly ever available and the doctor has to combine results o f several di­
agnostic tests, being aware o f their different values. The value o f a diagnostic test is 
dependent on its validity and its reproducibility.4
The symptoms cause the patients’ search for medical care. Therefore, diagnosing boo 
starts with a reliable assessment ofsymptoms. Several symptom scores have been devel­
oped and validated, o f which the International Prostate Symptom Score (ipss) is the 
most popular. As luts do not correlate well to boo , however, more objective diagnos-
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tic tools are used. Uroflowmetry is a rough method to estimate boo , by measuring the 
free flow rate and in particular the maximum flow rate (Qmax). Although this cheap 
and simple test can provide valuable information, the disadvantages o f it are: the Qmax 
is influenced by the voided volume, there is a large variation between various flows o f 
the same patient and it is doubtful whether patients are able to produce representative 
flows in the hospital flowmeter.5 Ultrasound measurement o f the prostate volume is o f 
importance in deciding the surgical approach o f the prostate, but the correlation be­
tween the size o f the prostate and boo is poor. In addition, urethrocystoscopy and 
measurement o f post-void residual volume are used in the diagnosis o f luts. All these 
parameters, however, are not well related to each other and to boo .6-11
Assessment of men with LUTS: urodynamics
Urodynamic studies determine the response o f the lower urinary tract to filling and 
emptying. The investigation consists o f a filling and voiding cystometry and intra­
vesical pressure recording to determine filling sensations, bladder capacity, compliance 
and to observe the presence o f detrusor contractions. During micturition the intravesi­
cal pressure and the uroflow are measured simultaneously (pressure-flow study). The 
relation o f pressure and flow can be visualized in a X -Y  graph, in which detrusor pres­
sure is plotted against flow rate during voiding. Usually, the detrusor pressure at 
maximum flow (pdetQmax) is used to prove or rule out boo , since a high intravesical 
pressure with a synchronous low flow is the characteristic o f boo . To determine the 
grade o f obstruction, pressure-flow plots can be drawn on the provisional ics- 
nomogram (three classes: obstructed, equivocal, unobstructed) or on the Schäfer no­
mogram (seven classes ranging from unobstructed to severely obstructed).12
To study patients with luts it is generally accepted that urodynamic studies including 
pressure-flow analysis are the ‘gold standard’ in differentiating between boo and im­
paired detrusor contractility or detrusor instability. The use o f urodynamic studies in 
the assessment o f patients with luts reduces the subjective failure o f turp sig­
nificantly.13,14 Owing to the invasiveness o f the test and the costs, however, the standard 
use o f urodynamic studies in the routine work-up o f patients with luts remains con-
12,14troversial.
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Treatments for LUTS
Transurethral resection o f the prostate (turp) is still considered the ‘gold standard’ 
treatment for b ph . Nevertheless, the disadvantage o f the considerable risk o f post­
operative morbidity o f approximately 18% and even a mortality rate o f approximately 
0.7%  is acknowledged.15 In addition to turp and open prostatectomy, the last two dec­
ades a large number o f new therapeutic modalities have become available, some o f 
which have achieved a definite place in the armamentarium o f urologists. The gap be­
tween watchful waiting and surgery stimulated the development o f these new medical, 
minimal invasive and surgical therapies that aim at diminished morbidity. The co­
morbidity o f the patient, which is frequently present in the population presenting with 
luts and fear o f surgery or anaesthesia may be other arguments to decide to minimal 
or non-invasive therapies.
Surgical alternatives for turp are vaporization or laser techniques, which destroy 
prostatic tissue without significant bleeding. Other minimal invasive techniques, such 
as microwave thermotherapy o f the prostate, use heat to relieve prostatic obstruction. 
The advantages o f these techniques are: no need o f anaesthesia, a low percentage o f 
serious complications, and an outpatient setting.
Pharmacotherapy can influence both mechanisms by which bph  produces boo . First, 
prostatic size can be reduced via a hormonal mechanism. The enzyme 5-alpha- 
reductase enables the transformation o f testosterone into dihydrotestosterone (dht), 
which stimulates prostate growth. A  pharmacologic inhibition o f 5-alpha-reductase can 
achieve reduction o f prostate size. Second, the factor o f obstruction that is caused by 
prostatic smooth muscle tone can be diminished by blockade o f sympathetic adrenergic 
nerves. Several pharmacologic agents are available that block alpha-i-adrenoceptors in 
the prostate and bladder neck.
Evaluation of treatment effect
Since symptoms result in the patient’s consultation o f a physician, the evaluation o f a 
treatment in an individual patient should start with an assessment o fa change in symp­
toms. Dependent on the mode ofaction ofa particular treatment, other more objective 
evaluation tools can be used. For example, i f  a treatment aims at reducing prostatic 
size, the reduction can be measured using transrectal ultrasound.
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The evaluation o f a new therapeutic modality for luts should include investigations 
that delineate the different aspects o f the pathophysiology o f the lower urinary tract, 
attempting to define the mechanism o f action o f the particular treatment, but also to 
acquire insight in the pathophysiology o f b ph . Therefore, it seems logical to include 
urodynamic studies in the evaluation o f new treatment modalities for patients with 
luts, besides other evaluation tools. I f  urodynamic studies are the best tool to establish 
boo , one can suppose that they are also the best means to evaluate the effect o f a spe­
cific treatment that aims at a reduction o f boo .
LUTS and the bladder wall
As luts are neither disease-specific to bph  nor characteristic o f boo , other parts o f the 
lower urinary tract may be involved in the pathogenesis o f luts. In men with luts 
changes o f the bladder, such as trabeculation, are frequently visible during urethro- 
cystoscopy. The condition o f the bladder may on itself cause luts or may be 
influenced by boo and play a role in luts suggestive o f boo . Furthermore, i f  uro- 
dynamics appear to be not such a reliable ‘gold standard’ to prove boo as we assumed, 
another diagnostic tool for men with luts may be useful.
Animal studies have shown an association between boo and morphologic changes in 
the bladder wall. I f  such a relation can be found in humans too, bladder wall histology 
may be useful in the assessment o f men with luts. Up till now, however, a clear asso­
ciation between boo in men and bladder wall histology has not been established and it 
has been suggested that histologic changes in the bladder wall o f elderly men should be 
more attributed to the effects o f aging than to boo .16 The indistictness on this subject 
needs clarification and lead to one o f the studies presented in this thesis.
Rationale
Extensive research has already been performed on urodynamic studies and many re­
ports on urodynamics can be found in literature. Most o f these reports describe 
theoretical and technical aspects ofurodynamic studies. In theory, urodynamic studies 
precisely describe the filling and voiding pattern o f a patient with luts and provide an 
exact degree o f obstruction. Little attention has yet been paid, however, to the clinical
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value o f urodynamic studies in the assessment and treatment o f men with luts. The 
assumptions regarding urodynamics in clinical practice, such as the reliability and the 
bother to the patient, are not based on solid research. Neither has the value o f urody- 
namics in medical treatment been thoroughly studied. It is not known whether 
urodynamics are the appropriate means to measure treatment effect or to predict 
treatment effect in an individual patient by a pre-treatment assessment o f boo . Fur­
thermore, until now there has not been developed a better or more reliable assessment 
tool in the diagnosis o f luts than urodynamics. I f  the condition o f the bladder would 
also be taken into consideration in the assessment o f a patient with luts, it is likely 
that a more reliable diagnosis can be made. In this thesis, an attempt is made to pro­
vide more understanding on the issues mentioned above.
Outline of the thesis
Urodynamic studies play a role in the assessment and follow-up o f men with lu ts . To 
what extent one may rely on the results o f these studies, however, needs further evalua­
tion. In part I  several aspects o f urodynamic studies are considered. First, a patient 
evaluation on the tolerability o f urodynamic studies is presented, including objective 
and subjective evaluation parameters. Furthermore, the results o f two studies on the 
reproducibility o f urodynamic studies are presented. The reproducibility o f two urody- 
namic studies performed at two different occasions was determined and the intra- &  
inter-investigator variation in the analysis o f 200 pressure-flow studies were analyzed.
Part II describes the urodynamic effects o f alpha-adrenoceptor antagonists, in short 
alpha-blockers, in men treated for luts. First, all available clinical trials on the urody­
namic effects o f alpha-blockers are reviewed. Second, a retrospective study is presented 
on the urodynamic effects in 163 patients treated for luts with alfuzosin, tamsulosin, 
or terazosin. Urodynamic studies were performed at baseline and six months treat­
ment. Third, a study is presented that assessed the risk o f retreatment and prognostic 
parameters regarding this risk in 316 patients treated with an alpha-blocker.
To gain insight in the pathogenesis o f luts and boo , a light-microscopic study on the 
bladder wall o f patients with luts was performed. Part III deals with the association 
between boo and histopathologic features in the bladder wall. In 63 patients with luts 
pre-treatment urodynamic parameters were correlated with histopathologic features o f 
bladder biopsies, obtained during prostate surgery.
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Pa r t  I
C o n sid e r a t io n s  r e g a r d in g
URODYNAMIC STUDIES

Chapter 1
Tolerability of urodynamic studies and 
flexible urethrocystoscopy
Kortmann BB, Sonke GS, d'Ancona FC, Floratos DL, Debruyne FM, de la Rosette JJ 
BJU 1999; 84: 449
Objective: To determine the overall tolerability of urodynamic studies, used in the assessment of men 
with lower urinary tract symptoms (luts), by assessing the objective and subjective morbidity experi­
enced during and after urodynamic studies. In addition, the voiding complaints caused by the 
combination of urodynamic studies with a flexible urethrocystoscopy were assessed.
Methods: One hundred and three men with luts received urodynamic studies with flexible urethro­
cystoscopy. They completed a questionnaire to assess objective and subjective symptoms and degree 
of bother with emphasis on the urodynamic study. Urine was analyzed and cultured. Seventy-eight 
patients received another urodynamic study and completed the questionnaire twice.
Results: Data of the first questionnaire showed that more than half of the patients experienced some 
urge after the urodynamic study and the urethrocystoscopy (56%). Thirty five percent of the patients 
experienced little and 19% experienced severe voiding discomfort following the combined investiga­
tions compared to 24% and 5% respectively following an urodynamic study alone. Three patients 
(3%) had a symptomatic urinary tract infection. Hematuria, increased voiding frequency, and in­
creased nycturia occurred occasionally. The majority of patients found the urodynamic study less 
bothersome than expected (64%) and only 9% found it worse than expected. The overall degree of 
discomfort experienced during and following the urodynamic study combined with a urethrocysto- 
scopy was low. After a second urodynamic study, this degree was even lower.
Conclusion: In contrast with earlier results, we found that in our clinic urodynamic investigations are 
associated with a low percentage of urinary tract infection and low objective and subjective morbid­
ity. The combination of an urodynamic study with a flexible urethrocystoscopy does not cause 
significant additional voiding complaints. Most patients experience urodynamic studies as tolerable 
and not very bothersome.
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Introduction
L ower urinary tract symptoms (luts) are common among elderly men.1 The ma­
jority o f these patients have symptoms that are caused by benign prostatic obstruction, 
whereas up to one third o f the symptoms have other causes o f luts, such as detrusor 
instability or detrusor underactivity.2
It is generally accepted that urodynamic studies, including pressure-flow analysis, are 
the ‘gold standard’ in making the diagnosis o f bladder outlet obstruction.34 Combina­
tions o f symptom scores, uroflowmetry, ultrasound measurement o f the prostate 
volume, urethrocystoscopy and post-void residual volume measurements have been 
unable to accurately identify the precise pathology behind luts.5-8 Moreover we have 
learned that treatment outcomes are better when bladder outlet obstruction has been 
confirmed by urodynamic studies with pressure-flow analysis.9 Consequently, the ics- 
‘b ph ’ study group advises to use such urodynamic studies in the evaluation and treat­
ment decision o f the patient presenting with luts.8 Disregarding these considerations, 
the need for urodynamic studies in the standard work-up o f patients with luts is still 
controversial.21011 Those who are not in favor o f the routine use o f urodynamic studies 
argue that they are invasive, costly, time-consuming and bothersome for the patient. 
Moreover, the success rate following surgery is also high, even though urodynamic 
documentation o f bladder outlet obstruction is not obtained.10
These are strong arguments not to perform urodynamic studies on a routine base. But 
are these arguments valid? Are these studies indeed very bothersome to the patients and 
to what extent does the invasive character o f urodynamic studies cause morbidity? Sev­
eral studies have been performed addressing the incidence o f urinary tract infections 
following urodynamic studies and the need o f antibiotic prophylaxis. Urinary tract in­
fection following urodynamic studies appeared to occur in approximately 2% o f the 
patients, independent o f the use o f prophylactic antibiotics.12-14 Apart from the infec­
tion rate associated with urodynamic studies, in only a few studies attention has been 
paid to the morbidity caused by urodynamic studies.1516 The objective morbidity (he­
maturia, fever, urinary tract infection, etc.), but especially the subjective experiences 
(discomfort, pain, urge, etc.) o f the patients have not yet been described profoundly. 
Only Gonnermann et al. included the acceptance o f urodynamics by patients.17 Ben- 
ness et al. evaluated the subjective symptoms and embarrassment associated with 
urodynamic studies in female patients.18
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To be able to justify the standard use o f urodynamic studies in the assessment o f pa­
tients with luts, we should take all aspects o f urodynamic studies into account and 
tolerability is one o f those. The aim o f the present prospective study was to determine 
the overall tolerability o f urodynamic studies, used in the assessment o f patients with 
luts, by evaluating the objective and subjective morbidity and discomfort experienced 
during and after an urodynamic study. In addition, we assessed the difference in toler­
ability o f a first and a second urodynamic study. Since we usually combine an 
urodynamic study with a flexible urethrocystoscopy in our standard work-up o f pa­
tients with luts, we also included the tolerability o f a urethrocystoscopy in our 
assessment and analyses.
Methods
One hundred and three consecutive patients, recruited from our Outpatient Depart­
ment, were included in this study. Patients are referred to the Outpatient Department 
by general practitioners or urologists from other hospitals. All patients presenting with 
luts received a standard diagnostic work-up including a free urinary flow, an urody­
namic study, a transrectal ultrasound o f the prostate and a urethrocystoscopy. The 
urethrocystoscopy was performed using a flexible cystoscope (15.5F, Storz, Germany). 
To exclude any influence o f these investigations on the urodynamic study, work-up 
was performed in this order. All patients received written information on the urody- 
namic study.
Each urodynamic study was performed under the same conditions. Before placing the 
catheters, an instillation gel, containing lidocaine and antibacterial agents (Farco 
Pharma, Germany), was used. An 8f catheter mounted with a micro-tip sensor (m tc , 
Dräger, Germany), used for intra vesical filling and recording intra vesical pressures 
was placed under sterile conditions. An 8f micro-tip catheter was used for recording 
rectal pressures. During cystometry the bladder was filled with physiologic saline o f 
2o°c at a filling rate o f 50 ml/min. Antibiotic prophylaxis was not used routinely. Only 
few patients who were known with repeated urinary tract infections or a post-void re­
sidual volume o f more than 100 ml received antibiotics. One week after the 
urodynamic study a urine specimen was obtained for chemical urinalysis and for urine 
culture to exclude urinary tract infection.
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After the urodynamic study and the urethrocystoscopy were performed, patients living 
in the neighbourhood o f our clinic, were asked to participate in a study, determining 
the reproducibility o f urodynamic studies. This study is the subject o f chapter 2.
Within the framework o f this study, from November 1997 through June 1998,103 male 
patients with luts, who underwent an urodynamic study, completed a questionnaire a 
week after the urodynamic study, independent from their agreement to participate in 
the reproducibility study. The questionnaire was designed to assess subjective symp­
toms, including urge, frequency, pain and dysuria (six questions) and objective 
symptoms, like hematuria, fever and incontinence (three questions) and degree o f 
bother (three questions). In addition, the questionnaire contained a validated visual 
analog scale (vas), to measure the degree o f overall discomfort experienced during the 
urodynamic study and in the week after the urodynamic study (with a range o f zero to 
ten, with zero indicating no discomfort and ten indicating extreme discomfort).19 The 
questionnaire emphasized the tolerability o f the urodynamic study and not the toler­
ability o f the urethrocystoscopy. Patients who participated in the reproducibility study, 
underwent a second urodynamic study within a period o f one to four weeks. Besides 
the urodynamic study, no other investigation was performed in the second session. 
One week after the second urodynamic study they completed the same questionnaire 
for a second time. Not all patients agreed to undergo a second urodynamic study and 
not all patients, who underwent a second urodynamic study, returned the question­
naire. Therefore, the numbers ofpatients that completed the second questionnaire was 
smaller than the number completing the first. There was no significant difference in 
tolerability o f the urodynamic study between those two groups. Seventy-eight patients 
completed the questionnaire twice. The difference in tolerability o f the urodynamic 
study, quantified by vas, between both groups was tested with the Wilcoxon rank sum 
test, and was not statistically significant.
Results
O f 103 patients, nine (9%) had a positive urine culture after the urodynamic investiga­
tion combined with an urethrocystoscopy. As expected, in one urine specimen o f the 
only patient with a supra pubic catheter several bacteria were cultured. Three patients 
(3% o f all patients) having a positive urine culture had symptoms indicating a possible 
urinary tract infection. Two (2% o f all patients) o f those had fever o f whom one also 
had a common cold. One ofthem visited his general practitioner because ofhis urinary
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tract infection symptoms and received antibiotics. None ofthe patients with a positive 
urine culture had a history o f repeated urinary tract infections or had post-void residual 
volumes. Consequently, these patients had not received antibiotic prophylaxis.
The frequencies o f micturition complaints during and the week after the investigations 
are summarized in table i. The symptoms urge and pain are mentioned most fre­
quently in the first as well as in the second questionnaire. More than half o f the 
patients experienced at least some urge after the urodynamic investigation (with or 
without urethrocystoscopy).
Table 1 Symptoms experienced during and after urodynamic study (UDS) number (%)
First UDS 
(n = 103)
Second UDS 
(n = 78)
Voiding frequency less than usual 15 (14.9) 14 (17.9)
as usual 70 (69 .3) 47 (60 .3)
more than usual 16 (15.8) 17 (21 .8)
Nycturia less than usual 21 (21.0) 16 (20.8)
as usual 74 (74 .0) 49 (63 .6)
more than usual 5 (5 .0) 12 (15.6)
Change in voiding no change 73 (72 .3) 52 (66 .7)
easier 22 (21.8) 23 (29 .5)
more difficult 6 (5 .9) 3 (3 .8)
Urge no 44 (44 .0) 34 (44 .2)
little 49 (49 .0) 38 (49 .3)
severe 7 (7 .0) 5 (6 .5)
Pain no 47 (46 .1) 55 (70 .5)
little 36 (3 5 .3) 19 (2 4 .4)
severe 19 (18.6) 4 (5 .1)
Hematuria no 82 (80 .4) 72 (92 .3)
little 18 (17.6) 5 (6 .4)
severe 2 (2.0) 1 (1.3)
Not all numbers count up to the total number of patients due to missing data.
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Figure 1 Distribution of visual analog scale (VAS) as a measure for discomfort experienced during and the week 
after urodynamic studies.
From all the questions regarding the degree o f bother and discomfort patients experi­
enced during and after the urodynamic study, it appeared that for most patients the 
investigation was ’less bothersome than they had expected’ (64%). O f all patients, 27% 
rated the investigation ’as expected’, while 9% thought the investigation was ’worse 
than expected’. O f 32 patients (31%), who considered the urodynamic study ’quite 
bothersome’, 26 patients found the transurethral introduction o f the catheter most un­
pleasant. Only one patient considered the urodynamic study ’very bothersome’. Both 
the results o f the questions regarding the degree o f bother experienced and the visual 
analog scale (vas), in which patients describe the overall discomfort experienced during 
and after the urodynamic study, show that patients experience the second urodynamic 
study as less bothersome than the first one (figure 1). The mean score on the vas (range 
0.0 to 10.o) was 2.7 (sd = 1.9) after the first urodynamic study. After the second urody­
namic study, the mean score was 2.0 (sd = 2.0).
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Discussion
The percentages o f positive urine culture and clinically significant urinary tract infec­
tion that we found are in accordance with the percentages o f about 10% and 2%, 
respectively, reported in literature and are rather low considering the fact that urody­
namic studies and urethrocystoscopies are minimal invasive investigations.13,16
During the first visit to the Outpatient Department, the urodynamic study was fol­
lowed by a flexible urethrocystoscopy and a transrectal ultrasound o f the prostate. 
From the questionnaires regarding the first urodynamic study it appeared that patients 
found it difficult to indicate the degree o f bother they experienced due to the urody- 
namic study apart from the other investigations. To the question what was most 
bothersome many patients answered that the introduction o f the cystoscope was most 
awkward. The voiding complaints and discomfort patients experienced following the 
urodynamic study combined with the urethrocystoscopy are probably caused by both 
investigations. To get a clear picture o f the discomfort caused by an urodynamic study 
itself, we should focus on the second questionnaire, in which the degree ofbother dur­
ing and after the second urodynamic study is described (table 1). Comparison o f the 
results o f the first and the second questionnaire reveals that patients experience less 
pain and hematuria after the second urodynamic study. The frequency o f other symp­
toms did not differ significantly between the first and second urodynamic study.
O f all lower urinary tract symptoms, only the occurrence o f urge (56%) and pain 
(30%) following urodynamic studies was considerable. Given the low percentage o f 
urinary tract infections following urodynamic studies, the symptoms ‘urge’ and ‘pain’ 
do not per se indicate urinary tract infection. This finding corresponds to the results o f 
Carter et al.16 Presumably dysuria following urodynamic studies has a mechanical and 
not a bacterial aetiology in most cases. The occurrence o f other micturition symptoms 
is low, which is in contrast with the results o f Klingler et al., who concluded that uro­
dynamic studies are associated with considerable complications and morbidity.15
It is remarkable that the percentage o f patients who report to void less frequently 
equals the percentage o f patients who report to void more frequently than usual. The 
same is true for the percentages o f change in nycturia. The reason that part o f the pa­
tients void less frequent than usual after an urodynamic study combined with a 
urethrocystoscopy may be related to the dilating effect o f the cystoscope, but it is re­
markable that after the second urodynamic study, which was not combined with a 
urethrocystoscopy, even more patients reported to void easier. In the first and in the
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second questionnaire 22% and 30% o f the patients, respectively, report to void easier 
than before the investigation. This improvement may also be explained by a minimal 
dilating effect o f the cystometry catheter, although a placebo effect o f the investigation 
on subjective symptoms is a more probable explanation.
In contrast with the small change in symptoms, the subjective degree o f discomfort 
experienced did decrease considerably. Besides the additional bother due to the ure- 
throcystoscopy performed at the first visit, the decrease may be due to habituation to 
the investigation. The fact that most patients agreed to participate in the study on re­
producibility o f urodynamics and to undergo a second urodynamic study also indicates 
that the investigation was generally well tolerated. This result confirms the high accep­
tance o f urodynamics reported by Gonnermann et al.17
Some o f the initially investigated patients declined subsequent urodynamic studies and 
some patients failed to complete the second questionnaire. Some selection bias may 
therefore be present. Therefore, we also analyzed the decrease in discomfort while re­
stricting the statistical analysis to the patients who underwent two urodynamic studies 
and completed two questionnaires. The degree ofdecrease in discomfort did not differ 
from the preceding analysis. Furthermore, there did not appear to be a difference in 
VAS-score between the patients who did and the patients who did not consent to subse­
quent testing after the first urodynamic study. Considering the decrease in discomfort 
after habituation to the investigation, it is important that patients receive clear infor­
mation in order to make them acquainted with the investigation in advance.
The results o f this study show that the invasive character o f urodynamic studies, which 
is widely used as an argument against the routine use o f urodynamics, does not cause 
unacceptable objective or subjective morbidity. We agree with Elbadawi, who stated 
that the invasive character on itself is not a realistic argument not to use urodynamics, 
considering the even more invasive diagnostic procedures, e.g. urethrocystoscopies and 
biopsies, which are commonplace in urologic practice and other disciplines.20 Although 
we did not focus on the tolerability o f urethrocystoscopy, we even found acceptable 
low morbidity for the combination o f urodynamic studies and urethrocystoscopy.
In the present study, we did not consider aspects o f costs and time. Nevertheless, we 
conclude that, considering the importance o f urodynamic studies in the diagnosis o f 
patients with luts and the low subjective and objective morbidity, there is no argu­
ment against the use o f this investigation in the routine assessment o f patients 
presenting with luts.
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Conclusion
Urodynamic studies with pressure-flow analysis are associated with a relatively low per­
centage o f urinary tract infection, despite the invasive character o f the investigation, as 
was already known from literature. We found that in our clinic urodynamic studies are 
associated with little subjective and objective morbidity. A  combination o f urodynamic 
studies with flexible urethrocystoscopy does not cause significant additional voiding 
complaints. Urge and pain, however, frequently occurred during the first few days after 
the investigation. Therefore, patients should be notified that they are likely to experi­
ence these symptoms. Finally, most patients experience urodynamic studies as tolerable 
and little bothersome. The second urodynamic study was better tolerated than the first 
one. This improvement is probably mainly due to acquaintance with the investigation.
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Chapter 2 
Variability of pressure-flow studies
Sonke GS, Kortmann BB, d'Ancona FC, Verbeek AL, Kiemeney LA, Debruyne FM, de la Rosette JJ 
Neurourol Urodynam 2000 ; 19: 637
Objective: To assess the short-term test-retest variability of pressure-flow studies (pfs) in men with 
lower urinary tract symptoms (luts). By choosing a short interval between two consecutive pfs, but 
notably not performing two tests within a single session, both tests represent the same routine testing 
procedure.
Methods: Eighty-nine patients with luts suggestive of bladder outlet obstruction or detrusor under­
activity, who received pfs, were asked to undergo a second urodynamic evaluation within four weeks 
following the initial test. At both visits, specialized physicians performed the pfs. Obstruction was 
quantified using the Abrams-Griffiths number (AG-number). Each patient was classified as obstructed, 
unobstructed or equivocally obstructed according to the International Continence Society nomo­
gram.
Results: No systematic difference was observed in AG-number between the first and the second visit at 
the group level. There was, however, considerable variation at the individual level. The average 
within-patient standard deviation was 14 cmH2o. This finding shows that if a patient’s AG-number is 
30 at the first visit, his true AG-number can be any value between 30 ± 1.96 * 14 = 3 to 57, due to ran­
dom variability alone. The average within-patient standard deviation did not differ significantly 
between subgroups of obstruction and other variates such as patient age, symptom score, prostate 
volume or residual volume. The variability appeared to increase slightly with an increased interval 
between visits. Of all patients, 39% changed at least one category of obstruction at the second visit 
and 3% changed from definitely obstructed to definitely unobstructed or vice versa.
Conclusion: There is a considerable variability in pfs. Therefore, they cannot stand the test of serving 
as a gold standard to identify bladder outlet obstruction in patients with luts.
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Introduction
T he most effective  treatment in men with lower urinary tract symptoms (luts) sec­
ondary to bladder outlet obstruction (boo), is removing the infravesical obstruction. 
Both symptoms and urodynamic effects improve after desobstructive therapy. Ap­
proximately one third o f men with luts do not have boo .1 In these cases, detrusor 
instability or detrusor underactivity is often responsible for the complaints. The pre­
treatment diagnostic assessment o f patients with luts therefore aims at establishing a 
correct probability o f the patient being obstructed. Measuring detrusor pressure and 
urinary flow rate simultaneously enables pressure-flow studies (pfs) to quantify urethral 
resistance. Although there is yet no consensus on the clinical relevance o f precisely 
grading the amount o f urethral resistance, pfs are considered the best objective way to 
establish the presence or absence o f boo .2 pfs are also used in the follow-up o f treated 
patients and to compare treatment modalities in clinical trials.
In order to justify the standard use o f pfs as a gold standard test, the test-retest vari­
ability must be small for practical purposes. Variability o f pfs outcomes has been the 
subject o f previous studies.3-8 The interval between test and retest in these studies, how­
ever, has been either too short or too long to draw definite conclusions. A  retest within 
the same session o f testing is not representative o f the initial test as it does not allow 
the detrusor muscle to regain strength and stretch receptors in the bladder wall may 
become less sensitive to filling.9 Furthermore, factors that may be related to the out­
come o f pfs are more similar within a single session than between visits. Some 
examples include the physician carrying out the investigation, the time since the last 
meal and serum hormone levels. Alternatively, a retest 26 weeks or more after the ini­
tial test cannot preclude systematic changes in urethral resistance or detrusor 
contractility. Therefore, to assess the variability o f pfs, we retested men with luts 
within a treatment-free period o f four weeks after the initial test, thus preventing im­
portant changes in the anatomic condition o f the lower urinary tract.
Methods
Patients enrolled in this study visited the Outpatient Department o f Urology o f the 
University Medical Centre Nijmegen with luts, suggestive o f boo between October 
1997 and June 1998. All patients received extensive routine diagnostic assessment in­
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cluding pfs. Patients living in the neighborhood o f our clinic were informed about the 
aim o f this study and were asked to be retested within four weeks o f the initial urody­
namic investigation. Patients who were on alpha-blocker therapy or other medication 
that alters the functions o f the lower urinary tract were excluded from the study. Fur­
thermore, patients who experienced severe problems during the initial pfs were not 
asked to participate.
Each pfs was performed under the same conditions by one o f three specialized physi­
cians. Before placing the catheters an instillation gel, containing lidocaine and 
antibacterial agents (Farco Pharma, Germany), was applied. An 8f catheter mounted 
with an microtip pressure transducer used for vesical filling and recording intra vesical 
pressures was placed under sterile conditions (m tc , Drager, Germany). Abdominal 
pressure was recorded rectally with an 8f microtip sensor catheter. The pressure sensors 
were calibrated at atmospheric pressure before induction. During cystometry, the 
bladder was filled with saline o f 20°c at a filling speed o f 50 ml/min with the patient in 
supine position. Filling was stopped when the patient expressed a strong urge to void 
and micturition was allowed in standing position. During micturition flow parameters, 
intravesical and abdominal pressures are recorded simultaneously. Flow rates are re­
corded by a rotating disk flowmeter (Dantec Urodyn flowmeter, Dantec, Skovlunde, 
Denmark). All data are digitally stored and analyzed with an urodynamic analysis pro­
gram, which was developed at our department (u ic/bme Research centre, Department 
o f Urology, University Medical Centre Nijmegen, the Netherlands). A  physician visu­
ally inspected all computer results, with correction for pressure or flow artefacts. Pfs 
were repeated if  the results were o f poor technical quality. To quantify obstruction, the 
Abrams-Griffiths number (AG-number) was calculated according to AG-number = 
pdetQmax - 2 * Qmax. In this formula, Qmax is the maximum flow rate and pdetQmax 
is the detrusor pressure at maximum flow rate. The International Continence Society 
(ics) nomogram was used to classify patients.10 AG-numbers above 40 indicate obstruc­
tion, AG-numbers between 20 and 40 are equivocal, and AG-numbers below 20 suggest 
the absence o f obstruction. The analyses were repeated using the urethral resistance 
factor ura instead o f the AG-number. U ra values above 29 cmH2o represent obstruc­
tion.11 The results o f both pfs sessions were evaluated independently.
The skewness and kurtosis o f AG-number and ura were calculated to indicate i f  a nor­
mal distribution could be assumed for these variates. I f  these parameters are between -1 
to +1, it is reasonable to assume a normal distribution. The presence o f systematic 
change in urethral resistance was evaluated by calculating the mean difference in ag-
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number between the patients’ first and second visit, and the null hypothesis o f no 
difference was tested with a paired sample t-test.
In general, repeated measurements in the same patient will vary around the true mean 
value, because o f measurement error and biologic variability.12 To quantify the variabil­
ity between consecutive measurements, the standard deviation (sd) o f repeated 
measurements on the same subject is calculated. The individual sds (or actually their 
variances) can be averaged, i f  we assume that the sd is the same for all subjects. To test 
this assumption, we assessed whether the variability was proportional to the size o f the 
measurement by plotting the individual sds against their associated mean values and 
calculated the coefficient ofregression. In addition, the relation between the individual 
sds and age, prostate volume, Qmax, voided volume, post-void residual urine, ipss, 
quality o f life and the period between visits was assessed using regression analysis. The 
average sd is also called the within-subject sd , and it can be used to calculate a con­
fidence interval around the estimated true mean o f each patient. For instance, i f  the 
average within-patient sd is 4 and the AG-number determined with pfs o f a particular 
patient is 30, his true AG-number can be any value between 30 ± 1.96 * 4 = 22 to 38, due 
to random variability alone. The coefficient 1.96 originates from the characteristic 
property o f the normal distribution that 95% o f all o f its observations fall within a 
range o f ±1.96 sd from the mean. To describe the clinical relevance o f the variability in 
pfs results, the percentage o f patients that moved from one category o f obstruction to 
another was determined.
Results
Eighty-nine patients were included in this study. Table 1 shows a summary o f the pa­
tient characteristics. All patients were retested within four weeks ofthe first visit. Table 
2 shows the characteristics o f both pressure-flow sessions for all patients. AG-number 
and ura were approximately normally distributed and no statistically significant differ­
ence was observed in filling and voiding variates. At the first visit, 33% o f the patients 
was unobstructed, 29% was obstructed, and the remainder o f 38% had equivocal re­
sults. The corresponding percentages at the second visit were 40%, 26% and 34%. 
These differences were not statistically significant (%2 = 1.2; p = 0.55). In conclusion, 
there is no evidence o f a systematic change between both visits.
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Table 1 Summary of clinical parameters
Mean Standarddeviation 2 .Sth
Centiles
SGth 97 .Sth
Age (years) eS 8 48 eS 79
IPSS (0-35) 1S 8 1 14 s1
Quality of life (0-6) s 1 G s e
Prostate volume (ml) se 17 1S s2 8s
Qmax (free flow) (ml/s) 1s 7 4 12 sG
Voided volume (free flow) (ml) 248 144 e7 229 e22
Post void residual urine (free flow) (ml) S1 8e G 1G 28G
Test-retest interval (days) 14 S e 1s 2S
IPSS, International Prostate Symptom Score; Qmax, maximum urinary flow rate
Table 2 Results of pressure flow studies
First visit Second visit
P-value Average within
Mean SD Mean SD patient SD
Cystometric capacity (ml) 4S1 14G 4s8 14G G.2S ee
Qmax (ml/s) 9 S 9 S G.71 2
pdetQmax (cmH2G) 4S 19 4S 2G G.7G 12
Abram-Griffiths-number (cmH2G) 28 2e 28 2S G.81 14
URA (cmH2O) 28 14 28 14 G.82 7
SD, standard deviation; Qmax, maximum urinary flow rate; pdetQmax, detrusor pressure at maximum flow rate 
P-value testing the null hypothesis of no difference in mean values between visit one and visit two.
Table 3 Number (%) of patients per obstruction category according to the International Continence Society 
nomogram at the first and second visit
Result at first visit
Result at second visit
Unobstructed Equivocal Obstructed
Unobstructed 21 (72) 7 (24) 1 (4)
Equivocal 13 (38) 1e (47) S(1S)
Obstructed 2(8) 7 (27) 17 (eS)
Percentages indicate the proportion of patients in each category at the second visit conditional on the result at the first visit
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Figure 1 Individual absolute differences in AG-number plotted against the associated mean
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Figure i plots the individual difference in AG-number between visit one and visit two 
against the associated average AG-numbers. This figure shows that the spread between 
both AG-numbers ranges between -50 and 50 cmH2o and does not depend on the (aver­
age) size o f the measurement. Thus, there is no evidence that the error depends on the 
grade o f obstruction. Furthermore, no significant relation was detected between the 
individual spread in AG-number and any other clinical variate, other than a weak rela­
tion with the time between visits (results not shown). The average within-patient sd 
was 14 cmH2o (95% confidence interval (ci): 12 -16 ). This means that the difference 
between a patient’s measured and true AG-number may be as large as 1.96 * 14 = 27 
cmH2o due to random variability alone. Thus, i f  a patient’s AG-number is 30 at the first 
visit, his true value can be anywhere between 3 and 57. The average sd in pdetQmax 
was 12 cmH2o, and in Qmax 2 ml/s. The average sd in ura was 7 cmH2o, which shows 
that a patient’s true ura may deviate 14 cmH2o from the ura value determined at a sin­
gle visit. Based on the ics provisional nomogram, 39% o f the patients changed at least 
one category o f obstruction and 3% changed from definitely obstructed to definitely 
unobstructed or vice versa (figure 2 and table 3). The majority o f changers had equivo­
cal results at the first visit. Based on Schafer’s classification o f obstruction, 63% o f the 
patients changed at least one category, and ii%  changed two or more categories.27
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Figure 2 Change in pressure-flow study result plotted on the International Continence Society provisional nomogram
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Discussion
Pressure flow studies are considered the gold standard test in the pre-treatment assess­
ment o f men with luts and are often used to evaluate the objective response to 
treatment. Standard use o f pfs, however, is not commonly accepted. Those who op­
pose standard use claim that its additional value to identify obstruction does not 
compensate the associated complications, physician time and expenses.2 In a previous 
report we showed that, contrary to common belief, the morbidity associated with pfs is 
relatively low.13 In the present study, we evaluated the variability o f pfs outcomes. The 
within-patient sd in AG-number o f 14 cmH2o shows that a considerable deviation o f 
approximately 27 cmH2o may exist between the observed and the true value. This vari­
ability is also reflected in the 39% o f patients moving between categories o f obstruction 
o f the ics nomogram between visits. As AG-number is determined by pdetQmax and 
Qmax, also its variance is determined by the variances o f Qmax and pdetQmax*. The 
variability in AG-number was influenced more by variability in pressure than by vari­
ability in flow.
Variability in test results can be caused by biologic variability and by measurement er­
ror. It is difficult to distinguish both sources o f variability. Measurement error is the 
extent to which a test yields identical results at multiple occasions in the absence o f a 
true change. Biologic variability can only be assessed accurately i f  the measurement 
error is known.
Technical problems may cause measurement error. It is o f great importance to exclude 
pfs with poor technical quality and have them repeated. For instance, pressing the mi­
cro-tip catheters against the bladder or rectum wall induces irregularities in pressure 
measurement. Thus being more prone to artifacts, this type o f catheters may also in­
crease the intra-individual variability compared to fluid filled catheters. In order to test 
the latter hypothesis, the study must be repeated with balloon catheters. Similarly, 
transurethral pressure measurement may be different from a suprapubic method.
Measurement error may be due to difficulties reading pfs recordings. There may be 
more than one potential Qmax value, with different corresponding detrusor pressures. 
Furthermore, the methods used by computer programs to exclude artifactual high ini-
* The variance in AG-number is equal to c A G  = c 2 Q  + 4 * c Q  - 4 *covariance(p Q  ,Q  ) ,  with o2
1  A G  PdetQ max Q max r  detQ max ^  max
indicating the variance.
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tial flow rates or sharply peaking flow rates and detrusor pressures are not always ade­
quate nor is there consensus on manual artifact correction. Nevertheless, Tammela and 
co-workers have recently reported excellent agreement between the pressure-flow read­
ings o f various investigators compared to a blinded central reader.14
The models used to estimate urethral resistance all simplify reality. Although likely to 
be useful for clinical purposes, modeling makes an obstructive index subject to varia­
tion. It has been suggested that various methods o f analysis score differently on 
reproducibility.15 When comparing their reproducibility, it is important to take the 
scale at which obstruction parameters are measured into account rather than the re­
spective mean values.
In our study, the biologic variability in grade o f the obstruction was only affected by 
random fluctuations, since we reassessed patients within four weeks o f the initial test, 
but notably not within the same session. This time frame is in accordance with most 
questionnaires assessing urinary symptoms, which also inquire about symptoms experi­
enced during the previous month. A  four-week period is likely to exclude important 
changes in the anatomic condition o f the lower urinary tract. In addition, systematic 
changes and similarities in the test environment resulting from performing two tests in 
a single session were prevented, although we had to repeat voidings in the same session 
due to poor technical quality in five patients. While assuring pfs o f high quality, these 
retests may have influenced our results.
The variation in test results appeared to increase slightly i f  the interval between visits 
was longer. This finding suggests that some factors influencing pfs outcome change 
over relatively short periods o f days or weeks. Fluctuations in pfs outcome may be 
caused by dynamic changes in prostatic smooth muscle tone and bladder response to 
rapidly changing neurologic stimuli. Ghoniem further suggested the presence or ab­
sence o f residual urine and the individual variability in responding to the test 
environment to contribute to variable urodynamics.9 Possibly, patients were more re­
laxed at the second visit as they were already familiar with the testing procedure, 
preventing inhibitory sphincter reflexes. Circadian changes, as have been described for 
free uroflowmetry, may also explain part o f the variability in pfs outcomes. Our study 
was conducted to describe the total variability present in everyday urologic practice and 
not to assess possible causes o f variation. Further investigations may help to identify 
variance components, and possibly to account for these components in decreasing pfs 
variability.
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In a previous study from our department, Rosier and coworkers studied the variability 
o f pressure flow variates in two sequential voidings in a single session.6 In agreement to 
our results, individual differences between the two voidings larger than one Schäfer 
class o f obstruction were found in less than 20% o f the patients. By performing test 
and retest within a single session, however, the testing environment will be more simi­
lar, and some sources o f variability will be eliminated. Moreover, systematic changes in 
the sensitivity o f the stretch receptors in the bladder wall and the contraction strength 
o f the detrusor muscle may occur.
Witjes et al. assessed the variability o f pfs outcome after a treatment free interval o f 26 
weeks.8 Because o f prostatic growth, an increase in urethral resistance can be expected 
during this period. There was indeed some evidence o f systematic changes in urethral 
resistance within subgroups o f obstruction, although these can readily be explained by 
regression to the mean. Forty-four percent o f the patients changed at least one ics 
category o f obstruction; seven percent changed from definitely obstructed to definitely 
unobstructed or vice versa. In an unpublished re-analysis o f these data, the within- 
patient sd in AG-number was 15 cmH2o.
Madsen et al. addressed the variability o f transurethral pfs outcome in a small sample 
o f seven patients, who were retested within the same session.5 None was urodynami- 
cally unobstructed and all but one were obstructed. One patient changed category at 
the second measurement. Although insufficient quantitative results are reported for 
easy comparison, we agree with the conclusions o f these authors that a single pressure- 
flow curve is o f limited value due to considerable within-patient variation o f the test.
Hansen and coworkers performed two sequential transurethral pressure-flow re­
cordings in a single session in 49 men with luts.4 A  systematic variation in various 
pressure-flow variates was observed but no result was given for an obstructive index like 
AG-number or ura. Using the Abrams-Griffiths nomogram, 12% o f the patients 
changed category o f obstruction at the second voiding.
Van de Beek and colleagues studied variability o f pfs outcome in 90 patients with 
luts, but did not state the test-retest interval.3 A  Pearson’s correlation coefficient as 
high as 0.95 for two consecutive ura measurements was reported. The coefficient o f 
correlation, however, has limited value in assessing the reproducibility o f individual 
outcomes. Indeed, the authors found a low reproducibility o f Schäfer’s classification, as 
it was observed that in more than 30% o f the cases the obstruction class differed be­
tween the first and the second voiding.
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Many randomized controlled trials (rcts) have been conducted in the field o f bph  with 
urodynamic outcome variates.7,16-24 The outcomes in the placebo arm o f rcts can be 
used to assess the variability o f pfs, i f  an unchanged anatomic condition o f the lower 
urinary tract can be assumed. Bosch provided a review o f urodynamic responses to pla­
cebo therapy.25 The interval between test and retest in most o f these rcts is six months 
or more. In addition, many studies are hampered by a small study size and usually the 
results are restricted to systematic changes between baseline and follow-up. Few reports 
mention individual variability in an obstructive index. Although systematic changes 
between consecutive testings may be absent, that is, at a group level the results o f both 
tests are similar, considerable changes may be present at an individual level. Therefore, 
it is not sufficient to show a statistically insignificant difference in pfs results between 
consecutive tests in order to draw reassuring conclusions regarding the variability o f 
test results. Instead, an evaluation o f intra-individual changes is needed.
Studies on the variability in pfs outcomes conducted in the placebo arm o f a rct use 
patients who were scheduled for treatment, whereas pfs in fact are often used to indi­
cate who will need treatment. These rcts will thus comprise relatively few 
unobstructive patients. Hence, generalization o f the results to a clinical population o f 
men with luts is difficult. On the other hand, we evaluated patients with all grades o f 
obstruction and did not observe different variability for obstructed patients compared 
to unobstructed patients.
Next to variability, correlation ofthe test results with those o fa  gold standard test must 
be assessed when determining the value o fa  diagnostic test. There is no superior refer­
ence to a gold standard test, and such a test is usually assumed to indicate true disease 
status based on theoretical grounds. When the gold standard test is likely not to be re­
liable, however, as we think is the case with pfs, more attention should be paid to the 
prognostic performance o f the test.26 In other words, treatment result should be con­
sidered as gold standard and pfs are evaluated for their ability to distinguish patients 
who will benefit from treatment from those who will not. Some o f the nomograms to 
divide obstructed from unobstructed patients have in fact been determined by analyz­
ing the success o f prostatic surgery in samples o f men who pre-operatively underwent
11,27
pfs .
It is well known that pfs provide valuable information on the function o f the lower 
urinary tract. We found considerable variation, however, in the results o f single pfs. 
Neither a numerical interpretation o f pfs results nor a classification into obstruction 
categories provides the physician and his patient with an unambiguous test result. In
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some urodynamic centres the large variation in pfs results is already recognized, and a 
second and sometimes third pfs are performed if  the first was not conclusive. This 
practice, however, brings forth other problems: How many pfs are sufficient? Are the 
results o f multiple pfs best summarized by their average obstruction grade, or is the 
lowest value more informative? What is the most valid, yet practical moment to repeat 
testing? These questions remain unanswered. Therefore, bearing the variability in 
mind, we conclude that pfs cannot stand the test o f serving as a gold standard to iden­
tify boo in patients with luts.
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Chapter 3
Intra- and inter-investigator variation in the 
analysis of pressure-flow studies
Kortmann BB, Sonke GS, Wijkstra H, Nordling J, Kallestrup E, Holm NR, de la Rosette JJ 
Neurourol Urodynam 2000 ; 19: 221
Objective: to assess the intra- and inter-investigator variation in the analysis of pressure-flow studies 
(pfs) that were performed in men with lower urinary tract symptoms.
Methods: Two hospitals were involved in this study. In each hospital, ioo pfs were selected. Six ex­
perienced investigators manually analyzed photocopies of printouts of all pfs, including 
determination of pdetQmax and Qmax. Afterwards all 200 pfs were analyzed again in a different or­
der. For each Qmax and accompanying pdetQmax the AG-number was calculated. With these ag- 
numbers the intra-investigator standard deviation (sd) and the inter-investigator sd and the intra- 
and inter-investigator sd combined were calculated.
Results: The intra- and inter-investigator sd combined was 10.7. This result implies that if one inves­
tigator analyzes a pfs once and determines an AG-number of 40, another investigator may determine 
an AG-number between 40 ± 2.77 * 10.7 = io - 70, using a 95% confidence interval. The inter­
investigator sd was 10.0 and the intra-investigator sd was 3.7.
Conclusion: The reproducibility of the manual analysis of urodynamic studies is moderate due to a 
considerable intra- and inter- investigator variation. This moderate reproducibility is mostly caused 
by the substantial intra-investigator variation.
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Introduction
Lower urinary tract symptoms (luts) are common among elderly men. The major­
ity o f these patients have symptoms caused by benign prostatic obstruction (bpo), 
whereas up to one third o f them have other causes o f luts, such as detrusor instability 
or detrusor underactivity.1
Urodynamic studies, including pressure-flow analysis, are considered the ‘gold stan­
dard’ in diagnosing bladder outlet obstruction (boo).2,3 The combinations o f symptom 
scores, uroflowmetry, ultrasonography o f the prostate, measurements o f post-void re­
sidual volume and urethrocystoscopy have been unable to predict the precise pathology 
underlying luts or to prove boo .4-8 Only pressure-flow studies (pfs) can distinguish 
between boo and detrusor problems. Moreover, treatment outcome is better when boo 
has previously been confirmed by urodynamic studies with pressure-flow analysis.9,10
In clinical practice a variety o f diagnostic tools provide information on the patients 
lower urinary tract and it may be questionable whether a very precise grading o f ob­
struction is always needed in the decision-making in that situation. It is obvious that in 
a research situation and in the evaluation and comparison o f new therapies for patients 
with luts a more accurate establishment o f grade o f obstruction is o f importance. In 
both situations we need to be aware to what extent we may rely on the test result. 
Therefore, the reproducibility o f it should be known.
In order to justify the standard use o f pfs as a ‘gold standard’ test in the diagnosis and 
follow-up o f individual patients the reproducibility o f the test must be high. In addi­
tion, with a high reproducibility, smaller numbers o f patients need to be included in 
studies in which pfs are used to evaluate treatment outcome and to compare treatment 
outcomes with placebo. Studying the reliability o f urodynamic studies, we should take 
into account all the factors that might influence this reliability.
The variation o f pressure-flow parameters in repeated cystometry has been subject o f 
several previous studies. In a recent study performed in our clinic we found a moderate 
intra-patient reproducibility o f pressure-flow studies.11 Better results concerning repro­
ducibility, however, have been reported earlier.12-16 A  distinction should be made 
between reproducibility within one session o f two pfs and reproducibility o f pfs two 
performed at different occasions. In the latter case variation can be the result o f real 
physiologic changes that may occur within weeks, days or even hours or o f pathologic 
changes in the patient’s lower urinary tract, which may occur after a longer period o f
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time. Other factors that may cause variation in pfs are the reliability o f the instruments 
that are used. When these factors have been ruled out, the interpretation o f pfs re­
mains a possible cause o f variation. Intra-investigator variation is the variation in two 
or more analyses that were performed by one investigator, o f the same pfs. Inter­
investigator variation is the variation in analyses that were performed by two or more 
investigators, who differ in their respective ways o f analysis o f the same pfs .
The variation o f the analysis o f measured parameters has been subject o f two previous 
studies o f which only abstracts have been published. Donovan et al. presented no 
quantitative result on variation in analyses. From their study they concluded that there 
was a minimal variation in readings for detrusor pressure at maximum flow 
(pdetQmax), and minor differences for minimum voiding detrusor pressure.17 Kir- 
schner et al. report on the variation o f manual analysis and they found a coefficient o f 
variation o f 6.6 for Qmax and 5.0 for pdetQmax.18 These data seem extremely high, but 
only limited information was presented on their methods. This lack o f information 
makes comparison with our study impossible.
In summary, a previous study performed in our clinic revealed a moderate reproduci­
bility o f repeated pfs. Probably, this moderate reproducibility is partly caused by a true 
intra-patient variation. In the present study the contribution o f the intra- and inter­
individual variation in the analysis o f pfs to the moderate reproducibility o f pfs is as­
sessed. This knowledge is o f additional importance when comparing results o f pfs 
performed in different urologic centres, as often happens in multi-centre studies.
Methods
Pfs were performed at the University Medical Centre Nijmegen, the Netherlands 
(henceforth named centre one) and at the University Hospital o f Copenhagen, Herlev, 
Denmark (henceforth named centre two). In both centres, each urodynamic study was 
performed under the same conditions. In Centre one the pfs were performed as fol­
lows: Before placing the catheters, an instillation gel, containing lidocaine and 
antibacterial agents (Farco Pharma, Germany), was used. An 8f catheter mounted with 
a micro-tip sensor (m tc , Drager, Germany), used for intravesical filling and recording 
o f intra vesical pressures, was placed under sterile conditions. An 8f micro-tip catheter 
was used for recording rectal pressures. Before introduction o f the catheters, the pres­
sure sensors were zeroed at atmospheric pressure. During cystometry the bladder was
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filled with physiologic saline o f 20°c at a filling rate o f 50 ml/min. Filling was stopped 
when the patient expressed a strong urge to void and micturition in standing position 
was allowed. During micturition, flow and intravesical and abdominal pressures were 
recorded simultaneously. Flow was measured by a rotating disk flowmeter (Dantec 
Urodyn flowmeter, Dantec, Skovlunde, Denmark). All data were digitally stored and 
analyzed with an urodynamic analysis program, which was developed at our depart­
ment (u ic/bme Research centre, Department o f Urology, University Medical Centre 
Nijmegen, the Netherlands).
In centre two, the procedure o f performing urodynamic studies corresponds with the 
method used in centre one. The bladder was emptied using a 14F LoFric catheter. An 
8f double lumen cystometry catheter was used for bladder filling and intravesical pres­
sure recording (mms), and an 8f balloon catheter used for rectal pressure measurement. 
External transducers (m ms) were fixed at the upper border o f the symphysis pubis. 
Urodyn 2000 hard- and software were used (m ms).
In each centre, 100 consecutive pre-treatment pressure-flow studies were selected. Six 
experienced investigators (three from each centre) manually analyzed all 200 pressure- 
flow studies without knowledge o f the computer analysis data. Photocopies o f the 200 
cystogram prints were distributed to the six investigators. The International Conti­
nence Society (ics) standards on the analysis o f urodynamics were appended.19 The 
manual analysis o f the pressure-flow studies consisted o f determination o f the follow­
ing parameters on black-and-white print-outs o f cystograms and pfs : baselines o f the 
cystograms, maximum flow rate (Qmax) in ml/s, detrusor pressure at maximum flow 
(pdetQmax) in cmH2o. After all investigators had returned their analyses, they received 
the same 200 copies o f the cystogram prints, but in a different order and were asked to 
perform the analyses in the same way as they did in the first set o f prints.
For each Qmax and accompanying pdetQmax the Abrams-Griffiths number (AG- 
number) was calculated to quantify obstruction on a continuous scale (AG-number = 
pdetQmax - 2 * Qmax). An AG-number classifies the degree o f obstruction as follows: 
below 20 indicates no obstruction, between 20 and 40 is equivocal and above 40 indi­
cates obstruction.20 This classification corresponds to the boundaries between 
obstructed, equivocal and unobstructed on the ics provisional nomogram.21 Variations 
were calculated for AG-number, Qmax and pdetQmax. Following the ics standard, the 
AG-number as a parameter o f obstruction. As the AG-number is a single parameter for 
obstruction on a continuous scale, calculation o f variation are possible.
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Statistical analysis
In general, repeated ratings o f a single test result vary around a true mean value. When 
consecutive patients are repeatedly analyzed by multiple investigators, three factors 
affect each analysis. First, natural variation exists in the condition o f patients’ lower 
urinary tract. Second, different investigators have different interpretations o f the same 
cystogram. Third, variation occurs between multiple analyses o f a single cystogram by 
the same investigator. Traditional analysis o f variance is unable to partition the total 
amount o f variation into these various components. Therefore, we used an analysis o f 
variance including random effects to analyze the data. These methods are explained in 
the appendix. The interpretation o f an intra-investigator standard deviation (sd) o f x  is 
that i f  an investigator determines an AG-number o fy, the second time the same investi­
gator may determine the AG-number o f the same pfs between y  ± 2.77 * x. The 
coefficient 2.77 is equal to 1.96 * V2, with 1.96 originating from the property o f the 
normal distribution that 95% o f all o f observations fall within the range o f ± 1.96 sd 
from the mean. The multiplication factor V2 accounts for the variances associated with 
the estimation o f AG-number by the first and the second observer.
Results
The patients in centre one were classified as more obstructed by all investigators than 
those in centre two. The mean AG-number o f all the pfs o f centre one was 58 (range 52­
66) versus a mean AG-number o f 49 (range 46-54) in centre two. Table 1 shows the re­
sults o f the analyses o f the six individual investigators. The second time five out o f six 
investigators judged the pfs more obstructed on average compared to the first time. 
This systematic change is taken into consideration in the statistical analysis.
Table 2 shows the results o f the analyses o f variance components with random effects. 
The mean AG-number was 54 cmH2o with an inter-patient sd o f 29. The overall intra­
observer sd in AG-number was 10.o cmH2o. Thus, i f  an investigator determines an AG- 
number o f 40, the second time the same investigator may determine an AG-number 
between 40 ± 2.77 * 10.o = 12 - 68. The intra-investigator sd ranged between 7 and 14 
across the investigators and set o f analyses. There was no evidence for systematic 
change in intra-investigator variation. Some investigators analyzed the first set o f pfs 
more consistently (1,3,4,5) while others performed better at the second set (2,6).
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Table 1 Results of two times 200 PFS analyses, stratified by observer
Observer
1 2 3 4 5 6
AG-number 1st reading (cmH2O) 48.6 51.9 50.0 55.1 55.2 57.1
AG-number 2nd reading (cmH2O) 50.4 51.5 50.2 59.2 55.3 58.9
Mean difference* -1.8 0.3 -0.2 -4.1 -0.1 -1.8
P-value 0.03 0.64 0.83 0.00 0.88 0.02
Mean absolute individual difference 7.7 4.9 7.2 7.8 5.6 5.2
2 .5th - 97th centile 0 - 41 0 - 30 0 - 41 0 - 36 0 - 21 0 - 41
The sd o f the combined inter- &  intra-investigator variation in AG-number was 10.7. 
Thus, i f  one investigator analyzes a pfs once and determines an AG-number o f 40, an­
other investigator may determine an AG-number between 40 ± 2.77 * 10.7 = 10 - 70.
The inter-investigator sd was estimated to be 3.7, but was not statistically different 
from zero (p = 0.12). Thus, given the considerable intra-investigator variation, the in­
vestigators are mutual relatively consistent. Nevertheless, the inter-investigator sd o f 4 
means that i f  one investigator determines a mean AG-number o f a pfs o f 40, a second 
investigator may determine a mean AG-number o f the same pfs between 40 ± 2.77 * 3.7 
= 30 - 50, using a 95% c i. The inter-investigator sd in AG-numbers was comparable at 
both sets o f analyses.
As the calculation o f the AG-number is based on Qmax and pdetQmax, the variance in 
AG-number depends on the variation in Qmax and the variation in pdetQmax . The in­
tra- and inter-investigator sds in Qmax was 1 ml/s and 0 ml/s respectively (rounded to 
the nearest integer). The corresponding figures for pdetQmax were 10 cmH2o and 3 
cmH2o. These figures show that the variation o f pdetQmax has more influence on the 
variation o f the AG-number than the variation o f Qmax.
* Variance (AG-number) = Variance (pdetQmax) + 4*V ariance (Qmax) - 4*Covariance (pdetQmax, Qmax)
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Table 2 Results of analysis of variance with random effects
Description Estimate
Model term 
(see appendix)
Overall mean AG-number (cmH2O) 53.6 a
Inter-patient SD (cmH2O) 29.3 V(Os)2
Inter- and intra-investigator SD combined 10.7 » V((Ob)2+ (a£)2)
Inter-investigator SD (cmH2O) 3.7 V(Qb)2
Overall intra-investigator SD (cmH2O) 10.0 V(a£)2
Investigator 1 (8.8; 11.1) ^ 4 ,1 ; Va212
Investigator 2 (8.8; 8 .3) ^ 4 , 1 ; ^ 4 , 2
, Investigator 3 Intra-investigator SD stratified (12.7 ; 14.0) ^ 4 , 1 ; ^ 4 , 2
by investigator (1,2....6) and
rating (1,2) (cmH2O)2 Investigator 4 (9 .1; 10.1) ^ 4 , 1 ; ^ 4 , 2
Investigator 5 (8 .1; 10.7) ^ 4 , 1 ; ^ 4 , 2
Investigator 6 (10.0 ; 7 .1) ^ 4 , 1 ; ^ 4 , 2
Discussion
From our data it appeared that there is a considerable variation in the manual analysis 
o f pfs. The contribution to this variation o f the intra-investigator variation is more 
than that o f the inter-investigator variation. An intra-investigator sd o f AG-number o f 
10 implies that pfs may be analyzed to be obstructed the first time and not obstructed 
the second time. In clinical practice the decision for desobstructive therapy is not solely 
dependent on pfs in most cases, but i f  it is, this intra-investigator variation may have 
quite some implications for the use o f pfs.
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T h e  range o f  the respective intra-investigator sds for b o th  sets o f  analyses is large. 
T herefore, n o t all investigators are equally consistent at interpreting the pfs  and m aybe 
th ey do n o t always act at the best o f  their abilities. In d aily practice, the intra­
investigator variation  m ay even be m ore, as it is lik e ly  that investigators, w h o  need to 
p erform  analyses for research purposes perform  better and m ore consistent than those 
w h o  perform  the analyses d u rin g  their d aily  duties.
T h eo retically , the inter-investigator sd  o f  four refers to the variation  in analysis o f  pfs 
w ith o u t an y effect o f  an intra-investigator variation. In d aily  practice, how ever, the in ­
tra-investigator variation  and the inter-investigator variation  always have effect on  the 
variation in analyses sim ultaneously. C o m b in in g  the intra- and inter-investigator varia­
tion  resulted in a sd  o f  10.7, w h ich  is n o t very different from  the intra-investigator s d . 
T h e  variation in pdetQ m ax seems to be the greatest cause o f  the variation in AG- 
n um ber betw een investigators. In case o f  an obstruction  w ith  a h igh  pdetQ m ax and a 
lo w  Qm ax, the influence on the AG-num ber is m ore than that o f  the Qm ax anyhow .
W e  have a com plete arsenal o f  d iagnostic tests for patients w ith  l u t s  at our disposal, 
bu t o n ly  urod yn am ic studies can establish or reject the diagnosis o f  b o o . N evertheless, 
the need for urod yn am ic studies in the standard w o rk-u p  o f  patients w ith  l u t s  is still 
controversial and in the past years w e have been able to fo llo w  the live ly  discussion on 
the p ro ’s and co n tra ’s o f  urod yn am ics.1,22,23 A rgu m en ts against their routin e use, w h ich  
also have been countered, are invasiveness, costs, co n su m p tio n  o f  tim e and bother for 
the patient. T h e  fact that for d iagnosing b o o  w e have n o th in g  m ore reliable than pres- 
sure-flow  studies, how ever, can n ot be d isproved.
Presum ing that pressure-flow  studies are the ‘gold  standard’ in d iagn osin g b o o , the 
question  rises w h at w e m ay expect from  a ‘go ld  standard’ . A s there is n o t a reference 
test available to provide us the ‘tru th ’ about the presence o f  obstruction , there is no 
w a y  to establish the diagnostic value o f  an existing test. It is recom m en d ed  b y  the ic s  
to use the provisional ic s  m eth o d  for d efin ition  o f  obstruction  in w h ich  urethral resis­
tance is specified b y  the m axim um  flo w  rate and the detrusor pressure at m axim um  
flo w  rate.19 T h ese  values are classified in three classes o f  obstruction: obstructed, 
equivocal and unobstructed. For clin ical use, the ic s  n om ogram  is a sim ple standard 
m eth o d  and possib ly sufficient for the diagnosis in ind ivid ual patients w ith  l u t s .
H ansen et al. investigated the short-tim e rep ro d u cib ility  o f  pressure-flow  studies.16 In 
20 patients th ey perform ed fo u r pressure-flow  studies in tw o sessions. O f  20 patients, 
five patients changed to another obstruction  class w h en  com p arin g the first vo id in g  o f
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the first session w ith  the first vo id in g  o f  the second session. T h e  stu dy does not provide 
in form ation  about the exact variation on a con tin uous scale or the variation o f  obstruc­
tion  w ith in  an obstruction  class. It is not m en tion ed  w h eth er the patients are recruited 
con secutively  or not.
In a recent stu dy perform ed in our clin ic, rep ro d u cib ility  o f  pressure-flow  studies was 
determ ined b y  calcu lating a w ith in -p atien t standard deviation  in AG-num ber, w h ich  is 
suggested as m easure o f  rep ro d u cib ility  o f  con tin u ou s m easures.24 W e  fo u n d  a m od er­
ate rep ro d u cib ility  at an ind ivid ual level. A lm o st 4 0 %  o f  the patients changed at least 
one obstruction  class at the second exam ination .11 In consequence o f  different m ethods 
and analyses these tw o studies are n o t com parable.
C o n sid erin g  w h ich  factors m ay have had  an influence on  the variation, there appear to 
be several problem s in the interpretation  and the analysis o f  the pressure-flow  studies. 
If, due to an y technical disturbance, the baseline o f  the detrusor pressure does n o t cor­
respond w ith  the zero on the axis in the beginning, the investigator can lift or low er the 
graph to zero. In our stu dy this problem  occurred in several pressure-flow  studies o f  the 
ones perform ed in centre one and in a few  o f  centre tw o, and it appeared that som e 
investigators felt uncertain  about the w a y  to deal w ith  this baseline problem .
R ead in g o f  the exact num bers that correspond w ith  the Qm ax and pdetQ m ax in the 
graph can be d ifficu lt especially on  in d istin ct printouts. In the present stu d y w e used 
photocopies o f  printouts, m aking exact m easurem ent o f  especially the detrusor pressure 
even m ore d ifficult. U n d er norm al con d ition s measures are p ro b ab ly  perform ed m ore 
precisely aided b y  com puter readings on  screen. T h e  scales on the Y-axis o f  detrusor 
pressure and flo w  are d ivided  in sections o f  10 cm H2o and 10 ml/s respectively, w h ich  
forces the investigator to estim ate the num bers in betw een the lines.
It can be d ifficu lt to determ ine the Qm ax in case o f  an artifact that causes a peak at the 
place o f  the Qm ax (figure i). A n o th er problem  rises w h en  there are tw o points in the 
flow curve o f  approxim ately sim ilar h eight that m ay be the Qmax. T h e  acco m p an yin g 
detrusor pressures can be very different values, causing a variation in degree o f  obstruc­
tion  (figure 2).
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Figure 1 Drawing of uroflowmetry: what is Qmax?
It is a p o in t o f  discussion w h ether it is relevant to analyze cystogram s m anually. In 
m ost clinics, the analysis o f  cystogram s is now adays com puterized. U n fortu n ately , 
com p u ter data o f  cystogram s are deceptive as cystogram s should  always be inspected 
and i f  necessary corrected for disturbances and artifacts. A lth o u g h  w e get the im pres­
sion o f  precise com p u ter data, due to the m anual correction  o f  these data their 
precision  is determ ined b y  the precision  o f  a m anual analysis. T h e  ic s - ‘BPH’-S tu d y 
G ro u p  stated that autom ated com puter analysis tod ay is n ot acceptable as substitute for 
careful inspection  and m anual graphical control. O n ly  6 o %  o f  their tracings w ere 
w ith o u t artifacts.17 M a k in g  a m ore precise agreem ent on  artifact correction , baseline 
correction  etceteras co u ld  reduce the variation  in the analysis o f  pressure-flow  studies. 
Som e have tried to m ake international agreem ents on the m eth o d  o f  analyzing and 
grading obstruction . Still different m ethods are used, w h ich  m akes com parison o f  o u t­
com es m ore d ifficult. In ad dition , urodynam icists should  be educated in accordance 
w ith  international agreem ents and th ey should  be fam iliar w ith  urod yn am ic back­
grounds, technical aspects, and possible com plications.
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Figure 2 Drawing of pressure-flow study: what is Qmax and what is pdetQmax?
Pressure-flow  studies m ay provid e us a lo t o f  in form ation , bu t w e should  bear in m in d  
that the rep ro d u cib ility  is m oderate and interpretations o f  various investigators do not 
necessarily correspond. A s pressure-flow  studies are n o t u nam biguou s, th ey should  be 
considered com plem en tary to other d iagnostic tools for l u t s .
Conclusion
T h e  rep ro d u cib ility  o f  the m anual analysis o f  urod yn am ic studies is m oderate due to a 
considerable intra- and inter- investigator variation. T h e  m oderate rep ro d u cib ility  is 
m o stly  caused b y  the substantial intra-investigator variation. T h e  variation on  itse lf 
m ay be largely responsible for the m oderate rep ro d u cib ility  o f  pressure-flow  studies. 
O th e r  factors that m ay influence the rep ro d u cib ility  o f  pressure-flow  studies still need 
to be investigated.
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Appendix
The term random effects in the context o f analysis o f variance is used to denote factors with levels 
that were not deliberately arranged by the experimenter, but which were sampled from a population 
o f possible levels instead. For example, since we are interested in the effect that various observers have 
on the quantification o f bladder outlet obstruction, we have selected a sample o f all observers to esti­
mate the amount o f variance in AG-number that is attributable to differences between observers. If we 
were to repeat the study, it is unlikely that we would select the same observers again. In contrast, if  we 
wanted to know the effect o f gender on AG-number, we would always arrange two fixed groups: men 
and women. The basic distinction between fixed and random effects is that the variation in the levels 
o f random factors is assumed representative o f the variation o f the whole population o f possible lev­
els. The variation in the levels o f fixed factors is instead considered to be arbitrarily determined by the 
experimenter (i.e., the experimenter can make the levels o f a fixed factor vary as little or as much as 
desired). Thus, the variation o f a fixed factor cannot be used to estimate its population variance.
In our study, the 200 included patients are regarded as a sample from a large population o f patients 
with l u t s  and each patient has an additive or subtractive effect from the mean AG-number o f all pa­
tients. The variance o f these effects represents the natural variability between the patients. Likewise, 
the six observers are regarded as a sample from a large population o f observers, each having an addi­
tive or subtractive effect from the mean effect o f all observers. The variance o f these random observer 
effects can be interpreted as the inter-observer variability. Finally, the residual variability in the ratings 
o f AG-number after accounting for the variability between patients and variability between observers, 
can be interpreted as the intra-observer variability. The intra-observer variability may be similar for all 
observers, but since some observers are more experienced in rating cystograms than others, and more­
over, since a second evaluation may be performed less accurately than an initial one we also estimated 
separate intra-observer variability for each observer and for both ratings o f each observers. We as­
sumed that the observations AGwh, the h* (h = 1,2) reading o f AG-number o f observer o (o = i,2 ,3 ,..,6 )  
on patient s (s = 1,2,3.. .,200) follow the following model:
A G so h  =  a  + b s +  c o +  £ soh
a  = the overall mean o f all A G  hsoh
bs = the random effects for the subjects (one random effect for each subject). These can be seen as the 
biologic differences between the subjects. These random effects are inter-independent and normally 
distributed with zero mean and variance a s2.
co = the random effects for the observers (one random effect for each observer). These can be seen as 
systematic differences between the observers and are inter-independent and normally distributed with 
zero mean and variance aO. This variance can be interpreted as the inter-observer variability.
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£oh = the measurement errors. These can be seen as the random differences between two readings of 
an observer and are independent and normally distributed with zero mean and variance a\ . We let 
t^ e.oh  ^° 2,oi ]  ^t^ e.ph  ^^.pi ] for all o ^p or h ^ z. In other words, a 2£ , which can be interpreted as the 
intra-observer variability, is different for all observers and for both interpretations o f each observer.
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Pa r t  II
U r o d y n a m ic  e ffe c ts  o f  a l p h a - 
a d r e n o c e p t o r  a n t a g o n is t s

Chapter 4
Urodynamic effects of alpha-adrenoceptor 
blockers: a review of clinical trials
Kortmann BB, Floratos DL, Kiemeney LA, Wijkstra H, de la Rosette JJ 
Urology 2001; (in press)
Objective: Alpha-adrenoceptor blockers are clinically effective, producing a significant relief o f symp­
toms and an increase in urinary flow. The effect o f the various alpha-blockers on bladder outlet 
obstruction, however, is less clear. This article reviews the urodynamic effects o f alpha-adrenoceptor 
blocking agents in patients with l u t s .
Methods: Fifteen studies on alpha-blockers were reviewed o f which the pre- and post-treatment 
evaluation includes pressure-flow studies.
Results: In all but one study administration o f an alpha-adrenoceptor blocking agent resulted in a 
decrease in detrusor pressure at maximum flow or in maximum voiding pressure. In the majority of 
the studies this decrease is small, although some studies show a decrease in urodynamic obstruction 
parameters o f up to 50%. Patients suffering from l u t s  may all benefit from an alpha-blocker, inde­
pendent from the grade o f bladder outlet obstruction. One study even indicated that unobstructed 
patients respond better to alpha-blockers with respect to improvement in symptoms and Qmax than 
obstructed patients.
Conclusion: The use o f alpha-adrenoceptor blockers results in a decrease in urodynamic obstruction 
parameters. Obstructed as well as unobstructed patients, however, may benefit from alpha-blockers.
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Introduction
T h e  p r e v a l e n c e  o f  low er urinary tract sym ptom s (l u t s) is h igh  in the m ale p o p u la­
tion  and an increasing n um ber o f  patients is seeking m edical help for their com plaints.1 
l u t s , how ever, are n ot p ath o g n o m o n ic  for benign prostatic hyperplasia (b p h ) or b lad­
der outlet obstruction  (b o o ). H a ld  clearly illustrated the relation betw een l u t s , b p h  
and b o o .2 Since l u t s  are n o t specific to b p h  or b o o , com plem en tary d iagnostic tools 
are necessary to establish or reject the diagnosis o f  b o o  in order to choose an appropri­
ate treatm ent.
Tran surethral resection o f  the prostate (t u r p ) is still considered the ‘gold  standard’ 
treatm ent for b o o , bu t the disadvantages o f  a considerable risk o f  postoperative m o r­
b id ity  o f  approxim ately 18% and even a m o rta lity  rate o f  approxim ately  0 .7 %  are 
ackn o w led ged .3 T h e  gap betw een w atch fu l w a itin g  and surgery encouraged the devel­
o p m en t o f  n ew  therapies, such as m edical, m in im ally  invasive and n ew  surgical 
therapeutic m odalities, a im in g at a low er m orbidity.
W ith  the in tro d u ctio n  o f  alternative treatm ents, urologists w ere faced w ith  a m ore 
co m p lex  patient selection and w ith  the necessity to develop m ethods to evaluate these 
treatm ents and to predict efficacy and d u rab ility  o f  treatm ents. T h e  urologist has a 
large arsenal o f  tests at his disposal in the diagnosis o f  b o o , such as sym ptom  scores, 
u ro flo w m etry  in clu d in g  m easurem ent o f  post-void  residual vo lu m e, m easurem ent o f  
the prostate vo lu m e and urethrocystoscopy. T h e  value o f  these param eters have been 
d o cu m en ted  in num erous studies.4"10
T o  stu dy patients w ith  l u t s  it, is generally accepted that urod yn am ic studies in clu d in g  
pressure-flow  analysis are the ‘go ld  standard’ in d ifferentiating betw een b o o  and im ­
paired detrusor co n tractility  or detrusor instability. A lth o u g h  the standard use o f  
urodynam ics in d aily  clin ical practice is controversial, the evaluation o f  a n ew  thera­
p eu tic  m o d ality  for l u t s  should  include investigations that delineate the different 
aspects o f  the p ath o p h ysio lo gy o f  the low er urinary tract, attem p tin g  to define the 
m echanism  o f  action  o f  the particular treatm ent, bu t also to acquire insight in the 
p ath o p h ysio lo gy  o f  b p h . T herefore, it seems logical to include u ro d yn am ic studies in 
the evaluation o f  n ew  m edical treatm ents, besides other evaluation tools.
In the m edical field, tw o types o f  pharm aceutical agents have becom e available: alpha- 
adrenoceptor-blockers and 5-alpha-reductase inhibitors. B ein g  interested in the indica­
tion  for and effects o f  m edical treatm ent, w e can ask several questions: D o es m edical
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treatm ent have an y effect on the grade o f  b o o  and i f  yes, h o w  does the effect on b o o  
relate to the effect on  other clin ical param eters such as sym ptom s and flow? Is m edical 
treatm ent o n ly  effective in patients w ith  b o o , or do patients w ith o u t b o o  also benefit 
from  m edication?
Several authors have review ed the role o f  a lp h a-b lockin g agents in the treatm ent o f  
b p h . M o st studies evaluatin g m edical therapies for l u t s  confin e the analyses to sym p­
tom  scores, free uroflow m etry, m easurem ent ofresid u al volum e, and assessment o fsid e  
effects.11-16 T h e  m ajo rity  o f  the existing studies have dem onstrated that alpha-blockers 
are clin ically  effective, p ro d u cin g  an increase in urinary flo w  and a significant re lie f o f  
sym ptom s. F ew  o f  the above-m en tion ed  reviewers in clud ed  u ro d yn am ic effects o f  al­
p h a-b lo ck in g  agents in their studies.
T o  answ er the aforem entioned  questions on the role o f  urod yn am ic studies in treat­
m ent w ith  alpha-adrenoceptor b lo ck in g  agents, w e surveyed the available literature and 
evaluated all clin ical trials in w h ich  alpha-blockers w ere tested w ith  urodynam ics in ­
clu d in g  pressure-flow  analysis.
Pathophysiology and pharmacotherapy
Preceding research supports the hypothesis that tw o m echanism s exist b y  w h ich  b p h  
m ay cause b o o . T h e  static factor is caused b y  m echanical com pression o f  the urethra 
b y  the b u lk  o f  the prostatic adenom a. T h e  alpha-adrenoceptor m ediated sym pathetic 
stim ulation o f  the prostatic sm ooth m uscle causes a fluctuatin g influence on b o o  and is 
therefore called the d yn am ic factor o f  b o o  and contributes up to 4 0 %  to the obstruc-
17
tion.
It has been proven that both  m echanism s can be influenced b y  pharm acotherapy. C o n ­
sidering the role o f  testosterone in the genesis o f  b p h , horm ones can interfere w ith  the 
d evelopm en t and m aintenance o f  the adenom a. T reatm en t w ith  the in h ib ito r o f  5- 
alpha-reductase, finasteride, w h ich  prevents conversion o f  testosterone to d ih ydrotes­
tosterone, results in an im provem ent in sym ptom s and Qmax w ith  few  side effects. T h e  
reduction  o f  b o o  m easured b y  urod yn am ic studies is less p ro n o u n ced .18-21
A s p o in ted  o u t above, the d yn am ic factor o f  b o o  is m ediated b y  alpha-adrenoceptors 
that are stim ulated b y  noradrenaline. M o re  than 20 years ago C a in e  et al. perform ed in 
vitro  experim ents that show ed a pred om in an ce o f  alpha-i-adrenoceptors in hum an
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prostatic strom a o f  w h ich  the greatest p ro p o rtion  is localized  in the prostatic capsule.22 
T h e y  also show ed a relatively slow  response to alpha-adrenergic stim ulation  in the 
bladder neck. Later w o rk  show ed that alpha-2-receptors are m ain ly  localized in the epi­
th elium  and b lo o d  vessels and con firm ed  that there is a pred om inance o f  alpha-i- 
receptors in the prostatic strom a.23
T h e  first a lpha-blocker used for b p h  was the co m b in ed  alpha-i/alpha-2-adrenoceptor 
antagonist, ph en oxyben zam ine. D espite  its efficacy, the use o f  it has been abandoned 
because o f  a significant incidence o f  side-effects and evidence o f  m u tagen icity  in bacte­
rial and m ouse-cell cultures.24 T h e  first alph a-blocking agents were originally developed 
for the treatm ent o f  hyperten sion  as th ey also act on the alpha-adrenoceptors in the 
cardiovascular system , w here th ey cause ven od ilatation . T h is  m echanism  accounts for 
the side effects o f  alpha-blockers w h en  used for patients w ith  l u t s . T h e  first alpha­
b locker that was o rig in ally  developed for the treatm ent o f  hyperten sion and was later 
also used for l u t s , was prazosin, a selective alph a-i-adrenoceptor antagonist. W ith  the 
recogn ition  o f  the p ossib ility  to use these agents in b lo ck in g  the sym pathetic action  in 
the prostate, attention  has turned to the d evelopm ent and therapeutic use o f  selective 
alpha-i-andrenoceptor antagonists w ith  reduction o f  the unintended, usually m ild  side- 
effects, such as headache, dizziness, postural sym ptom s and drowsiness.
W h ile  lo o k in g  for effects o f  alpha-blockers that are m ore prostate specific, several al- 
ph a-i-ad ren ocep tor subtypes have been clon ed  and identified  in the prostate. T h e  
con cep t o f  uroselectivity, how ever, is com plex  and p h arm acologic uroselectivity does 
not necessarily correspond w ith  functional/physiologic or clinical uroselectivity.25-27 T h e  
con tem p orary alpha-blockers, such as alfuzosin, doxazosin, tam sulosin and terazosin, 
appear to have a very  sim ilar therapeutic efficacy, p ro d u cin g  a 20-30%  increase in 
Qm ax and a significant im provem ent in patients’ sym ptom s. T h e y  have a rapid onset o f  
action  and are lik e ly  to be effective in m an y patients w ith in  days to w eeks. T h ese 
effects are in contrast w ith  those o f  5-alpha-reductase-inhibitors, w h ich  take m onths to 
sh ow  therapeutic result. T h e  subtype selectivity and pharm acokinetics o f  the various 
alpha-blockers d iscrim inate betw een them .
In sum m ary, the con tem p orary alpha-blockers have proved  to be efficacious for b o th  
sym ptom s and urinary flow , w ith  an acceptable rate o f  usually m ild  side effects. N ever­
theless, the effect o f  alpha-blockers on b o o  is n o t that clear yet.
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Table 1 Summary of study designs
Medication Nr References N (Final) daily dose Duration of treatment Study method
Prazosin 1 Hedlund28 20 4 mg 4 weeks double-blind, placebo-controlled, crossover
2 Hedlund29 8 4 mg 4 weeks double-blind, placebo-controlled, crossover
3 Chapple30 22 4 mg 12 weeks double-blind, placebo-controlled
4 Chapple31 34 4 mg 12 weeks double-blind, placebo-controlled, performed in two centres
5 Kirby32 28 4 mg 4 weeks double-blind, placebo-controlled
Doxazosin 6 Janknegt33 50 1-4 mg 5 weeks double-blind, placebo-controlled, performed in two centres
7 Abrams34 & 
Chapple35
67 4 mg 14 weeks double-blind, placebo-controlled, performed in two centres
8 Gerber36 44 4 mg 12 weeks open label
9 Gerber37 17 2-8 mg 15 months open label
Terazosin 10 Gleason38 19 10 mg 3-9 months open label
11 Risi39 45 5 mg 26 weeks double-blind, placebo-controlled
12 Witjes40 33 10 mg 26 weeks open label
Alfuzosin 13 Martorana42 50 5 mg 4 weeks 
+8 weeks
double-blind, 
open label
placebo-controlled, followed by single-blind
Tamsulosin 14 Abrams44 35
30
32
0.2 mg 
0.4 mg 
0.6 mg
4 weeks double-blind, placebo-controlled
15 Miyatake45 18 0.2 mg 4 weeks open label, (Japanese language)
N = number of patients treated with alpha-blocker and with a complete urodynamic follow-up
'*7
9
Table 2 Effects on urodynamic parameters and symptoms of various alpha-blockers
Medication Nr Change 
Qmax (ml/s)
P-value Change pdetQmax 
(cmH2O)
P-value Change pmaxvoid 
(cmH2O)
P-value Change symptoms
Prazosin 1 2.01 < 0.00 -7 .43 ns -2.1 ns improvement (obstructive symptoms)
2 2.01 ns -133 ns -6 ns not described
3 3 .22 ns -14.7 s -17.7 s no significant changes
4 -0 .92 ns -14.2 ns no significant changes
3 .22 s -17.1 s
5 4 .81 < 0.005 -13 ns 60% of patients improved
Doxazosin 6 2.21 s -9.1 s 30-60% improvement
7 2.62 0.09 -4.7 s 30-60% improvement
8 1.52 0.20 -10.6 0.15 49% improvement (IPSS)
9 2.12 0.18 -23.5 0.04 36% improvement (IPSS)
Terazosin 10 5 .02 0.0007 0 ns improved stream and emptying
11 4 .02 s -8.5 ns 45% improvement (Boyarski)
12 2 .32 < 0.01 -13.2 < 0.01 52% improvement (IPSS)
Alfuzosin 13 15.62a < 0.01 -38.2 < 0.01 -40.1 < 0.01 25% improvement (Boyarski)a
3 .72b < 0.01 -28.9 < 0.01 -25.7 < 0.01
Tamsulosin 14 1.12 ns -11.2 ns -14.6 ns 20% improvement (modified Boyarski)
2 .32 0.03 -26.6 ns -21.1 ns 29% improvement (modified Boyarski)
1.82 < 0.05 -18.0 ns -21.3 ns 28% improvement (modified Boyarski)
15 mprovemen ns decrease s significant improvement (IPSS)
1: Qmax during UDS 2: Qmax of free urinary flow 3: Intravesical pressure at Qmax 4: Maximum intravesical voiding pressure
a: alfuzosin group b: placebo-alfuzosin group s: significant ns: not significant
In studies 6 & 7 the pressure-flow data were obtained from a table in the article by Janknegt et al. Considering the number of patients and the results of the study of Chapple et al, we 
assume that this report concerns the same study as that of Janknegt et al. and Abrams et al. With respect to study nr 13: Since the patients of the first study of Martorana are included in 
the second, multi-centre study, only the results of the multi-centre study are presented in the tables and figures. Unfortunately in study nr 15 no quantitative value was presented.
Urodynamic effects o f alpha-blockers in clinical trials
Starting in 1980, w e gathered literature b y  M ed lin e  search, from  references in relevant 
literature, and from  personal files. In the available literature w e identified  15 studies 
that evaluated alpha-blockers u sin g urodynam ics in clu d in g  pressure-flow  analysis.28-45 
T h ere  are m ore articles reportin g prelim in ary results o f  the sam e studies, bu t in this 
review  w e o n ly  in clu d ed  the m ost com plete reports. W e  approached pharm aceutical 
com panies o f  alpha-blockers to find  ou t w h ether studies had  been perform ed o f  w h ich  
the results have n o t been published, in order to exclude a p u b licatio n  bias. W e  in ­
cluded b o th  p lacebo-controlled  and open label studies. T h e  designs o fth e se  studies are 
sum m arized in table 1. In the fourth  co lu m n , the num bers o f  patients refer to patients 
w h o  w ere treated w ith  an alpha-blocker and w ith  a com plete fo llow -u p  in clu d in g  pres- 
sure-flow  studies. T h u s, patients w h o  were in the placebo-arm  o f  the stu dy are not 
in clu d ed  in this num ber. S tu d y  n um ber four was perform ed  in tw o centres and since 
the results o f  the tw o centres w ere presented separately, w e presented the urod yn am ic 
data separately in the tables and graphs.
T h e  m ajor u ro d yn am ic and clin ical o u tco m e param eters o f  these studies on alpha- 
adrenoceptor blockers are sum m arized in table 2. Som e factors com plicate com parison 
o f  the various studies: In som e studies the detrusor pressure at m axim um  flow  
(pdetQm ax) is used as the param eter o f  obstruction  w h ile  in other studies the m axi­
m u m  vo id in g  detrusor pressure (pm axvoid) is used. O fte n  little or no in form ation  is 
provid ed  on confidence intervals o f  the effects on obstruction  param eters. In table 2 w e 
b o th  presented absolute values and significance as stated in the articles. In all bu t one 
study, there is a decrease in u rod yn am ic obstruction  param eters ranging from  0 to 38.7 
for pdetQ m ax and from  2.1 to 40.1 for pm axvoid .
In 1996, G erber et al. reported a significant subjective benefit o f  doxazosin and a de­
crease in pdetQ m ax.36 T h e  results o f  pre-treatm ent urod yn am ic evaluation co u ld  not 
predict subjective treatm ent response and the m ajo rity  o f  patients had persistent b o o  
after treatm ent w ith  doxazosin. In 1997, the same group reported the results o f  doxa­
zosin treatm ent at 15 m o n th s.37 C o m p ared  to the values at three m onths o f  fo llow -u p , 
there was a deterioration o f  subjective sym ptom s despite co n tin u ed  im provem ents in 
Qm ax and pdetQ m ax. W itjes et al. report on the urod yn am ic effects o f  terazosin and 
categorized their patients in responders and non-responders and in an obstruction  and 
a n o n -o bstru ction  gro u p .40,41 T h e y  fo u n d  a significant im provem en t in Qm ax and 
sym ptom  score in both  patients w ith  and w ith o u t b o o . U ro d yn am ic im provem ent was
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seen in patients w ith  b o o , bu t in patients w ith o u t obstruction , urod yn am ic changes 
w ere not detected. Patients w ith o u t obstruction  w ere m ore lik e ly  to im prove in Qm ax 
and sym ptom s, com pared  w ith  those w ith  obstruction . T h e  three above described 
studies w ere n o t in clud ed  in the tables due to the problem s explained.
Discussion
A lm o st all studies on the effects o f  the various alpha-blockers dem onstrate an im ­
provem en t in l u t s  and an increase in m axim um  and/or m ean urinary flow . Several 
reviewers have already extensively discussed these effects. In the studies review ed here, 
the im provem en t in sym ptom s ranged from  20 to 6 0 % , w ith o u t a clear difference be­
tw een the different alpha-blockers studied. In these studies, the increase in Qm ax was 
on  average 2.9 ml/s w ith  a range o f  -0.9 to 5.6 ml/s, w ith  a ten d en cy o f  a larger im ­
p rovem en t in favour o f  terazosin and alfuzosin  (3.8 and 4.6  ml/s respectively). 
H ith erto , the effect o f  the various alpha-blockers on  outlet obstruction  has been stud­
ied scarcely. A fte r  an extensive search, w e co u ld  o n ly  id en tify  15 separate studies in 
w h ich  this effect was m easured. W e  fo u n d  som e other publications, bu t these reports 
appeared to concern  the same studies.
It is d ifficu lt to com pare the urod yn am ic effects o f  the various alpha-blockers. Initially  
it was p lann ed  to perform  a form al m eta-analysis. Because o f  too m an y h in d erin g  fac­
tors, this analysis was im possible for these studies. T h ere  are differences in stu dy 
designs, inclusion  criteria, and the num bers o fp a tien ts  that are enrolled, the duration 
o f  treatm ent and som etim es in the dose o f  m edication . In ad dition , the n um ber o f  
studies that have been perform ed differs for each type o f  alpha-blocker. In five ou t o f  15 
studies, a significant decrease in urod yn am ic param eters o f  obstruction  was found. Sta­
tistical significance, how ever, depends on  effect size and stu dy size, b o th  o f  w h ich  are 
different in all studies.46 W e  w ere n o t able to dem onstrate con fid en ce intervals for the 
effects on urodynam ics, as o n ly  a few  studies p rovid ed  standard errors.
O n e  m igh t question  the pow er o f  the current study, n o t in clu d in g  a m eta-analysis. 
O b v io u sly  there is a need to address the value o f  urod yn am ic studies in the assessment 
and fo llo w -u p  o f  patients using m edical treatm ent, bu t the possibilities to perform  an 
objective, quantitative assessment are lim ited . T herefore, w e are con vin ced  that this 
analysis contributes to the our kn ow led ge about this issue, as it provides an overview  o f  
the o n ly  available in form ation  on the clin ical effect o f  alpha-blockers on  b o o .
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In order to present the u ro d yn am ic results in the various studies, w e p lo tted  the differ­
ences betw een the pdetQ m ax and/or pm axvoid  before and after treatm ent (figure i). It 
is striking that in all bu t one stu dy there is a decrease in u ro d yn am ic obstruction . T h e  
m agn itude o f  this difference is n o t depen dent o f  stu dy size nor o f  the significance that 
was stated in the respective article. A s expected, m an y studies o f  sm aller size tend to 
sh ow  results that are n o t statistically significant.
In figure i the differences in obstruction  param eters are stratified b y  type o f  alpha­
blocker. T h e  largest decreases in detrusor pressures are seen w ith  alfuzosin  and tam su- 
losin, although the nu m ber o f  studies on these alpha-blockers is lim ited. T h ere  is o n ly  
one stu dy w ith  quantitative results on tam sulosin and one stu dy on  alfuzosin. O th e r 
investigators have n ot yet confirm ed the results o f  these studies. Figure i shows that the 
average pre-treatm ent u ro d yn am ic param eters differ for each stu dy group. In som e 
studies m ore obstructed  patients w ere in clu d ed  than in other studies. V e r y  obstructed 
patients m ay im prove m ore than sligh tly obstructed patients. T o  exclude this ph e­
n o m en o n  w e calculated the percentage im provem en t in u ro d yn am ic param eters for 
each stu dy group, bu t that revealed no significant difference.
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In figure 2 the absolute differences in obstruction  param eters are stratified b y  duration 
o f  treatm ent. From  this figure no correlation  can be deduced  betw een the duration  o f  
treatm ent and the urod yn am ic effect. From  the study b y  G erber et al. w e can conclud e 
that the u rod yn am ic effect o f  alpha-blockers seems to be persistent over a longer period 
o f  tim e.37 In this study, how ever, the initial im provem en t in subjective sym ptom s did 
n o t last d u rin g  a longer period  o f  fo llow -u p . T herefore, it seems that u ro d yn am ic pa­
ram eters are n o t predictive for subjective treatm ent ou tcom e. F our studies are open- 
labeled, w h ile  the others have a d ou ble  blind, p lacebo-con tro lled  design. N o  ten d en cy 
can be identified  that open label studies have better u ro d yn am ic results.
In the in tro d u ctio n  w e posed the question  w h o  w ill benefit o f  alpha-adrenoceptor 
b lo ck in g  treatm ent. A n  im portan t con clusion  can be draw n from  the stu dy b y  W itjes 
et al. T erazosin  treatm ent resulted in a decrease o f  obstruction  in obstructed  patients, 
bu t no significant u ro d yn am ic effect was fo u n d  in n on -obstructed  patients.40 T h e  u n ­
obstructed  patients seem ed to respond better to terazosin treatm ent w ith  respect to 
im provem en t in sym ptom s and Qm ax than obstructed patients. T h is  differential effect 
suggests that alpha-blockers have a w ell-justified  place in the m anagem ent o f  patients 
w h o  are n o t suitable for desobstructive treatm ent.
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U sin g  alpha-blockers for patients w ith  l u t s , w e should  ask ourselves w h ether w e in ­
tend to treat b o o  or to treat l u t s . E n suin g from  this question w e should  ask w h ether 
w e sh ould  consider the u ro d yn am ic changes or the changes in l u t s  using sym ptom  
scores w h en  evaluating treatm ent effects. W h e n  prescribing alpha-blockers to relieve 
the patien ts’ bothersom e l u t s , there is no strong in d ication  to perform  urod yn am ic 
studies, as all patient w ith  l u t s  m ay benefit from  the use o f  alpha-blockers. In ad di­
tion, urodynam ic changes after alph a-blocking therapy are not an im portant variable in 
the evaluation o f  the treatm ent effect, since a decrease o f  b o o  can be achieved w ith o u t 
an im provem en t o f  sym ptom s and vice versa.
T h ere  is no clue yet that indicates an y predictive value o f  obstruction  class in p red ict­
in g  d u rab ility  o f  treatm ent effect. M o st o f  the studies that have been review ed had a 
relatively short p eriod  o f  fo llo w -u p . It w o u ld  be interesting to k n o w  in advance w h o 
w ill need a m ore invasive prostatic therapy after a certain period  and w h o  w ill not. T h e  
degree o f  b o o  m igh t be indicative, bu t this field still needs to be unraveled.
Conclusion
A d m in istratio n  o f  an alpha-adrenoceptor b lo ck in g  agent results in a sm all reduction o f  
b o o , a lthough a decrease in u rod yn am ic obstruction  param eters o f  up to 50%  has been 
show n. Patients suffering from  l u t s  m ay all benefit from  the use o f  alpha-blockers, 
w h ether or n o t th ey have severe b o o . T h ere  is an ind ication  that unobstructed  patients 
respond better to alpha-blockers w ith  respect to sym ptom s and Qm ax than obstructed 
patients. G enerally, there is no strong indication  to perform  urod ynam ic studies, w h en 
prescribing alpha-blockers to relieve the p atien ts’ bothersom e l u t s .
References
1. Abrams P. New words for old: lower urinary tract symptoms for “prostatism”. BM J1994; 
308: 929.
2. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate 1989; suppl 2: 69.
3. Mebust W K, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: 
immediate and postoperative complications. A  cooperative study o f 13 participating 
institutions evaluating 3885 patients. J  Urol 1989; 141: 243.
69
4- Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus 
impaired detrusor contractility: the role o f uroflow. J  Urol 1991; 145: 810.
5. Sirls LT, Kirkemo AK, Jay J. Lack o f correlation o f the American Urological Association 
Symptom 7 Index with urodynamic bladder outlet obstruction. Neurourol Urodynam 1996; 
15: 447.
6. Ezz el Din K, Kiemeney LA, de Wildt MJ, Rosier PF, Debruyne FM, de la Rosette JJ. The 
correlation between bladder outlet obstruction and lower urinary tract symptoms as measured 
by the international prostate symptom score. J  Urol 1996; 156:1020.
7. Ezz el Din K, Kiemeney LA, de Wildt MJ, Debruyne FM, de la Rosette JJ. Correlation 
between uroflowmetry prostate volume postvoid residue and lower urinary tract symptoms as 
measured by the International Prostate Symptom Score. Urology 1996; 48: 393.
8. Madersbacher S, Klingler H C, Djavan B, Stulnig T, Schatzl G, Schmidbauer CP, Marberger 
M. Is obstruction predictable by clinical evaluation in patients with lower urinary tract 
symptoms? Br J  Urol 1997; 80: 72.
9. De la Rosette JJ, Witjes WP, Schäfer W , et al. Relationships between lower urinary tract 
symptoms and bladder outlet obstruction: results from the i c s - 'b p h ' study. Neurourol 
Urodynam 1998; 17: 99.
10. Rollema HJ, van Mastrigt R, Janknegt RA. Urodynamic assessment and quantification of 
prostatic obstruction before and after transurethral resection ofthe prostate: standardization 
with the aid o f the computer program c l im .  Urol Int 1991; 47 Suppl 1: 52.
11. Chapple CR. Role o f alpha-adrenergic blocking drugs in the treatment o f bladder outflow 
obstruction. Eur Urol 1993; 2:162.
12. Eri LM, Tveter KJ. Alpha-blockade in the treatment o f symptomatic benign prostatic 
hyperplasia. J  Urol 1995; 154: 923.
13. Kirby RS, Pool JL. Alpha adrenoceptor blockade in the treatment o f benign prostatic 
hyperplasia: past, present and future. Br J  Urol 1997; 80: 521.
14. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1- 
adrenoceptor subtype-specific blockade. Br J  Urol 1998; 81 Suppl 1: 34.
15. Narayan P, Tewari A. Overview o f alpha-blocker therapy for benign prostatic hyperplasia. 
Urology 1998; 51: 38.
16. Nickel JC. Long-term implications o f medical therapy on benign prostatic hyperplasia end 
points. Urology 1998; 51: 50.
17. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T , Izumi T , Abiko Y. Alpha-adrenergic 
activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J  Urol 1982; 
128: 836.
7 °
18. Tammela TL, Kontturi MJ. Urodynamic effects o f finasteride in the treatment o f bladder 
outlet obstruction due to benign prostatic hyperplasia. J  Urol 1993; 149: 342.
19. Tammela TL, Kontturi MJ. Long-term effects o f finasteride on invasive urodynamics and 
symptoms in the treatment o f patients with bladder outflow obstruction due to benign 
prostatic hyperplasia. J  Urol 1995; 154:1466.
20. Kirby RS, Vale J, Bryan J, Holmes K, Webb JA. Long-term urodynamic effects o f finasteride 
in benign prostatic hyperplasia: a pilot study. Eur Urol 1993; 24: 20.
21. Kirby RS, Bryan J, Eardley I, et al. Finasteride in the treatment o f benign prostatic 
hyperplasia. A  urodynamic evaluation. Br J  Urol 1992; 70: 65.
22. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, 
prostatic capsule and bladder neck. Br J  Urol 1975; 47:193.
23. Lepor H, Tang R, Kobayashi S, Shapiro E, Forray C, Wetzel JM, Gluchowski C. 
Localization o f the alpha iA-adrenoceptor in the human prostate. J  Urol 1995; 154: 2096.
24. Anonymous. Phenoxybenzamine for symptoms o f bladder neck obstruction. Drug TherBull 
1983; 21:15.
25. Andersson KE. The concept o f uroselectivity. Eur Urol 1998; 33 Suppl 2: 7.
26. Martin DJ, Angel I, Arbilla S. Functional uroselectivity. Eur Urol 1998; 33 Suppl 2:12.
27. Lepor H. Alpha i-adrenoceptor selectivity: clinical or theoretical benefit? Br J  Urol 1995; 76 
Suppl 1: 57.
28. Hedlund H, Andersson KE, Ek A. Effects o f prazosin in patients with benign prostatic 
obstruction. J  Urol 1983; 130: 275.
29. Hedlund H, Andersson KE. Effects o f prazosin and carbachol in patients with benign 
prostatic obstruction. Scand J  Urol Nephrol 1988; 22:19.
30. Chapple CR, Christmas TJ, Milroy EJ. A  twelve-week placebo-controlled study o f prazosin 
in the treatment o f prostatic obstruction. Urol Int 1990; 45 Suppl 1: 47.
31. Chapple CR, Stott M, Abrams PH, Christmas TJ, Milroy EJ. A  12-week placebo-controlled 
double-blind study o f prazosin in the treatment o f prostatic obstruction due to benign 
prostatic hyperplasia. Br J  Urol 1992; 70: 285.
32. Kirby RS, Coppinger SW, Corcoran M O , Chapple CR, Flannigan M, Milroy EJ. Prazosin in 
the treatment o f prostatic obstruction. Br J  Urol 1997, 60:136.
33. Janknegt RA, Chapple CR. Efficacy and safety o f the alpha-i blocker doxazosin in the 
treatment o f benign prostatic hyperplasia. Eur Urol 1993; 24: 319.
7 1
34. Abrams P. Urodynamic effects ofdoxazosin in men with lower urinary tract symptoms and 
benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Eur 
Urol 1997; 32: 39.
35. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, Abrams P. A  three 
month double-blind study o f doxazosin as treatment for benign prostatic bladder outlet 
obstruction. Br J  Urol 1994; 74: 50.
36. Gerber GS, Kim JH, Contreras BA, Steinberg G D , Rukstalis DB. An observational 
urodynamic evaluation o f men with lower urinary tract symptoms treated with doxazosin. 
Urology 1996; 47: 840.
37. Gerber GS, Contreras BA, Zagaja GP, Kim JH, Steinberg G D , Rukstalis DB. Doxazosin in 
men with lower urinary tract symptoms: urodynamic evaluation at i5 months. Urology i997; 
50: 229.
38. Gleason DM , Bottaccini MR. Effect o f terazosin on urine storage and voiding in the aging 
male with prostatism. Neurourol Urodynam 1994; 13: i.
39. Risi O, Blefari F, Rocchi B, Pino P. Efficacy and safety o f terazosin for the treatment of 
symptomatic benign prostatic hyperplasia. Long-term results. Urodinamica i994; 4: 249.
40. Witjes W P, Rosier PF, de Wildt MJ, van Iersel MP, Debruyne FM, de la Rosette JJ. 
Urodynamic and clinical effects o f terazosin therapy in patients with symptomatic benign 
prostatic hyperplasia. J  Urol i996; 155: iii7.
41. Witjes WP, Rosier PF, Caris C T , Debruyne FM, de la Rosette JJ. Urodynamic and clinical 
effects o f terazosin therapy in symptomatic patients with and without bladder outlet 
obstruction: a stratified analysis. Urology i997; 49: i97.
42. Martorana G, Giberti C, Pacella M, Casadei G, Pacifico P, Giuliani L. Effects ofalfuzosin on 
outlet obstruction o f b p h  patients measured by means o f urodynamic pressure/flow study. 
Urodinamica i994; 4: 245.
43. Martorana G, Giberti C, di Silverio F, et al. Effects o f short-term treatment with the a i- 
blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic 
hyperplasia. Eur Urol i997; 32: 47.
44. Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A  dose-ranging study o f the efficacy 
and safety o f tamsulosin, the first prostate-selective alpha iA-adrenoceptor antagonist, in 
patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J  
Urol i997; 80: 587.
45. Miyatake R, Park YC, Koike, et al. Urodynamic evaluation o f alpha-i blocker tamsulosin on 
benign prostatic hyperplasia using pressure-flow study. Nipp Hinyok GakZass i996; 87: i048.
46. Sonke GS, Rovers MM . Roaming through methodology XXIX. P. Ned Tijdschr Geneeskd 
200i; 145: 74.
7 2
Chapter 5
Alpha-blockade improves symptoms 
suggestive of bladder outlet obstruction but
fails to relieve it
Rossi C, Kortmann BB, Sonke GS, Floratos DL, Kiemeney LA, Wijkstra H, de la Rosette JJ 
J Urol2001; 165: 38
Objective: We investigated the effect o f the alpha-blockers alfuzosin, terazosin, and tamsulosin on 
urodynamic parameters after six months o f therapy.
Methods: Between February 1992 and June 1998,163 patients with lower urinary tract symptoms sug­
gestive o f bladder outlet obstruction were treated with alfuzosin (60), terazosin (66) and tamsulosin 
(37). Patients were evaluated with urodynamic studies including pressure-flow analysis, before treat­
ment and after six months o f therapy. Initially, all patients were also assessed by the International 
Prostate Symptom Score (ipss) questionnaire and measurement o f urinary flow rate.
Results: The majority o f patients had no clear improvement in obstructive parameters, regardless of 
the alpha-blocker used, as urethral resistance factor and detrusor pressure at maximum flow rate de­
creased by only 4 cmH2o. There was a clear subjective and statistically significant decrease in ip ss and 
in quality o f life scores o f six and two points, respectively. No relevant statistical difference was noted 
among the effects o f the three alpha-blockers on relieving symptoms or improving urodynamic pa­
rameters o f obstruction.
Conclusion: The alpha-blockers are effective for treating symptoms suggestive o f bladder outlet ob­
struction in patients presenting with lower urinary tract symptoms but not for treating the 
obstruction.
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Introduction
In  t h e  1970S, the p ion eerin g  w o rk  o f  C a in e  et al. led  to the d iscovery o f  alpha-i- 
adrenoceptor predom inance in the prostatic strom a and capsule. T h is  fin d in g triggered 
the search for alpha-receptor b lo ck in g  agents in patients w ith  low er urinary tract sym p­
tom s (l u t s ) suggestive o f  bladder o u tflo w  obstruction  (b o o ) .1 T h e  initial agents w ere 
derived from  antihypertensive drugs because o f  the alpha-receptor b lo ck in g  capability.2 
M o re  recently, several prostate specific drugs have been introduced.
D u rin g  the last tw o decades the therapeutic efficacy o f  these drugs has been clearly 
dem onstrated in several clin ical trials and to d ay  alpha-adrenoceptor blockers are the 
first line m edical treatm ent for patients w ith  l u t s  suggestive o f  b o o .3 T h e  alpha­
blockers are valued  for rapid onset o f  action, effectiveness independent o f  prostate size, 
m in im al influence on  sexual fu n ctio n  and g o o d  therapeutic profile. T h e  latter is sup­
ported  b y  the d evelopm ent o f  selective alph a-i-ad renocep tor antagonists and b y  the 
excellent pharm acokinetics o f  these n ew ly  developed drugs.4
B o o  can be attributed  to a static co m p o n en t due to an enlarged prostate and a d y­
nam ic co m p o n en t related to the increased sm ooth  m uscle tone o f  the fibrom uscular 
strom a inside the prostatic capsule and the bladder n eck .5 B lockage o f  the alpha-i- 
adrenoceptors reduces urethral resistance b y  relaxation o f  the prostate sm ooth  m uscle, 
thus, actin g  on the d yn am ic co m p o n en t o f  obstru ctio n .6 Surprisingly, there have o n ly  
been a few  reports on the u ro d yn am ic effect o f  a lph a-i-b lockers.7-13 M oreover, the use 
o f  urod yn am ic studies at baseline and fo llo w -u p  to evaluate changes in b o o  in patients 
treated w ith  alpha-blockers rem ains controversial.14-15 D o  alpha-blockers really relieve 
b o o ? Is there a difference in urodynam ic im provem ent am on g different alpha-blocking 
agents? Is it possible, based on urod yn am ic findings at baseline, to select patients w h o 
w ill respond favorably to treatm ent? W e  describe the effect o f  alpha-i-blockers on uro­
d yn am ic param eters after six m onth s o f  therapy and address these questions.
Methods
B etw een F ebruary 1992 and June 1998,163 patients w ith  l u t s  suggestive o f  b o o  w ere 
treated w ith  alpha-blockers and un d erw en t urod yn am ic studies before and after six 
m onth s o f  therapy. A ll patients participated  in different p rotocols on the effect o f  al­
pha-blockers that for purpose o f  stu dy in clu d ed  urod yn am ic evaluation at six m onths
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fo llo w  up. Patients w ith  prostatic cancer, urethral stricture or n eu rologic  disorders 
affecting low er urinary tract fu n ction , and those w h o  previously had und ergone pros­
tate surgery or been treated w ith  finasteride w ere excluded from  study.
T reatm en t consisted o f  2.5 m g  alfuzosin  three tim es d aily  in 60 cases, 0.4 m g  tam su­
losin  d aily  in 37 and 5 m g  terazosin d aily  in 66. Patients w ere selected to receive one o f  
the three drugs based on availability at that tim e and not on baseline characteristics. A ll 
patients underw ent routin e investigation, consisting o f  m edical history, assessment o f  
sym ptom s and q u ality  o f  life accord in g to the International Prostate Sym p to m  Score 
(ip ss), m easurem ent o f  serum  prostate specific antigen, d igital rectal exam ination, 
transrectal ultrasonography o f  the prostate, and uroflow m etry, in clud in g determ ination 
o f  vo id ed  and post-void  residual vo lu m e (p v r ).
E ach pressure-flow  stu dy was perform ed identically. A n  8f catheter m o u n ted  w ith  a 
m icrotip  pressure transducer (m t c , D rager, G erm any) used for vesical filling and re­
co rd in g  intravesical pressure was placed under sterile conditions. A b d o m in a l pressure 
was recorded intrarectally w ith  a 7F m icrotip  sensor catheter. T h e  pressure sensors were 
calibrated at atm ospheric pressure before in trod u ction . Intra-abdom inal pressure was 
subtracted electronically  from  the intravesical pressure to obtain  detrusor m uscle pres­
sure. C y sto m e try  was perform ed w ith  the patient sitting, and the bladder was filled 
w ith  w ater at room  tem perature at a m ed ium  fillin g  speed o f  50 m l/m in. F illin g  was 
stopped w h en  the patient expressed a strong urge to vo id  and vo id in g  was allow ed in 
standing position . D u rin g  vo id in g , flo w  param eters and intravesical, abd om in al and 
detrusor pressures were recorded sim ultaneously. A ll data were d igitally  stored and ana­
lyzed  w ith  an urod yn am ic analysis com puter program  developed at our departm ent 
(u ic /b m e  Research centre, D ep artm en t o f  U ro lo g y, U n iversity  M ed ica l C en tre  N i­
jm egen , the N etherlands). A n  experienced physician  visually inspected all com puter 
results using m anual correction  for artifacts.
T o  q u an tify  obstruction  the urethral resistance factor (u r a ) was determ ined b y  fittin g  
the pressure-flow  p lo t at the p o in t o f  m axim um  flo w  (detrusor pressure at m axim um  
flow ). W e  chose u r a  as it is a contin uous param eter suitable for stu dyin g sm all changes 
in the severity o f  b o o . U r a  values greater than 29 cm H 2o represent obstruction. 
C h an ges in urod yn am ic param eters betw een baseline and six m onth s fo llo w  up w ere 
determ ined and p-values w ere calculated w ith  the W ilc o x o n  signed rank test. T h e  cor­
relation betw een subjective (change in ip ss) and objective (change in u r a ) 
im provem en t was d eterm ined w ith  Spearm an’s correlation  coefficient. T o  evaluate 
w h ether changes in clin ical param eters differed a m o n g the three drugs w e used the
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K ruskal-W allis test, w h ich  is the equivalent o f  a W ilc o x o n  signed rank test for m ore 
than tw o treatm ent groups. D ifferences in baseline characteristics a m o n g the three 
drugs w ere also com pared  u sin g the K ruskal-W allis test.
Results
Patient characteristics at baseline and six m o n th  fo llo w -u p  are presented in table i. A l­
ph a-blocker treatm ent resulted in subjective and objective im provem ent. T h e  changes 
w ere relatively sm all, how ever, com pared  to patients w h o  received transurethral resec­
tion  o f  the prostate (t u r p ) .16 Subjective im provem en t was m easured w ith  the ipss  and 
was six points. M ed ian  im provem en t was 4 cm H 2o in u r a  and i ml/s in m axim um  flow  
rate (Qmax).
T h e  figure shows the correlation  betw een subjective im provem en t represented b y  ipss 
on  the Y-axis and objective im provem en t represented b y  u r a  on the X -axis. E ach dot 
represents an in d ivid ual patient. T h e  Spearm an coefficient o f  correlation was 0.09 (p- 
value = 0.39), in d icatin g  that there was no significant correlation betw een urod yn am ic 
and sym ptom atic im provem ent. W e  evaluated w h ether the effects o f  alpha-blockers 
differed betw een patients w h o  w ere obstructed  at baseline (u r a  > 29 cm H2o) and those 
w h o  w ere unobstructed. U ro d yn a m ic  changes betw een baseline and six m onth s w ere 
greater in the obstructed than in the unobstructed group. PdetQ m ax and u r a  decreased 
6 and 7  cm H 2o, respectively, in the obstructed  group and one and tw o in the u n o b ­
structed group; p-values com p arin g classes w ere 0.02 for pdetQ m ax and 0.00 for u r a . 
S ym p to m atic  im provem en t and increase in Qm ax w ere identical in b o th  groups.
T a b le  2 shows the baseline characteristics o f  patients treated w ith  alfuzosin, tam sulosin, 
and terazosin. D espite  the lack  o f  random ization , no statistically significant difference 
in baseline characteristics was present a m o n g the three groups.
C h an g es in clin ical param eters betw een baseline and six m onth s fo llo w -u p  for each 
d ru g are sum m arized in table 3. A ll param eters im proved  in each treatm ent group 
w ith o u t significant differences am on g the effects o f  the different types o f  m edication. A  
decrease in p v r  was o n ly  noted  for alfuzosin. D espite  a statistically significant differ­
ence (p = 0.027), how ever, a reduction  o f  i5 m l in the p v r  has no clin ical im portance.
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Table 1 Clinical and urodynamic outcomes of all the patients at baseline and after six months of treatment with 
alpha-blockers.
Number of Centiles 50th (25th - 75th)
patients Baseline Six Months Difference
Age (years) 163 64 (56-70) - - -
Qmax (ml/s) [free flow] 156 10 (8 ; 13) 11 (8 ; 14) 1 (-1 ; 4) 0.002
PVR (ml) 154 36 (0 ; 94) 17 (0 ; 56) 19 (-41; 15) 0.018
IPSS (0 - 35) 151 18 (13 ; 23) 12 (7 ; 16) -6 (-10 ; -1) 0.000
QoL (0 -6) 87 4 (3 ; 4) 2 (2 ; 3) -2 (-2 ; 0) 0.000
Qmax (ml/s) [PFS] 163 6 (5 ; 8) 7 (6 ; 11) 1 (0 ; 3) 0.000
pdetQmax (cmH2O) 163 50 (36 ; 65) 46 (33 ; 63) -4 (-15 ; 8) 0.015
URA (cmH2O) 163 31 (23 ; 41) 27 (18 ; 38) -4 (-11 ; 3) 0.001
* p-value baseline versus six months
Qmax indicates maximum urinary flow rate; PVR indicates post void residual volume at free flow; IPSS indicates international 
prostate symptoms score; QoL indicates quality of life score; pdetQmax indicates detrusor pressure at maximum flow rate; URA 
indicates urethral resistance factor.
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obstruction, after six months of treatment with alpha-blockers.
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Table 2 Baseline values stratified by treatment.
Centiles: 50,h (25th ; 75th)
P-value*
Alfuzosin (N = 60) Tamsulosin (N = 37) Terazosin (N = 66)
Age (years) 64 (58 ; 71) 61 (54 ; 68) 64 (55 ; 72) 0.445
Qmax (ml/s) 10 (8 ; 12) 10 (7 ; 13) 9 (7 ; 14) 0.961
PVR (ml) 40 (3 ; 95) 12 (0 ; 79) 40 (10 ; 95) 0.100
IPSS 19 (14 ; 24) 17 (12 ; 25) 18 (14 ; 23) 0.855
QoL 4 (3 ; 4) 4 (3 ; 5) 4 (3 ; 4) 0.853
UDQmax (ml/s) 7 (5 ; 8) 6 (5 ; 10) 7 (5 ; 8) 0.622
pdetQmax 50 (33 ; 59) 51 (39 ; 68) 50 (35 ; 67) 0.690
URA (cmH2O) 30 (23 ; 38) 29 (23 ; 48) 32 (23 ; 42) 0.494
Prosvol (ml) 32 (27 ; 50) 31 (22 ; 41) 33 (25 ; 48) 0.123
* p-value comparing treatments. Abbreviations as in table 1.
Table 3 Difference at baseline versus six months: median and 25th; 75“ 
treatment per drug.
1 centiles, with p-value testing the effect of
Treatment
P-value*
Alfuzosin (n = 60 ) Tamsulosin (n = 37) Terazosin (n = 66)
Qmax (ml/s) 1 (-1 ; 5) 1 (-1 ; 4) 1 (-1 ; 4) 0.91
0.02 0.10 0.03
PVR (ml) -15 (-60 ; 4) 0 (-35 ; 24) 0 (-39 ; 26) 0.03
0.00 0.72 0.69
IPSS -6 (-10 ; -1) -5 (-9 ; -1) -7 (-11 ; -1) 0.42
0.00 0.00 0.00
QoL 0 (-2 ; 1) -1 (-2 ; 0) -1 (-2 ; 0) 0.33
0.45 0.00 0.00
UDQmax (ml/s) 0 (-1 ; 2) 1 (0 ; 3) 1 (0 ; 3) 0.01
0.17 0.00 0.00
pdetQmax (cmH2O) -4 (-13 ; 11) 0 (-15 ; 8) -5 (-17 ; 5) 0.48
0.36 0.49 0.02
URA (cmH2O) -2 (-8 ; 5) -4 (-12 ; 5) -5 (-13 ; -1) 0.06
0.30 0.07 0.00
* p-value comparing differences in effect between treatments 
Abbreviations as in table 1
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Discussion
F o llo w in g  A b ra m s’ statem ent that “pressure-flow  investigation is the o n ly  w a y  o f  diag­
n o sin g  b o o ” , som e investigators consider the necessity o f  an assessment o f  pressure- 
flo w  changes in the evaluation o f  the effects o f  m edical therapy m an d atory.14 O thers 
focus on  the role o f  sym ptom atic im provem en t o f  a lpha-i-blockers and ju d ge  urody- 
nam ic studies too invasive, too expensive and n o t predictive o f  treatm ent o u tco m e.9-15
W e  present the results o f  u ro d yn am ic studies fo llo w in g  m edical therapy in order to 
evaluate the effect o f  three different a lp h a-b lo ck in g agents on  b o o , establish possible 
differences in u ro d yn am ic outcom es am o n g the three drugs used, as to date there are 
o n ly  three head-to-head trials available in the literature and id en tify  selection criteria 
for m edical treatm ent, based on  urod yn am ic fin d in gs.17-19
O u r  stu dy is retrospective and n on-rand om ized . Patients w ere selected on  availability 
o f  the d ru g at that tim e, how ever, and n otab ly not on baseline characteristics. T h is  w a y  
o fp a tie n t selection resulted in three h om ogen eous and com parable groups o fp a tien ts  
w h o  w ere m od erately sym ptom atic and sligh tly obstructed, w ith  relatively p o o r flow  
and sm all-to-m oderate prostate enlargem ent (table 2). T h e  outcom es are com parable to 
other studies on u rod yn am ic findings after alpha-blockade that in general reveal a m ild  
decrease in obstructive param eters.10,11,18,19 O n ly  one stu dy show ed a considerably 
greater decrease in b o o .12 A lth o u g h  there was no clin ically  significant re lie f o f  b o o , pa­
tients were satisfied w ith  m edical therapy since th ey had  sym ptom atic im provem ent. 
T h is  result confirm s on ce again the p o o r relation betw een the severity o f  sym ptom s 
and the grade o f  b o o .20
O u r  results reveal that 2.5 m g  alfuzosin  three tim es daily, 0.4 m g  tam sulosin d aily  or 5 
m g  terazosin d aily for l u t s  suggestive o f  b o o  p rovid ed  com parable subjective and o b ­
jective  im provem en t after six m onth s o f  therapy. A lfu zo sin , terazosin, and tam sulosin 
in d u ced  o n ly  sm all increases in urinary flo w  (m edian i ml/s), and alfuzosin  was the 
o n ly  alpha-blockers that was effective in decreasing p v r , a lth ough  this im provem en t 
was o f  no clin ical significance (15 m l). T h e  decrease in ipss  reflects the subjective im ­
provem ent. O n c e  again, no statistically significant difference was detected am o n g the 
effects o f  the three alpha-blockers.
T h ere  was im provem en t in u r a  and pdetQ m ax w ith o u t statistically significant differ­
ences the effects o f  the three drugs. T h e  decrease in obstructive param eters was too 
sm all to be considered a genuine clin ical desobstruction . T h e  m ajority  o f  patients had
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objective evidence o f  persistent b o o  after six m onths o f  treatm ent regardless the alpha­
blocker used.
W e  d ivid ed  patients at baseline into obstructed  and u n o b stru cted . It appeared that 
those w ith  obstruction  had the m ost im provem en t from  m edical therapy, as u r a  de­
creased 7  versus 2 cm H 2o and pdetQ m ax 6 versus 1 cmH2o in the unobstructed  
pop u lation . O n c e  again, how ever, this statistically significant im provem en t was too 
sm all to be considered a clin ically  relevant predictive param eter for treatm ent outcom e.
W e  confirm  that terazosin, alfuzosin  and tam sulosin are three effective drugs for pa­
tients w ith  l u t s  suggestive o f  b o o . E ven i f  there was n o t a genuine clinical 
am elioration  in urinary flow , p v r  and obstruction  param eters at six m o n th  fo llo w  up, 
patients w ere satisfied w ith  the m edical therapy, w h ich ever alpha-blocker was used, as 
sym ptom s w ere referred to as less bothersom e and q u ality  o f  life im proved.
In our study, no im portan t clin ical im provem en t in b o o  was detected after six m onths 
o f  treatm ent w ith  alpha-blockers, despite the statistically significant decrease in o b ­
structive param eters, and urod yn am ic status at baseline was not predictive o ftreatm en t 
outcom e. R ecent basic and clinical research reveals m an y other possible m echanism s b y  
w h ich  alpha-blockers m ay in fluence l u t s . E xtraprostatic localization  o f  alpha- 
adrenoceptors seems to be in volved  in the pathogenesis o f  l u t s . E xcept for the pres­
ence o f  alpha-adrenoceptors in the prostatic strom a, th ey occu r in the detrusor, 
trigone, urethra, ganglia, spinal, and supraspinal structures. T h e  re lie f o f  fillin g  sym p­
tom s can be explained b y  a beneficial effect o f  alpha-blockers on bladder com pliance 
and/or capacity. A n  additional m echanism  suggested is in d uction  o fp ro sta tic  apoptosis 
b y  alpha-blockers in patients w ith  b p h , bu t is in unclear w h ether this m echanism  adds 
to the therapeutic effect o f  the d rug.21 M a n y  studies, in clu d in g  ours, suggest in vo lve­
m en t o f  m echanism s other than a decrease o f  the d yn am ic co m p o n en t o f  obstruction. 
T h e  clinical significance o f  these various possible m odes o f  action, how ever, rem ains to 
be established.
Because o f  the com plex relation betw een l u t s , b o o  and b p h , attention should be given 
to the m ost appropriate initial evaluation o f  patients affected b y  v o id in g  sym ptom s, 
n o t o n ly  as a m eans to choose the appropriate therapy, bu t also to assess response to 
m edical or surgical treatm ent. F rom  our results, urod yn am ic studies do n o t appear to 
be h elp fu l in evaluating patients w ith  l u t s  before and after m edical treatm ent, as the 
o u tco m e fo llo w in g  m edical treatm ent is unrelated to the grade o f  b o o  and to the 
choice o f  alpha-blockers. D u ra b ility  o f  treatm ent outcom e, how ever, m ay be related to
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the grade o f  b o o  at baseline. T h e  literature is still lackin g  on this theory, and studies on 
d u rab ility  m ay provide outcom es on  b o o  different from  those o btain ed  after a short 
period o f  treatm ent. N evertheless, this factor was not w ith in  the scope o f  our stu dy and 
deserves attention  in a separate analysis.
Conclusion
W e  co u ld  n o t find  an y significant clin ical im provem en t in the param eters o f  b o o  after 
six m onths o f  therapy w ith  alfuzosin, tam sulosin, and terazosin. T h ere  was no im p o r­
tant statistical difference in the subjective and objective effects o f  the three drugs. 
A lth o u g h  w e achieved the best statistical results in patients w h o  w ere obstructed at 
baseline there was no correlation  betw een statistical and clin ical im provem ent, or 
stated differently, urod yn am ic status at baseline does n o t seem to be a selection crite­
rion  to pred ict response to therapy. Because o f  these results, w e can assert that alpha­
blockers are effective for treating the sym ptom s suggestive o f  b o o  in patients w ith  lu ts  
bu t n o t for treating the obstruction .
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Chapter 6
Long-term risk of retreatment in patients 
using alpha-blockers for lower urinary tract
symptoms
Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA, de la Rosette JJ 
Submitted
Objective: The efficacy o f alpha-adrenoceptor blockers in the treatment o f lower urinary tract symp­
toms ( l u t s )  has been proven in numerous studies. Little is known, however, about the efficacy on the 
longer term. We investigated the long-term risk o f retreatment in patients using alpha-adrenoceptor 
blockers for l u t s  and the parameters that influence this risk.
Methods: We reviewed 316 files o f patients with l u t s ,  who were treated in our department with the 
alpha-blockers terazosin, alfuzosin, or tamsulosin. Baseline and follow-up data up to five years were 
assessed. Retreatment percentages were calculated in each treatment group and predictive values for 
retreatment o f the baseline parameters were calculated.
Results: At five years o f follow-up the retreatment percentages o f patients with mild, moderate and 
severe symptoms were 27, 33 and 70%. O f  patients with a maximum uroflow o f less than 10 ml/s and 
more than 10 ml/s the percentages were 58 and 47%, o f patients with a prostate volume o f less than 
40 ml and more than 40 ml these were 48 and 72%, and o f unobstructed versus obstructed patients 
44 and 59%. At three years o f follow-up, the retreatment percentages o f the different alpha-blockers 
were 27% for tamsulosin, 37% for alfuzosin, and 49% for terazosin.
Conclusion: Patients using alpha-blockers for l u t s  have a considerable risk o f retreatment. Severe 
symptoms, a poor uroflow, an enlarged prostate, and urodynamically proven bladder outlet obstruc­
tion increase the risk o f treatment failure. Pre-selection o f the best suitable candidates for alpha­
blockade may reduce this risk.
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Introduction
L o w e r  u r in a r y  t r a c t  s y m p t o m s  (l u t s) suggestive o f  bladder outlet obstruction  
(b o o ), form erly  called ‘prostatism ’, is a prevalent m ictu ritio n  disorder in the m ale 
p o p u la tio n .1,2 A n  enlarged prostate in the presence o f  m oderate to severe l u t s  and/or a 
decreased urinary flo w  occurs in about 25% o f  m en in the com m u n ity, rising from  14%  
in m en aged 40-49 years to 43%  in m en aged 60-69 years.3 In the past, l u t s  w ere usu­
ally  treated b y  either w atch fu l w aitin g  or surgery, p rim arily  transurethral resection o f  
the prostate (t u r p ), bu t the disadvantages o f  the invasiveness and m o rb id ity  o f  such a 
surgical in terven tion  w ere acknow ledged. T h e  last tw o decades m edical therapy has 
filled the gap betw een the tw o treatm ent options.
Preceding research supports the hypothesis that tw o m echanism s exist b y  w h ich  benign 
prostatic hyperplasia (b p h ) m ay cause b o o : T h e  static factor is caused b y  m echanical 
com pression o f  the urethra b y  the b u lk  o f  the prostatic adenom a. T h e  alpha- 
adrenoceptor m ediated sym pathetic stim ulation  o fth e  prostatic sm ooth  m uscle causes 
a flu ctu atin g  influence on  b o o  and is therefore called the d yn am ic factor o f  b o o . T h e  
last factor contributes up to 4 0 %  to the obstru ctio n .4 It has been proven  that b o th  
m echanism s can be in fluenced  b y  pharm acotherapy: 5-alpha-reductase inhibitors re­
duce the size o f  the prostatic adenom a, and alph a-i-ad renocep tor blockers relax the 
prostatic sm ooth  m uscles.
D ru g  therapy is recom m en d ed  for patients w ith  m oderate to severe sym ptom atic dis­
ease, for patients w h o  are aw aitin g surgery and for those w h o  are n o t candidates for 
surgery at all. N ow ad ays, alpha-blockers are w id e ly  used as a first line m edical treat­
m en t for patients affected b y  l u t s  as their safety and effectiveness have been proven in 
num erous random ized  studies.5 It was righ tly  asserted that this class o f  drugs has the 
advantage o f  bein g  fu lly  adapted to the natural h istory o f  b p h  as alpha-blockers p ro ­
duce a rapid re lie f o f  sym ptom s d u rin g  an exacerbation o f  l u t s  and m ay be 
tem porarily  stopped in case o f  rem ission o f  disease. Reasons o f  d iscon tin u ation  o f  al­
ph a-blocker therapy m ay be satisfaction or dissatisfaction w ith  the actual m ictu ritio n  
pattern. T h u s, d iscon tin u ation  is not sim ilar to treatm ent failure.
Little  is k n o w n  about the effect o f  alpha-blockers on the course o f  l u t s  in d aily  prac­
tice. T h e  evaluation o f  this aspect necessitates an analysis o f  the long-term  efficacy o f  
these drugs, w h ich  can be based on the rate o f  secondary interventions. T h e  rate o f  
treatm ent failure and con sequ en tly  the risk o f  retreatm ent for these patients are one 
aspect o f  alpha-adrenoceptor blockers that received little  attention  in previous studies.
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In particular, long-term  risk o f  retreatm ent (> three years) has n o t yet been evaluated, 
alth ough  m ost patients suffer from  l u t s  for m an y years. In addition, little  is kn o w n  
about predictive factors for treatm ent outcom e. Increased kn ow led ge o f  predictive fac­
tors for long-term  treatm ent success m ay help to select the best suitable candidates for 
alpha-blocker-treatm ent.
C u rren tly , there are several alpha-blockers in clinical use. O n  the short term , th ey have 
com parable results con cern in g im provem en t in sym ptom s and flo w  rate, but th ey m ay 
differ in pharm acokinetics, side effects, and alpha-adrenoceptor subtype selectivity. 
D ifferences in long-term  risk o f  retreatm ent are not k n o w n  yet. T h e  aim  o f  the present 
stu d y was to investigate the long-term  risk o f  retreatm ent in patients using alpha- 
b lo ck in g  agents for l u t s  and the param eters that influence this risk.
Methods
W e  review ed the files o f  3I6 n ew ly  d iagnosed patients w ith  l u t s  suggestive o f  b o o , 
w h o  w ere treated w ith  alpha-blockers in our departm ent betw een F ebruary I992 and 
June I99S. O u r  c lin ic  is a referral university hospital, to w h ich  patients are referred b y  
their general practitioner or b y  a urologist from  another hospital. N o  patien t had been 
treated for his com plaints yet. T reatm en t consisted o f  2.5 m g  alfuzosin three tim es 
d aily  in I26 cases, 0.4 m g  tam sulosin d aily in 96 and 5 m g terazosin d aily in 94. Pa­
tients received one o f  the three drugs based on the availability  at that tim e and n o t on 
baseline param eters. Patients w ith  prostate cancer, a urethral stricture, n eu rologic  dis­
orders affecting the low er urinary tract fu n ctio n  and those previously  surgically or 
m ed ically  treated w ere excluded from  the study.
T h e  assessment and fo llow -up  schedule was standardized and sim ilar for all groups. A ll 
patients w ere investigated at baseline w ith  m edical history, assessment o f  sym ptom s 
and quality o f  life according to the International Prostate Sym ptom  Score (ipss), digital 
rectal exam ination, transrectal u ltrasonography o f  the prostate, m easurem ent o f  serum 
prostate specific antigen, urinalysis, u roflow m etry in clu d in g determ ination o f  post vo id  
residual vo lu m e (p v r ) and an urod yn am ic stu dy in clu d in g  pressure-flow  analysis.6 T o  
q u an tify  obstruction , the urethral resistance factor (u r a ) was calculated.7
A  database was m ade in clu d in g  baseline data o f  the patients and fo llo w -u p  data up to 
five years. Patients w h o  received an y form  o f  retreatm ent d u rin g  the fo llo w -u p  period
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w ere classified as non-responders. Patients w h o  co n tin u ed  u sin g alpha-blockers w ere 
classified as responders. Patients w h o  were lost to fo llo w -u p  and patients w h o  stopped 
usin g alpha-blockers w ith o u t retreatm ent were censored at the date o f  last reported 
treatm ent use. Baseline param eter values (age, ip s s , prostate vo lu m e, m axim um  flow  
rate, vo id ed  volum e, p v r , b o o  defined b y  u r a) in the groups o f  patients treated w ith  
the three types o f  alpha-blockers w ere calculated and differences w ere tested u sin g the 
M a n n -W h itn ey -U -test. T h e  overall d iscon tin u ation  percentage was calculated after 
three and five years o f  fo llow -up . T h e  risk o f  retreatm ent in the w h o le  group was calcu­
lated w h ile  acco u n tin g  for loss-to-follow -up  using K ap lan -M eier survival analysis. 
D ifferences in risk o f  retreatm ent w ere tested w ith  the L o g-R an k  test. T h e  predictive 
value for treatm ent failure o f  other baseline param eters, in clu d in g  treatm ent was evalu­
ated in the same w ay. Finally, w e perform ed  a C o x  p roportion al hazard analysis to 
evaluate the retreatm ent rate o f  each baseline param eter w h ile  acco u n tin g  for all other 
baseline param eters. T h e  predictive values o f  all baseline param eters w ere calculated up 
to five years o f  fo llow -u p , except for the type o f  alpha-blocker, for w h ich  w e calculated 
the predictive value at three years o f  fo llo w -u p . T h e  fo llo w -u p  data from  the tam su- 
losin  group w ere restricted to three years, due to the recent date that this drug has 
becom e available. T h e  analyses were perform ed using SAS 6.12 for w ind ow s (SAS Insti­
tute, C ary , N o rth  C arolin a).
Results
Baseline characteristics o f  all patients and o f  patients d ivid ed  b y  type o f  alpha-blocker 
are show n in table 1. C a lcu latio n  o f  differences in baseline param eters betw een the al­
fuzosin, tam sulosin and terazosin group revealed statistically significant differences for 
p v r , pdetQ m ax, and prostate volum e. A ll the other param eters were com parable for the 
three groups. M ea n  p v r  after free u ro flo w  was low er in the group o f  patients treated 
w ith  tam sulosin (9 m l) than in the alfuzosin or terazosin group (31 and 40 m l respec­
tively).
In the w h o le  group the d iscon tin u ation  percentage was 64%  after three years and 7 9 %  
after five years o f  fo llo w -u p  (standard errors (se) w ere 3%  for b o th  percentages). T h e  
overall retreatm ent percentage was 38% after three years and 54% after five years o f  fo l­
lo w -u p  (ses w ere 4 %  and 5% , respectively).
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Table 1 Baseline characteristics of all patients
Median (centiles 25 ; 75)
P-valueAll patients 
(n = 316)
Alfuzosin 
(n = 126)
Tamsulosin 
(n = 96)
Terazosin 
(n = 94)
Age(years) 62 (55 ; 68) 63 (55 ; 68) 61 (55 ; 67) 63 (55 ; 69) 0.67
Qmax(ml/s) 10 (8 ; 13) 10 (8 ; 12) 10 (8 ; 13) 10 (7 ; 14) 0.82
PVR(ml) 26 (0 ; 80) 31 (0 ; 87) 9 (0 ; 49) 40 (11 ; 94) 0.00
IPSS 18 (14 ; 23) 19 (14 ; 24) 18 (13 ; 23) 18 (14 ; 23) 0.69
Quality of Life 4 (3 ; 4) 4 (3 ; 4) 4 (3 ; 4) 4 (3 ; 5) 0.91
pdetQmax 47 (34 ; 66) 49 (35 ; 66) 44 ( 32 ; 59) 52 (35 ; 71) 0.05
URA (cmH2O) 28 (21 ; 37) 29 (22 ; 37) 27 (21 ; 36) 29 (21 ; 38) 0.76
Prostate volume (ml) 31 (25 ; 43) 32 (26 ; 45) 27 (22 ; 38) 34 (26 ; 50) 0.00
Figure i shows the retreatm ent percentage up to five years o f  fo llo w -u p  for patients 
w ith  m ild, m oderate, and severe sym ptom s (total ipss  o f  0-7; 8-19 and 20-35 respec­
tively). Patients w ith  severe sym ptom s at baseline had the highest risk o f  retreatm ent at 
five years (70 % ), w h ile  patients w ith  a baseline ipss  betw een 0 and 7  and 8 and 19 had 
a retreatm ent percentage o f  27 to 33 at five years, respectively.
F igure 2 shows the retreatm ent percentage up to five years o f  fo llo w -u p  for a baseline 
m axim um  flo w  (Qmax) o f  less than 10 ml/s and m ore than 10 ml/s. T h ere  is a sm all 
difference in retreatm ent percentage o f  58% and 4 7 % , respectively, betw een the tw o 
groups (p-value = 0.19). U sin g  a c u t-o ff value o f  15 ml/s the difference in risk o f  re­
treatm ent becom es obvious: 58% and 21%  for a Qm ax o f  < 15 ml/s and > 15 ml/s, 
respectively. T h u s, patients w ith  a Qm ax o f  less than 15 ml/s are m u ch  m ore lik e ly  to 
receive a retreatm ent w ith in  five years than patients w ith  a h igher Qmax. R etreatm ent 
percentages w ere also calculated for vo id ed  vo lu m e and p v r , bu t d id  n o t sh ow  an y sig­
n ificant difference using a c u t-o ff value o f  150 m l for b o th  vo id ed  vo lu m e and p v r .
Figure 3 shows the difference in retreatm ent percentage w ith  prostate vo lum e as predic­
tive param eter. Patients w ith  prostates larger than 40 m l are m ore lik e ly  to receive a 
retreatm ent w ith in  five years than patients w ith  a sm aller prostate (72%  versus 48% ).
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Figure 3 Retreatment stratified by prostate Figure 4 Retreatment stratified by obstruction
volume
Figure 4 illustrates the rate o f  failure o f  m edical treatm ent in obstructed (u r a  > 29) and 
in u nobstructed  (u r a  < 29) patients. T h o se  w h o  were obstructed at baseline had a re­
treatm ent in 59%  o f  cases, w h ile  patients w ith o u t obstruction  received retreatm ent in 
the 4 4 %  o f  cases after five years o f  fo llow -u p .
Figure 5 shows the retreatm ent rate, d iv id in g  patients b y  type o f  alpha-blocker, up to 
three years o ffo llo w -u p . T h e  differences in retreatm ent percentages betw een the three 
types o f  a lpha-blocker w ere significant. T erazosin  had the greatest p ro p o rtion  o f  treat-
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m en t failure (49% ), fo llo w ed  b y  alfuzosin (37% ), w h ile  tam sulosin had a retreatm ent 
rate o f  2 7 % . A s the baseline values for m ean prostate vo lu m e differed for the treatm ent 
groups, w e corrected the retreatm ent percentages o f  the three alpha-blockers for pros­
tate vo lu m e. T h is  adjustm ent d id  not have an in fluence on the results. In the first tw o 
years o f  fo llo w -u p , the lines representing alfuzosin  and terazosin run parallel and d i­
verge after the second year o f  fo llo w -u p , w h ile  the line representing tam sulosin is the 
low est th ro u gh o u t the w h o le  period.
T a b le  2 shows the results o f  the m ultivariate analysis. E specially the risk o f  retreatm ent 
rem ains significantly different for the sm all and the larger prostates. For the other base­
line param eters sim ilar trends are visible as in the survival analyses.
Follow-up (years)
Figure S Retreatment percentages of three alpha-blockers during three years of follow-up
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Table 2 Proportional hazard analysis evaluating the retreatment rate of each baseline parameter, while accounting 
for the other baseline parameters
Label N Hazard Ratio(95% CI) P-value
Treatment alfuzosin 101 1 -
tamsulosin 86 0.59 (0.30 - 1.18) 0.14
terazosin 79 1.16 (0 .6 7 - 2 .01) 0.59
IPSS 0-7 11 1.00
7-19 143 0.85 (0.26 - 2 .80) 0.79
20-35 112 1.30 (0.40 - 4 .27) 0.66
Obstruction absent 132 1.00 -
present 134 1.27 (0.75 - 2 .14) 0.38
Qmax > 10 117 1.00 -
<= 10 149 1.12 (0.67 - 1.89) 0.66
Prostate volume < 40 187 1.00 -
>= 40 79 2.11 (1.28 - 3 .47) 0.00
Discussion
Success o f  a treatm ent for b p h  is usually defined b y  im provem en t in u ro flo w m etry  pa­
ram eters and sym ptom s, but it also depends on  the necessity for retreatm ent and the 
interval betw een the initial treatm ent and the tim e o f  retreatm ent. In m ost studies on 
the effect o fa lp h a-b lo ckers, retreatm ent is n o t in clud ed  in the evaluation, as it requires 
a longer period  o f  fo llo w -u p  o f  preferably several years. F ew  reports on open-label ex­
tensions o f  p lacebo-con tro lled  trials exist that evaluate long-term  efficacy o f  alpha­
blockers. Jardin et al. report the long-term  results o f  alfuzosin  treatm ent after 30 
m onth s fo llo w -u p , bu t a w ith draw al rate can n o t be deduced from  their stu dy.8 Lepor 
et al. show ed 43%  w ith draw al from  terazosin treatm ent after 42 m onths fo llo w -u p .9 In 
a stu dy on  the long-term  effects o f  doxazosin b y  L epor et al. 4 9 %  o f  patients d iscon ­
tin u ed  the use o f  doxazosin w ith in  four years o f  fo llow -u p . In a study on  the long-term  
efficacy o f  tam sulosin b y  Schulm an et al. a d iscon tin u ation  rate o f  60 %  after three 
years o f  fo llo w -u p  is m en tio n ed .10,11 In these studies the w ith draw al rate due to adverse 
events ranges from  15 to 2 0 % . T h e  w ith draw al rate in the present stu dy o f  6 4 %  after 
three years corresponds w ith  the results b y  Schulm an et al.
T h e  considerations u n d erlyin g the decision to p u t em phasis on retreatm ent and not on 
d iscon tin u ation  in this analysis are as follow s. T h e  d iscon tin u ation  rate includes pa­
tients w h o  do not need therapy anym ore, as their l u t s  are sufficiently relieved, patients
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w h o  prefer to bear their l u t s  w ith o u t therapy and patients w h o  need a retreatm ent. 
Patients lost to fo llo w -u p  m ay also be in clud ed  in the d iscon tin u ation  rate. T herefore, 
d iscon tin u ation  rate is n o t a g o o d  m easure to determ ine the efficacy o f  a treatm ent. 
R etreatm ent rate, on  the other hand, includes o n ly  those patients w h o  need additional 
therapy, as their l u t s  are n o t relieved. T h e  disadvantage o f  using retreatm ent rates is 
that th ey do n o t includ e patients w h o  are n o t satisfied w ith  a treatm ent, bu t do not 
w an t additional therapy.
Patients enrolled  in a clin ical trial under rand om ized  and d ouble-b lin d , placebo co n ­
trolled  con d ition s rather differ in term s o f  their percep tion  o f  treatm ent effectiveness 
and their reaction to m in im al or no sym ptom  im provem en t from  those patients, w h o 
are treated outside o f  trials, in private practices and co m m u n ity  settings. T h e  present 
study is not a prospective, random ized study. W e  retrospectively evaluated the group o f  
patients that w ere treated w ith  alfuzosin, tam sulosin, or terazosin in our clin ic  and u n ­
derw ent a standardized assessment and fo llo w -u p  schedule. T herefore, this stu dy gives 
a realistic p icture o f  the course o f  these patients in the d aily  practice. A  n o n ­
rand om ized  treatm ent assignm ent does not m ake evaluation o f  predictive param eters 
im possible, i f  all the progn ostic factors are incorporated  into  the analysis.12
F rom  our results, several baseline param eters appeared to be predictive for the risk o f  
retreatm ent w ith in  five years. In patients w ith  severe sym ptom s alpha-blocker treat­
m en t w ill fail in 50%  after three years and in 7 0 %  after five years. It is interesting that 
in the first tw o years o f  fo llo w -u p  the risk o f  retreatm ent seems sim ilar, regardless o f  
the total sym ptom  score. A  lo w  Qmax, w h ich  often  goes together w ith  a higher grade o f  
b o o , increases the risk o f  retreatm ent. M a n y  studies on  alpha-blockers use a cu t-o ff 
value for inclusion  o f  15 ml/s for Qm ax, a lth ough  urologists and general practitioners 
often  prescribe alpha-blockers for l u t s  in patients w ith  a better flow . A pparently, these 
patients are satisfied w ith  alpha-blocker treatm ent for a longer period.
Patients w ith  larger prostates have h igher retreatm ent percentages than those w ith  
sm aller prostates. T h ere  has n o t been a guideline yet that tells us n o t to treat som eone 
w ith  a b ig  prostate w ith  an alpha-blocker. T herefore, these results m ay help the d octor 
to choose betw een an alpha-blocker and finasteride in a specific patien t based on the 
p a tien t’s estim ated prostate vo lu m e. A  patient w ith  a large prostate m ay be better o ff  
w ith  a 5-alpha-reductase in h ib itor, as this d ru g has proven to be m ore effective for b ig ­
ger prostates, w h ile  a patien t w ith  a sm aller prostate m ay need an alpha-blocker, 
because his sym ptom s are m ain ly  caused b y  a d yn am ic obstruction.
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C o m b in in g  baseline param eters enables the identification  o f  patients w ith  the highest 
risk o f  retreatm ent. For patients w ith  an ipss  < 20 and for patients w ith  a Qm ax > 15 
ml/s the risk o f  retreatm ent stabilizes after tw o years, bu t for all the other predictive 
param eters this risk gradually increases d u rin g  the years. I f  w e extrapolate the lines, one 
m ay expect that after five years o f  treatm ent the risk o f  retreatm ent w ill co n tin u e to 
increase. S u ch  an increase m ay be explained b y  the th eo ry  that alpha-blockers do not 
influence b p h  progression, a lth ough  th ey do relieve sym ptom s.
T h e  different retreatm ent percentages after tw o years are sm all for m ost param eters. 
O n ly  after three or m ore years, the lines diverge. T h is  fin d in g  underlines the necessity 
for studies w ith  a long-term  fo llo w -u p  i f  one is interested in differences in efficacy o f  
treatm ents. W e  cannot conclude from  our study w hether the differences in retreatm ent 
rate are caused b y  a difference in efficacy or in side effects. Patients m ay w ell be less 
co m p lian t or choose another treatm ent based on  the experienced side effects.
M o reo ver, one m ay question  w h ether the stu dy groups w ere identical at baseline. As 
patients w ere n o t random ized  to use one o f  the three alpha-blockers, one m ay expect 
differences in baseline characteristics betw een the three groups. A fter calculation  o f  
these differences, it appeared that o n ly  p v r , pdetQ m ax, and prostate vo lu m e w ere not 
statistically com parable. T h e  m ean p v r  in the tam sulosin group was evidently less than 
in the other groups, bu t alth ough  the difference was statistically significant, it is not 
clin ically  relevant. T h e  sam e holds for the statistically significant differences in 
pdetQ m ax and prostate vo lu m e betw een the three groups. T h e  difference betw een a 
prostate o f  27, 32 or 34 m l is clin ically  irrelevant as th ey are all in the range o f  ‘sm all 
prostates’ . O n e  co u ld  even ask w h ether these differences in p v r  and prostate vo lu m e 
are real, considering the rep ro d u cib ility  o f  the m easurem ent o f  p v r  and prostate v o l­
um e using transabdom inal and transrectal u ltrasound respectively.
Since the prevalence o f  m en w ith  l u t s  is h igh  in the co m m u n ity , there is a b ig  need 
for alpha-blockers. T h e y  are w id e ly  prescribed b y  fam ily  practitioners and urologists 
w ith o u t pre-treatm ent patien t selection. In other w ords, in all m en w ith  l u t s  one can 
give an alpha-blocker on a trial base. In this w a y  o f  prescribing alpha-blocker, treat­
m ent has a substantial m acro-econom ical im pact. T herefore, im provem ent in selection 
o f  patients w h o  w ill benefit from  alpha-blocker treatm ent on the lo n g  term  w ill have 
considerable consequences for health service costs. T h e  results o f  this stu dy enable us to 
define patients w ith  a h igh  risk o f  retreatm ent, i.e., the patient w ith  severe sym ptom s, a 
p o o r u roflow , a b ig  prostate, and significant u ro d yn am ic obstruction . M oreover, this 
stu d y indicates that d urability  o f  alpha-blockers m ay be different.
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Pa r t  III
U r o d y n a m ic s  a n d  h is t o p a t h o l o g y
OF THE BLADDER WALL

Chapter 7
Bladder outlet obstruction does not change 
bladder wall morphology
Kortmann BB, Holm NR, Smedts F, Horn T, Nordling J, Kiemeney LA, de la Rosette JJ 
Submitted
Objective: Histologic changes in the human bladder wall are believed to be related more to aging 
than to bladder outlet obstruction. These changes however, have never been correlated with urody- 
namic obstruction parameters. The aim of this study was to determine if there is a correlation 
between microscopic changes in the bladder wall and urodynamic obstruction parameters.
Methods: Deep bladder biopsies were taken in 63 consecutive patients who underwent a transurethral 
resection of the prostate. The biopsies were independently evaluated using light microscopy by two 
pathologists for the following histologic features: fibrosis, elastosis, inflammation and muscle cell de­
generation, after which consensus was achieved. The pre-surgical clinical and urodynamic data were 
correlated with the histologic observations.
Results: O f  the 63 biopsies, 54 could be evaluated. More than half o f the biopsies were normal. No 
correlation was found between the histologic features and Schäfer class, u r a ,  instability, post-void 
residual volume, symptom score, and prostate volume. Furthermore, no correlation was found with 
patient age, although in the group o f patients with histologic abnormalities, severity increased with 
age.
Conclusion: Histologic changes in the bladder wall do not correlate with urodynamic obstruction 
parameters, clinical parameters, or patient age.
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Introduction
In  t w o  t h ir d s  o f  the cases, low er urinary tract sym ptom s (l u t s) are caused b y  benign 
prostatic obstruction  (b p o ), a disease w ith  a generally gradual onset and a lo n g  dura­
tio n .1 C o n sid erin g  the close relationship betw een prostate and bladder, it seems 
probable that bladder outlet obstruction  (b o o ) effects the an atom y and fu n ction  o f  the 
bladder.
A n im a l studies sh ow  that b o o  m ay result in m o rp h ologic  and fu n ction al changes in 
the bladder w all. A rtificia l b o o  in anim al species, such as the rabbit, rat, cat and pig, 
sh ow  that b o o  causes an eight- to ten fo ld  increase in bladder w eigh t attributable to 
hypertrophy and hyperplasia o f  sm ooth m uscle cells and increased interstitial collagen.2- 
9 In all these studies the m ost o utstan d in g fu n ction al change caused b y  b o o  is an im ­
paired ab ility  to em p ty  the bladder w ith o u t a decrease in m axim um  vo id in g  pressure. 
R ecovery after short-term  artificial partial b o o  occurs rapidly bu t in com pletely. T h e  
bladder w eigh t rem ains h igh  com pared to controls and the ab ility  to em p ty the bladder 
rem ains partially im paired .3,10 Based on the results o f  these anim al studies it was h y ­
pothesized  that changes in the h um an  bladder w all m ay be correlated w ith  b o o  and 
l u t s . G ilp in  et al. observed sm ooth  m uscle h yp ertro p h y and increased interstitial co l­
lagen in the detrusor bundles in response to b o o .11 O th e r  studies, how ever, do not 
confirm  the relationship betw een h isto logic  features and obstruction . Som e suggest 
that m o rp h o lo gic  changes in the bladder w all related to agin g m ay m ake it d ifficu lt to 
evaluate the effects attributable to b o o .12 H o lm  et al. studied the presence o f  fibrosis o f  
the detrusor in m en w ith  l u t s  suggestive o f  b o o  and in controls. T h e y  observed sim i­
lar degrees o f  fibrosis in b o th  obstruction  and agin g.13
H isto lo gic  changes in the bladder w all cou ld  be essential in explaining the variability  in 
therapeutic results o f  desobstructive therapy, particularly in cases in w h ich  therapeuti­
cal in terven tion  does n o t result in alleviation o f  l u t s . In this last group o f  patients, a 
bladder b iop sy m ay have a role in pre-treatm ent w o rk-u p . T o  our know led ge, a stu dy 
in w h ich  u rod yn am ically  proven b o o  has been correlated w ith  ligh t m icroscop ic his­
to lo gic  features has never been perform ed. T h u s, to date, there is no clear concep t 
regarding the effect o f  b o o  on the h u m an  bladder w all. In this study, w e assessed the 
correlation betw een h isto logic  features in the h um an  detrusor m uscle and the grade o f  
obstruction  as assessed b y  u ro d yn am ic studies in clu d in g  pressure-flow  analysis.
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Methods
Sixty-three consecutive patients w ith  l u t s , w h o  were eligible for transurethral resection 
o f  the prostate (t u r p ) based on the diagnostic w ork-up results, w ere recruited from  our 
outpatien t clin ic  (D ep artm en t o f  U ro lo g y, U n iversity  M ed ica l C en tre , N ijm egen , the 
N etherlands) for this study. W o rk -u p  in clu d ed  assessment o f  sym ptom s using the In­
ternational Prostate Sym ptom s Score (ipss), digital rectal exam ination, b lo o d  and urine 
analysis, uroflow m etry, and m easurem ent o f  post-void  residual vo lum e, transrectal u l­
trasound m easurem ent o f  prostate volum e, urethrocystoscopy and urod yn am ic studies 
in c lu d in g  pressure-flow  analysis.
A ll u rod yn am ic studies w ith  pressure-flow  analysis were perform ed under standardized 
con d ition s. B efore in tro d u cin g  the catheters an instillation  gel, co n ta in in g  lidocaine 
and antibacterial agents (Farco Pharm a, C o lo g n e, G erm any), was applied. A n  8f cathe­
ter m o u n ted  w ith  a m icro-tip  sensor (m t c , D rager, G erm an y), to fill the bladder and 
to record intravesical pressures, was introduced under sterile conditions, w h ile  a second 
8f m icro-tip  catheter was used to record rectal pressures. D u rin g  cystom etry, the blad­
der was filled w ith  ph ysio lo gic  saline o f  20°c  at a fillin g  rate o f  50 m l/m in. D u rin g  
m icturition , uroflow , and intravesical and abdom inal pressures were recorded sim ulta­
neously. F lo w  rate was m easured w ith  a rotatin g  disk flow m eter (D an tec U ro d yn  
flow m eter, D an tec, Skovlun d e, D en m ark). A ll data w ere d ig ita lly  stored and analyzed 
w ith  an urod ynam ic analysis program  developed in our departm ent (u ic /b m e  Research 
centre, D ep artm en t o f  U ro lo g y, U n iversity  M ed ica l C en tre  N ijm egen , the N e th er­
lands).
D u rin g  the transurethral surgery, co ld -cup  full thickness biopsies were taken from  the 
bladder w all. C are  was taken n o t to includ e tissue from  the trigone. D ire ctly  after re­
m oval the tissue, sam ples w ere snap frozen in liq u id  n itrogen  and stored at -70 °c . A ll 
biopsies w ere transferred to a 4 %  buffered form alin  solu tion  for approxim ately  24 
hours after w h ich  th ey w ere processed th rou gh  paraffin. T h e  rem aining biopsies w ere 
stored for future im m u n oh istoch em ical and b ioch em ical studies. From  each paraffin 
b lock, ten consecutive 4 |im th ick  sections were cut and m ou n ted  on coated slides. Sec­
tions w ere stained for m icroscop ic evaluation w ith  H & E , V a n  G ieson , p icric acid and 
orcein  m ethods for routine evaluation, assessment o f  sm ooth  m uscle, fibrous tissue, 
and elastin fibers respectively.
T w o  experienced pathologists (T H , FS) separately evaluated the fo llo w in g  features in 
each biopsy: Intra- and interfascicular (i) fibrosis and (2) elastosis o f  the detrusor m us-
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cle, (3) degenerative changes o f  the detrusor m uscle cells, (4) signs o f  inflam m ation and 
(5) any other rem arkable change. A n  overall diagnosis o f  norm al or abnorm al was given 
for each biopsy, w h ich  in the case o f  an abn orm ality  was graded. A fo rem en tio n ed  fea­
tures w ere sem iquantitatively scored accord in g to the fo llo w in g  scale: absent: (-), 
m ild ly  present: (+), m od erately present: (++), severely present: (+++). A fte r  in d ep en d ­
ent evaluation, the pathologists re-evaluated each b iop sy d u rin g  a consensus m eeting. 
T h e  results o f  this jo in t evaluation w ere used in the analyses. H isto lo g ic  features w ere 
correlated w ith  the urodynam ic obstruction parameters, several clinical parameters, and 
patien t age.
Statistical analysis
In order to evaluate the effect o f  u ro d yn am ic obstruction  and age (as w ell as other 
clin ical param eters such as prostate vo lu m e, p ost-void  residual vo lu m e after free 
uroflow m etry, bladder instability, com pliance and bladder capacity) on h isto logy o f  the 
bladder w all, w e used logistic regression analyses. In these analyses, the consensus d iag­
nosis o f  b o th  pathologists (norm al versus abnorm al) was considered as independent 
variable. T h e  obstruction  param eters urethral resistance factor (u ra ), detrusor pressure 
at m axim um  flo w  (pdetQm ax), and Schäfer class and age were considered possible pre­
dictors. In order to avoid arbitrary c u t-o ff values all these param eters w ere entered in 
the m odels as con tin u ou s variables. For each h isto logic param eter three m odels w ere 
constructed: age + u r a , age + Schäfer score, and age + pdetQ m ax. Furtherm ore, a step­
w ise m od el (inclusion and exclusion criteria p = 0.10 and p = 0.15, respectively) was 
constructed  for consensus diagnosis and age, u r a , prostate vo lu m e, post-void  residual 
vo lu m e, bladder instability, bladder com pliance, and bladder capacity as possible pre­
dictors.
In order to visualize the strength o f  the association betw een the predictors and the his­
to lo gic  features, w e sum m arized the results in receiver operating characteristic (r o c ) 
curves. T h e  area under the curve (a u c ) was calculated as a single m easure for associa­
tion . In case a (com bin ation  of) predictor(s) has no influence on histology, the a u c  is 
close to 0.5. In case there is a strong association, the a u c  w ill be close to 1.0. A bsen ce o f  
the value 0.5 in the 95%  con fid en ce interval for the a u c  indicates a statistically sig­
n ificant predictive value. T h e  analyses w ere perform ed  using SPSS release 9.0.
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Results
O f  the 63 patients, 54 co u ld  be further evaluated. N in e  patients w ere n o t in clu d ed  be­
cause their biopsies d id  not includ e detrusor m uscle, and in three patients the 
urod yn am ic studies w ere incom plete. T a b le  1 shows the d istribution o f  the various his­
to lo gic  features observed in the bladder biopsies. Intra-fascicular fibrosis, intra- 
fascicular elastosis, and fatty  infiltration  are m ost frequ en tly  observed (figures 1-3). A t ­
ro p h y  o f  detrusor m uscle, degenerative changes in the artery w all, fibrosis o f  the 
m ucosa, h yp ertro p h y o f  the m uscularis m ucosae and variation  in the nuclear density 
w ere sporadically observed in the biopsies.
T a b le  2 shows the correlation betw een the overall h isto logic diagnosis and the grade o f  
b o o , expressed in Schäfer class. T h ere  was n o t an y patien t w ith o u t obstruction  
(Schäfer class ‘0 ’). T h e  h istologic features are equally distributed over all Schäfer classes 
and in each Schäfer class at least h a lf  the patients have a bladder b iop sy diagnosed as 
norm al (figure 4). T h ere  was no correlation  betw een the features; intra- and inter­
fascicular fibrosis, intra- and inter-fascicular elastosis and fatty  infiltration  and the uro­
d yn am ic obstruction  param eters Schäfer class, u r a  and pdetQ m ax. T h ere  was no 
correlation betw een h isto logic  features and patien t age. T h ere  was a w eak  correlation 
betw een the severity o f  h isto logic  features and age.
Table 1 Distribution of histologic features in 54 bladder biopsies from patients with bladder outlet obstruction
Absent
(-)
Mildly present 
(+)
Moderately 
present (++)
Severely 
present (+++) Missing
Intra-fascicular fibrosis 35 11 4 4 0
Inter-fascicular fibrosis 45 2 3 2 2
Intra-fascicular elastosis 38 12 4 0 0
Inter-fascicular elastosis 48 4 1 0 1
Muscle cell degeneration 50 3 1 0 0
Inflammation* 49 5 - - 0
Fatty infiltration* 38 16 - - 0
* only present or absent
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Figure 1 Severe intrafascicular fibrosis of the bladder wall. Individual and small groups of muscle fibers are 
separated by collagenous tissue. (Magnification 400x, AZAN staining)
Figure 2 Intrafascicular elastosis of the bladder wall. The detrusor muscle is split up by darkly staining 
elastic fibers. (Magnification 250x, van Gieson's elastin staining)
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Figure 3 Fatty infiltration of the bladder wall. Note the fatcells as oval to round white spaces just above the 
detrusor muscle. Note also the lymphocytic infiltration between urothelium and fat. (Magnification 
250x, HCE staining)
Figure 4 Normal bladder biopsy lined by four to five layers of urothelial cells lying on a narrow mucosa 
under which there is a normal detrusor muscle. (Magnification 250x, HCE staining)
O n e  patient w ith  severe b o o  had severe fibrosis and elastosis o f  the detrusor and a h y ­
p ertrophic m uscularis m ucosae. T h is  59-year o ld  patien t also had  severe l u t s , a 
prostate o f  32 gram s, a trabeculated bladder on cystoscopic exam ination, bu t a stable 
bladder d u rin g  cystom etry. H e  had a m ild  urinary tract in fection  tw o m onth s before 
surgery, bu t had  no evidence o f  an y other disease that m igh t have in flicted  the bladder 
con d itio n .
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Table 2 Correlation between Schäfer class and overall histologic diagnosis of biopsy
Schäfer class
Diagnosis
Normal Abnormal Very abnormal Highly abnormal
One 2 2 0 0
Two 6 2 2 0
Three 10 0 3 1
Four 13 4 0 1
Five 3 1 0 0
Six 0 0 0 1
Figure 5 shows r o c  curves illustrating h o w  age and u ro d yn am ic param eters can dis­
crim inate betw een abnorm al and norm al bladder biopsies. Sm all areas under the curve 
indicate a w eak  predictive value o f  the urod yn am ic obstruction  param eters and age, 
w hatever obstruction  param eter was used. Figure 5D shows that instability o f  the detru­
sor, residual vo lu m e after free uroflow m etry, and prostate vo lu m e are n o t able to 
predict h istologic changes either, as they w ere n o t in clud ed  in the final stepwise m odel. 
C o m p lia n ce  and capacity o f  the bladder, how ever, do have a sm all and statistically sig­
n ificant predictive value.
Discussion
In the present analyses, the h isto logy o f  the bladder w all does not appear to correlate 
w ith  b o o  nor w ith  an y other clin ical param eter, in clu d in g  age. T h e  last is in contrast 
w ith  a ligh t m icroscop ic stu dy b y  H o lm  et al. and a stu dy using quantitative m o r­
p h o m etry  b y  L epor et al. sh o w in g an association betw een b o o  and age.12,13
T h e  o n ly  rem arkable result was observed in the group o f  patients w ith  one or m ore 
abnorm alities in the detrusor m uscle. In this group, there was a positive correlation 
betw een the severity o f  the h isto logic changes and age. T h is  observation can be ex­
plained  b y  accep tin g  that in som e people the detrusor m uscle can w ith stan d  agin g  and 
retain its norm al m o rp h o lo g y  w h ile  in others the detrusor is susceptible to aging, 
w h ich  is accom p an ied  am ongst others b y  severe fibrosis. O n e  patien t had  severe b o o  
and severe h isto logic  changes. A lth o u g h  this is o n ly  one case, it m ay indicate that se­
vere b o o  does cause dam age to the detrusor.
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i-specificity i-specificity
i-specificity i-specificity
Figure S ROC curves depicting the ability of age and urodynamic parameters to discriminate between an abnormal versus 
a normal bladder wall.
A: age and URA
B: age and pdetQmax
C: age and Schäfer class
D: stepwise model with inclusion and exclusion criteria p = O.iO and p = 0 .i5
A lth o u g h  an association co u ld  be expected betw een the u ro d yn am ic bladder fu n ctio n  
param eters and h isto lo g y  o f  the bladder w all, w e o n ly  fo u n d  a w eak  correlation  be­
tw een bladder com plian ce and capacity, m easured b y  urodynam ics, and h isto logy. A n  
im portant question is w h y  w e d id  not observe a correlation betw een b o o  and h istology
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o f  the bladder w all, as opposed  to anim al studies, in w h ich  clear correlations have been 
reported. C lo se ly  related to this question, is there indeed no correlation or are w e just 
n o t able to dem onstrate it?
In this stu dy the intra- &  inter- investigator variation betw een tw o pathologists in the 
m icroscop ic evaluation o f  h isto p ath o lo gy o f  bladder biopsies w ere considerable. T h e  
variation  was n o t o n ly  lim ited  to ind ivid ual features bu t also to the overall diagnosis o f  
norm al or abnorm al (tables 3 & 4). T h is  fin d in g  underlines the con clusion  that evalu­
atin g biopsies w ith  respect to various features and co m in g  to a diagnosis o f  norm al or 
abnorm al is n o t u n am biguou s and perhaps very  d ifficult. Several explanations are pos­
sible. First, one sm all b iop sy w ith  a diam eter o f  approxim ately 2 m m  m ay n ot be 
representative o f  the w h ole  bladder. Second, d urin g evaluation o f  the b iop sy a p ath olo­
gist m ay place m ore or less em phasis on a particular feature, especially i f  it is o n ly  
m argin ally present. T h is  problem  is n o t un ique for the evaluation o f  bladder biopsies, 
the w h o le  problem  o f  intra- and inter-observer variation  has been extensively re­
searched e.g. in the uterine cervix and particularly in low -grade pre-m alignant cervical 
lesions m oderate kappa correlations are the very  best one can achieve.14 Furtherm ore 
pathologists concede that w h at constitutes a norm al b iop sy in the con text o f  patient 
age is d ifficu lt to define.
U ro d yn am ic studies, in clu d in g  pressure-flow  analysis, are considered the gold  standard 
to assess b o o , bu t have their lim itations as a diagnostic to o l.15,16 First, there are factors 
that influence the rep ro d u cib ility  o f  the urod yn am ic results. Second, the investigation 
is perform ed in an iatrogenic and n o n -p h ysio lo gic  environm ent. T h ird , operator and 
technical equipm en t influence test results. Furtherm ore, there m ay be p h ysiologic vari­
ab ility  in the grade o f  obstruction . T h e  m axim u m  flo w  appears to fluctuate due to a 
circadian rh y th m .17 T h is  circadian rhythm  in u ro flo w  m ay very  w ell be caused b y  a 
fluctuation  in b o o  or detrusor contractility. T h is  m atter has n o t been clarified.
Table 3 Intra-observer variation in biopsy evaluation
Conclusion one
Conclusion two
Normal Abnormal Very abnormal Highly abnormal
Normal 14 6 0 0
Abnormal 5 13 2 0
Very abnormal 1 4 2 0
Highly abnormal 0 0 1 0
six biopsies were considered inconclusive in at least one of the two evaluations
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Table 4 Inter-observer variation in biopsy evaluation between the pathologists TH and FS
Conclusion TH
Conclusion FS
normal abnormal very abnormal highly abnormal
normal 17 3 0 0
abnormal 3 15 2 0
very abnormal 1 5 3 0
highly abnormal 0 0 1 0
four biopsies were considered inconclusive by at least one of the two pathologists
R ecently, w e perform ed tw o studies on  the rep ro d u cib ility  o f  pressure-flow  studies, in 
w h ich  w e fo u n d  a m oderate intra-patient rep ro d u cib ility  o f  pressure-flow  studies, per­
form ed  d u rin g  tw o different sessions and a considerable intra- and inter-investigator 
variation  in the analysis o f  pressure-flow  studies.18,19 A  fluctuation  in the grade o f  o b ­
struction  m akes correlation w ith  bladder w all h isto lo g y  d ifficult, but, to date, w e have 
no better tool to establish b o o  than urodynam ics.
U ro d yn a m ic studies provide a random  picture o f  the low er urinary tract at a particular 
m om en t. M ean w h ile  bladder biopsies m ay sh ow  effects that are caused b y  p o o rly  defi­
ned p ath o logic  processes o f  u n k n o w n  duration, such as b o o , aging, in fection , and 
other factors that m ay influence bladder w all m orp h ology.
In contrast to h um an  studies, b o o  in all anim al studies was created artificially b y  a ure­
thra stenosis. C on sequen tly, a perm anent, constant degree o fo b stru ctio n  is created and 
the tim e o f  im plem en tation  is precisely kn o w n . T h e  degree o f  obstruction  is related to 
fu n ction al and structural changes.20
T h e  above-m en tion ed  factors m ay explain w h y  w e d id  n o t find  a correlation. Larger 
num bers o f  patients m ay be needed. O u r  overall patien t group was n o t very  large, but 
especially the fact that m ost h isto logic features w ere n o t frequent, m ay be im portant. 
O n  the other hand, there m ay be m ore sensitive h isto logic param eters, than fibrosis 
and elastosis o f  the detrusor to determ ine changes caused b y  b o o . B etter correlations 
m ay be fo u n d  using other techniques, such as quantitative m o rp h o m etry  or im m u n o - 
histochem istry. I f  changes due to b o o  are too subtle to be ligh t m icroscop ically  
identified, electron m icroscop y m ay give better results. E lbadaw i perform ed extensive 
studies in this field co n clu d in g  that b o o  is associated w ith  specific ultrastructural 
changes in the detrusor m uscle that can explain resultant vo id in g  d ysfu n ctio n .21,22
109
A ll patients enrolled  in this stu dy had l u t s  suggestive o f  b o o  and w ere ju d ged  to be 
eligible for t u r p , a lth ough  som e patients had  o n ly  m ild  b o o , as established b y  urody- 
nam ics. O f  course, a stu dy w ith  biopsies from  a control group o f  age-m atched m en 
w ith o u t l u t s  and b o o , w o u ld  have been preferable. U n derstandably, it is d ifficu lt to 
recruit m en for this con tro l group w h o  are w illin g  to undergo u ro d yn am ic studies and 
bladder biopsies.
Conclusion
T h is  stu dy shows that there is no correlation betw een urod ynam ic obstruction  param e­
ters and fibrosis or elastosis o f  the detrusor m uscle. T h ese features are observed in both  
severely obstructed patients and in patients w ith  o n ly  m ild  obstruction  and in the pres­
ence o f  b o o  b ladder w all m o rp h o lo g y  m ay be co m p letely  norm al. Furtherm ore, it 
shows that the h isto lo gy  o f  the bladder w all does n o t significantly correlate w ith  c lin i­
cal param eters, in c lu d in g  patien t age. T h u s, elderly m ales w ith  b o o  m ay have norm al 
appearing bladder walls, w h ile  yo u n ger males w ith  hard ly  an y b o o  m ay have bladder 
walls that sh ow  considerable abnorm alities.
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G en er a l  d is c u s s io n

Summary
T his th esis  ad dresses  aspects o f  urodynam ic studies in men w ith lower urinary tract 
sym ptom s (lu ts). There are different underlying causes o f  l u t s , but luts are usually 
associated w ith  benign prostatic hyperplasia (b p h ). U p till now, the pathogenesis o f  
luts has not been com pletely clarified and the assessment o f  luts  is not unam biguous.
In the introduction, the concept o f  luts and the supposed relationship between lu ts , 
bph  and bladder outlet obstruction (b o o ) are explained. D ifferent tools in the assess­
m ent o f  luts are sym ptom  scores, uroflowmetry, transrectal ultrasound o f  the prostate, 
and urodynam ic studies including pressure-flow analysis. U rodynam ic studies are con­
sidered the gold standard to diagnose b o o , but the standard use o f  urodynam ic studies 
in the diagnosis o f  lu ts is controversial.
There are several treatments for luts suggestive o f  b o o , such as medical, m inim al inva­
sive and surgical therapies. As urodynam ics are considered the best tool to establish 
b o o , they should also be part o f  the evaluation o f  the treatment effect.
O n e o f  the arguments not to use urodynam ics in the standard work-up o f  men w ith 
l u t s , is the invasiveness o f  the investigation. In part I, a study on the tolerability o f  
urodynam ic studies is presented. U rodynam ic studies in our clinic appeared to be asso­
ciated w ith a low  proportion o f  urinary tract infection, and low  subjective and 
objective m orbidity. M ost patients found urodynam ic studies tolerable and not very 
bothersome. Furthermore, we studied the reproducibility o f  pressure-flow studies (pfs) 
by assessing the variability o f  pfs, perform ed at two different occasions and the intra- 
and inter-investigator variation in the analysis o f  p f s . A  considerable variability in the 
results o f  a single pressure-flow study was present. T h e reproducibility o f  the manual 
analysis o f  pfs was moderate ow ing to a considerable intra- and inter-investigator varia­
tion, m ostly caused by a substantial intra-investigator variation. This variation in itself 
m ay be largely responsible for the moderate reproducibility o f  pf s .
Part II addresses the urodynam ic effects o f  alpha-adrenoceptor antagonists in the 
treatment o f  l u t s . A  literature review revealed that alpha-blocker treatment generally 
results in a small decrease o f  urodynam ic obstruction parameters. A ll patients w ith 
l u t s , however, m ay benefit from  an alpha-blocker w ith respect to symptoms and 
uroflow, whether they have b o o  or not. In our clinic, a retrospective study was per­
form ed on the urodynam ic effects o f  the alpha-blockers, alfuzosin, tamsulosin, or
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terazosin, in i63 patients. T h e results o f  this study showed that the m ajority o f  patients 
had a significant im provem ent in sym ptom  score, but no clear im provem ent in urody­
nam ic obstructive parameters, irrespective o f  the alpha-blocker used. Furthermore, we 
retrospectively reviewed 3i6 patients treated w ith an alpha-blocker for lu ts to deter­
m ine the efficacy on the long-term . Retreatment percentages and the parameters that 
influence the risk o f  retreatment were calculated. T h e  overall retreatment percentage 
after five years o f  follow-up was 54%. Severe symptoms, a poor uroflow, an enlarged 
prostate, and urodynam ically proven bladder outlet obstruction appeared to increase 
the risk o f  treatment failure.
In part III, a study on the correlation between urodynam ic obstruction parameters and 
histologic features o f  the bladder wall in men w ith lu ts is described. O f  54 evaluable 
bladder wall biopsies, h a lf did not show any abnorm ality. N o  correlation was found 
between the histologic features and urodynam ic obstruction parameters or clinical pa­
rameters, such as sym ptom  score, post void residual volum e, prostate volum e, and 
patient age. Thus, in our clinical study in men w ith luts we could not confirm  the 
results o f  animal studies that show a clear relation between b o o  and histologic changes 
in the bladder wall.
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Future perspectives
Urodynamic studies in men with LUTS
U r o d y n a m ic  stu d ies  m a y  provide us w ith valuable inform ation on the function o f  
the lower urinary tract. It is inform ative about the presence o f  instable contractions o f  
the bladder, the com pliance, and bladder capacity, sensations ofbladder filling and oc­
currence o f  incontinence. T h e pressure-flow analysis shows the pressures in the bladder 
generated during m icturition. W e should bear in mind, however, that the reproducibil­
ity o f  pressure-flow studies (pfs) is moderate and interpretations o f  various 
investigators do not necessarily correspond. N o w  the question rises in w hich cases uro­
dynam ic studies should be perform ed and how  m any pfs should be perform ed to be 
conclusive.
I f  on the basis o f  simple diagnostic tools bladder outlet obstruction (b o o ) due to be­
nign prostatic hyperplasia (b p h ) is strongly suspected in an individual patient, 
additional urodynam ic studies are not indicated. I f  there is any uncertainty about the 
diagnosis urodynam ic studies m ay be useful. O n e should be prepared, however, to re­
peat the investigation once or twice i f  the quality o f  the investigation was not optimal, 
an artifact occurred or any unreliability is suspected. Furthermore, i f  the result o f  the 
pressure-flow study does not correspond w ith  other diagnostic test results o f  the same 
patient, the investigation should be repeated. In this case, the test result m ay vary ow ­
ing to true variation in obstruction in the patient or to the moderate reproducibility o f  
the test itself.
U rodynam ic studies should continue to play a role in the evaluation o f  a new treat­
m ent m odality for luts as urodynam ic studies m ay provide insight in the m ode o f  
action o fa  particular treatment. In an individual patient, the moderate reproducibility 
o f  pressure-flow studies m ay have a great im pact on a single test result. T h e  disadvan­
tage o f  the moderate reproducibility o f  urodynam ic studies has less im pact on the 
results o f  a group o f  patients when larger numbers o f  patients are tested, w hich is usu­
ally the case in efficacy studies o f  new treatment modalities.
U rodynam ic studies in the w ay they are perform ed at present are costly, tim e­
consum ing and m inim al invasive. N ew  techniques are under developm ent, w hich aim
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at providing valuable inform ation on bladder function and bladder outlet obstruction. 
T h e y  should be non-invasive and easy to perform  and to repeat. A  technique that can 
be perform ed on an am bulatory basis in the hom e situation is preferable, because it 
displays the normal m icturition pattern during the day. A n  example o f  non-invasive 
urodynam ics is measurement o f  isovolum etric bladder pressures during m icturition 
using a pressure transducer attached to the penis w ith a condom  catheter.1,2 A nother 
non-invasive m ethod is bladder electromyography to measure bladder contraction.3 U p 
till now, however, none ofthese techniques have proven to be preferable in clinical use 
to m inim al invasive urodynamics.
Alpha-blockade for LUTS
Alpha-blockade w ill continue to play a role in the treatment o f  men w ith lu ts , as their 
efficacy and safety have been firm ly established. In the last decade, drugs have been de­
veloped that block prostatic alpha-i-adrenoceptors selectively, aim ing at an 
im provem ent in uroflow  and elim ination o f  luts w ithout bothering side effects. N ew  
developments in this field will aim at more uroselectivity. Better results as for uroflow 
and decrease o f  sym ptom s are not to be expected, as the efficacy o f  the present alpha­
blockers is practically comparable, irrespective o f  the degree o f  uroselectivity. Side 
effects m ay be further reduced using alpha-blockers that are more selective.
It has been assumed that the w orking mechanism o f  alpha-blockers is relieving the dy­
nam ic com ponent o f  prostatic obstruction by blocking the sym pathetic stim ulation o f  
alpha-adrenoceptors in the prostate. T h e w ork presented on the urodynam ic effects o f  
alpha-blockers, however, cannot confirm  a decrease in obstruction. From  these results, 
we m ay conclude that even in the presence o f  b o o , luts  can be relieved significantly 
w ith an alpha-blocker w ithout a decrease in obstruction. Recent research revealed other 
possible mechanisms by w hich alpha-blockers m ay influence lu t s . Extra-prostatic lo­
calizations o f  alpha-adrenoceptors, such as the urethra, detrusor, trigone, ganglia, and 
spinal and supra-spinal structures, seem to be involved in the pathogenesis o f  l u t s . 
Further research is necessary to clarify w hich mechanism is responsible for the thera­
peutic effect o f  alpha-blockers. Generally, when prescribing alpha-blockers to relieve 
the patients’ lu ts , there is no strong indication to perform urodynam ic studies, as pa­
tients w ith and w ithout b o o  both m ay benefit from  an alpha-blocker.
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In view  o f  the high costs o f  medical care, patient selection w ill be more emphasized in 
future to reduce these costs. Looking for the best suitable candidate for long-term  al­
pha-blocker treatment, urodynam ics m ay help to identify these patients. Results 
presented in this thesis indicate that patients w ith  significant b o o  need more often a 
retreatment on the long term than patients w ithout obstruction.
LUTS and the bladder wall
From  the results o f  the studies perform ed we could not confirm  any relation between 
histology o f  the bladder wall and b o o , symptoms or any other clinical parameter. This 
result does not im ply, however, that no relation exists. U p  till now, lim ited research 
has been done on the hum an bladder wall in men w ith l u t s . A nim al studies have 
shown a clear association between histology and obstruction, but those studies are per­
form ed in a m uch more controllable situation. Bladder biopsies m ay show the effects 
that are caused by poorly defined processes o f  unknown duration, such as b o o , but also 
aging, infections or other factors m ay influence the bladder wall m orphology. It w ould 
be interesting to investigate the changes in bladder wall m orphology that have taken 
place after a de-obstructive therapy. It w ould show w hich histologic features are caused 
by b o o  and are reversible.
Better correlations m ay be found using other techniques, such as m orphom etry, imu- 
nohistochem istry or electron m icroscopy. Elbadawi perform ed extensive studies on 
ultrastructural changes in the detrusor associated w ith b o o .4 This association, however, 
could not be confirm ed by the results o f  a study that was perform ed in a collaborating 
hospital in D enm ark (unpublished data).
W ith  our current knowledge, bladder wall histology w ill not be o f  any value in the di­
agnosis o f  men w ith l u t s . Nevertheless, knowledge on the condition o f  the bladder in 
patients w ith  lu ts remains im portant and diagnostic tools should be developed to in­
vestigate the bladder condition. Earlier reports showed an association between bladder 
wall thickness and b o o .5 b o o  causes an increase in bladder w eight attributable to hy­
pertrophy and hyperplasia o f  sm ooth muscle cells and increased interstitial collagen.6-8 
Bladder wall thickness can be measured using transabdominal ultrasound. This tech­
nique m ay be used as a diagnostic tool in men w ith lu ts in the future. T h e  feasibility 
and reliability o f  such a test should be investigated.
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The concept o f LUTS reconsidered
T h e pathogenesis o f  lu ts has not been com pletely clarified yet. As the term luts im ­
plies, it only is a collection o f  sym ptom s w ithout com prehension o f  any underlying 
disease. In two third o f  cases luts are attributed to b o o , although a clear correlation 
between luts and b o o  has never been established. T h e  studies on the urodynam ic 
effects o f  alpha-blockers give rise to the question whether lu ts should be attributed to 
b o o , even when an obstruction has been established urodynam ically.
Treatm ent outcom es o f  transurethral resection o f  the prostate (t u r p) are better when 
b o o  has previously been confirm ed by urodynam ic studies, but most patients w ith 
luts w ithout proven obstruction also benefit from a t u r p .9,10 B y resecting the prostate 
one does not only remove obstructing tissue. Sensory nerves are eliminated, receptors 
are rem oved and the anatom y o f  the prostatic urethra is changed. T h e  local anatom y 
changes from an enlarged prostate pressing on the surrounding tissues and often bulg­
ing into the bladder to a large cavity from  trigone to verum ontanum . T his anatomical 
change probably has more influence on the function o f  the low er urinary tract than 
just the removal o f  a resistance.
T h e mechanism o f  m icturition is com plex and needs a many-sided approach, consider­
ing anatomical, neurologic, functional and psychologic aspects, and their interaction. A  
more com plete view  at the lower urinary tract m ay give us more understanding as for 
possible disturbances and modes o f  therapeutic intervention. For example in the field 
o f  neurourology a disturbance in the neurologic balance o f  the lower urinary tract, 
w hich is needed for the storage and voiding function, can be influenced. A t present for 
urgency, frequency an urge-incontinence neurom odulation or percutaneus stimulation 
o f  the posterior tibial nerve is used.11,12 T h e  precise w orking mechanisms and indica­
tions o f  these therapies still have to be determ ined and maybe in the future they will 
play a role in the treatment o f  men w ith luts as well.
Considering the com plex nature o f  luts and the difficulties in the diagnosis o f  lu ts , 
there are two different approaches o f  a patient w ith l u t s . T h e first is a straightforward 
trial-and-error approach, using only simple diagnostic tools and starting a therapy 
w ithout a reliable diagnosis. T h e  advantage o f  this approach is that no sophisticated 
diagnostic equipm ent and knowledge about the equipm ent is needed. Starting w ith 
alpha-blocker therapy is a good choice as it is generally harmless and treatment can be 
interrupted w ithout lasting consequences. T h e disadvantage o fth is  approach is that a 
considerable period m ay pass before an effective therapy is selected, while trying differ­
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ent therapies is quite expensive. T h e  second approach consists o f  a com plete diagnostic 
w ork-up including determ ination o f  predictive factors for treatment outcom e o f  the 
various treatment modalities and a treatment is chosen based on the highest probability 
o f  success. In future, neural networks m ay prove useful in im proving prediction o f  
treatment outcom e. T h e y  have the ability to detect non-linear relations and com plex 
interactions between variables. T h e role o f  neural networks in the diagnosis o f  men 
w ith luts has recently been investigated. Neural networks turned out to have no addi­
tional value over traditional regression analysis at present.13 T h e  disadvantage o f  the 
extensive approach is that all the necessities should be at one’s disposal including 
knowledge about the various diagnostic tests and trained personnel. Based on the pros 
and cons o f  the different diagnostic approaches, an algorithm  should be developm ent 
to guide urologists and general practitioners in the assessment and choice o f  therapy in 
men w ith l u t s .
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D it  pr o efsch rift  be h an d e lt  verscheidene aspecten van het urodynamisch onderzoek 
in mannen m et lagere urinewegsym ptom en (lower urinary tract sym ptom s o f  kortweg 
lu ts). Er zijn verschillende onderliggende oorzaken van lu ts , maar meestal worden 
luts veroorzaakt door benigne prostaat hyperplasie (b p h ). D e pathogenese van luts is 
echter nog niet geheel opgehelderd en de diagnostiek van lu ts  is niet eenduidig.
In de introductie worden het concept lu ts  en de relatie tussen l u t s , bph  en blaasuit- 
gangsobstructie uitgelegd. D e verschillende m iddelen in de diagnostiek van mannen 
m et luts zijn symptoomscores, urinestraalmeting, transrectaal echo-onderzoek van de 
prostaat en het urodynam isch onderzoek inclusief pressure-flow analyse. H et urody­
namisch onderzoek w ordt beschouwd als de gouden standaard in de diagnostiek van 
blaasuitgangsobstructie, maar het standaard gebruik van het urodynam isch onderzoek 
is controversieel.
Er zijn verschillende behandelingen voor l u ts , zoals medicatie, minimaal invasieve be­
handelingen en operatieve ingrepen. Aangezien het urodynam isch onderzoek geacht 
w ordt het beste m iddel te zijn om  blaasuitgangsobstructie vast te stellen, m oet het ook 
een onderdeel van de evaluatie van een (nieuwe) behandelm ethode zijn.
Een van de argumenten om  het urodynam isch onderzoek niet standaard te gebruiken 
in de diagnostiek van mannen m et lu ts is de invasiviteit van het onderzoek. In deel I 
w ordt een studie beschreven naar de tolerantie van het urodynam isch onderzoek. H et 
urodynam isch onderzoek bleek w einig urineweginfecties te veroorzaken en w einig sub­
jectieve en objectieve m orbiditeit. D e  meeste patiënten vonden het onderzoek tolerabel 
en niet erg vervelend. Verder hebben we de reproduceerbaarheid van pressure-flow 
studies (pfs) onderzocht, door m iddel van een studie naar de variabiliteit van pfs, ver­
richt op twee verschillende tijdstippen en een studie naar de intra- en inter- 
onderzoeker variatie in de manuele analyse van p f s . Er werd een aanzienlijke variabili­
teit gevonden in de resultaten van een pfs . D e  reproduceerbaarheid van de manuele 
analyse van pfs was m atig als gevolg van een aanzienlijke intra- en inter-onderzoeker 
variatie. D it werd grotendeels veroorzaakt door de grote intra-onderzoeker variatie. 
D eze variatie op zich kan al verantwoordelijk zijn voor de matige reproduceerbaarheid 
van pf s .
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D eel II behandelt de urodynam ische effecten van alpha-adrenoceptor antagonisten in 
de behandeling van l u t s . Een literatuuronderzoek liet zien dat behandeling m et een 
alpha-blokker over het algemeen resulteert in een kleine verm indering van urodynam i- 
sche obstructie parameters. Echter, alle patiënten kunnen baat hebben bij een alpha- 
blokker wat betreft verbetering in sym ptom en en plasstraal, onafhankelijk van de aan­
wezigheid van blaasuitgangsobstructie. In onze kliniek is een retrospectieve studie 
verricht naar de urodynamische effecten van de alpha-blokkers alfuzosin, tamsulosin en 
terazosin in I63 patiënten. D e resultaten van deze studie lieten zien dat het merendeel 
van de patiënten een significante verbetering in sym ptom en hadden, maar geen duide­
lijke verbetering in urodynam ische obstructie parameters, onafhankelijk van het type 
alpha-blokker dat w erd gebruikt. Verder hebben we 3I6 patiënten, die behandeld wer­
den m et een alpha-blokker voor lu ts , retrospectief onderzocht om  het lange termijn 
effect vast te stellen. Herbehandelingspercentages en de parameters die het risico van 
herbehandeling beïnvloeden werden berekend. H et herbehandelingspercentage van de 
hele groep na v ijf  jaar follow -up was 54%. Ernstige sym ptom en, een slechte plasstraal, 
een vergrote prostaat en urodynamisch bewezen blaasuitgangsobstructie bleken de kans 
op falen van de behandeling te vergroten.
In deel III w ordt een studie beschreven waarin urodynam ische obstructie parameters 
werden gecorreleerd m et histologische kenm erken in de blaaswand van m annen met 
l u t s . V an  54 evalueerbare blaaswandbiopten liet de helft geen afwijkingen zien. Er 
werd geen correlatie gevonden tussen de histologische kenm erken en urodynam ische 
obstructie parameters noch klinische parameters, zoals symptoom score, blaasresidu, 
prostaat volum e and leeftijd van de patiënt. O nze klinische studie in mannen met luts 
kon dus de resultaten van dierstudies, die een duidelijk verband laten zien tussen blaas­
uitgangsobstructie en histologische veranderingen in de blaaswand, niet bevestigen.
H et urodynamisch onderzoek kan ons waardevolle informatie verschaffen over de func­
tie van de lagere urinewegen. O m dat de reproduceerbaarheid van het onderzoek slechts 
m atig is en om dat de interpretatie van het onderzoek lang niet altijd eenduidig is, kan 
het urodynam isch onderzoek niet functioneren als de gouden-standaard-test in de dia­
gnostiek van mannen m et l u t s . W anneer er op basis van simpele diagnostische tests 
geen betrouwbare diagnose kan worden gesteld, kan een urodynam isch onderzoek zin­
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vol zijn. In dat geval m oet men echter bereid zijn het onderzoek te herhalen wanneer 
de kwaliteit van het onderzoek niet optimaal is.
H et urodynam isch onderzoek m oet een rol blijven spelen bij de evaluatie van nieuwe 
behandelmethoden, aangezien het onderzoek inzicht kan geven in het werkingsm echa­
nisme van een specifieke behandeling.
Urodynam ische onderzoeken, zoals deze momenteel w orden uitgevoerd, zijn kostbaar, 
tijdrovend en minim aal invasief. Daarom  worden nieuwe technieken ontw ikkeld die 
inform atie verschaffen over de functie van blaas en blaasuitgang, zoals het isovolum e­
trisch meten van de blaasdruk met een drukmeter, die aan de penis w ordt vastgemaakt 
m et een condoom catheter o f  het meten van de blaasdruk middels electromyografie. In 
de praktijk blijken deze technieken nog niet beter te zijn dan het urodynam isch onder­
zoek.
In de behandeling van lu ts  zullen alpha-blokkers een rol blijven spelen, om dat de 
effectiviteit en veiligheid van deze m edicijnen duidelijk zijn vastgesteld. Er is veronder­
steld dat alpha-blokkers de dynamische com ponent van blaasuitgangsobstructie 
opheffen. D e resultaten van het onderzoek beschreven in dit proefschrift konden een 
verm indering van blaasuitgangsobstructie door alpha-blokkade niet bevestigen. W an ­
neer alpha-blokkers worden voorgeschreven is er geen sterke indicatie om  tevoren een 
urodynam isch onderzoek te verrichten, aangezien zowel m annen met als zonder blaas- 
uitgangsobstructie baat kunnen hebben bij een alpha-blokker.
M et onze huidige kennis zal blaashistologie geen rol spelen in de diagnostiek van m an­
nen m et lu t s , om dat er geen relatie kon worden aangetoond tussen blaashistologie en 
luts o f  blaasuitgangsobstructie. Bij gebruik van andere onderzoekstechnieken zoals 
morfometrie, im m unohistochem ie ofelectronen microscopie, zal wellicht wel een der­
gelijke relatie worden gevonden.
D e pathogenese van luts is nog niet geheel opgehelderd. D e studies in dit proefschrift 
doen de vraag rijzen o f  luts wel geheel toegeschreven m oeten worden aan blaasuit­
gangsobstructie, zelfs wanneer obstructie bewezen is. H et m ictiem echanism e is 
com plex en behoeft een veelzijdige aanpak, waarbij anatomische, neurologische, func­
tionele en psychologische aspecten en hun interactie beschouwd m oeten worden. Een 
volledige kijk op de lage urinewegen zorgt wellicht voor meer begrip betreffende m oge­
lijke verstoringen en aangrijppunten voor therapeutische interventie. O p  het gebied 
van de neurourologie bijvoorbeeld kan een verstoring in het neurologisch evenwicht
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van de lage urinewegen worden verholpen middels neuromodulatie ofpercutane stimu­
latie van de nervus tibialis posterior. H et precieze werkingsm echanism e van deze 
technieken en de indicaties m oeten nog vastgesteld w orden en misschien zullen zij in 
de toekom st ook een rol spelen in de behandeling van lu t s .
D e com plexe aard van luts en de m oeilijkheden in de diagnostiek ervan in ogen­
schouw nem end, zijn er twee benaderingen m ogelijk van een patiënt m et lu t s . D e 
eerste is een proefondervindelijke aanpak, waarbij gestart w ordt met een therapie zon­
der betrouwbare diagnose. D e tweede aanpak bestaat uit een com pleet diagnostisch 
traject, inclusiefhet bepalen van prognostische factoren voor het behandelingsresultaat 
van de verscheidene behandelingsm ogelijkheden. Bij deze aanpak w ordt een behande­
ling gekozen m et de meeste kans op succes. Beide benaderingen hebben 
vanzelfsprekend hun voor- en nadelen. O p  basis van deze voor- en nadelen zou een 
algoritm e ontw ikkeld m oeten worden om  urologen en huisartsen te leiden in de dia­
gnostiek en behandelingkeuze bij mannen met l u t s .
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List of abbreviations
A G -n u m b e r  Abrams-Griffiths number
a u c  Area Under the Curve
b o o  Bladder Outlet Obstruction
b p e  Benign Prostatic Enlargement
b p h  Benign Prostatic Hyperplasia
b p o  Benign Prostatic Obstruction
c i  Confidence Interval
CV Coefficient ofVariation
d h t  Dihydrotestosterone
i c s  International Continence Society
ip ss  International Prostate Symtom Score
l u t s  Lower Urinary Tract Symptoms
p d e tQ m a x  Detrusor pressure at maximum flow rate
p fs  Pressure-Flow Studies
p s a  Prostate Specific Antigen
p v r  Post-Void Residual Volume
Q m a x  Maximum urinary flow rate
QOL Quality of Life
r c t  Randomised Controlled trial
r o c  Receiver Operating Characteristic
SD Standard Deviation
s e  Standard Error
t r u s  Transrectal ultrasound of the Prostate
t u m t  Transurethral Microwave Thermotherapy
t u r p  Transurethral Resection of the Prostate
u d s  Urodynamic Study
u r a  Urethral resistence index
u t i  Urinary Tract Infection
v a s  Visual Analogue Scale
1 2 9

Dankwoord
D it is dan m ijn proefschrift en op de kaft staat m ijn naam. M aar, een proefschrift 
schrijf je niet alleen. Integendeel. Zonder de hulp van anderen was dit was dit boekje er 
nooit geweest. Ik ben velen dank verschuldigd. Bij deze wil ik dan ook iedereen be­
danken die hier direct o f  indirect een kleine o f  grote bijdrage aan heeft geleverd. Een 
aantal mensen w il ik persoonlijk bedanken:
M ijn  prom otor, Professor F.M .J. Debruyne, bedankt voor de m ogelijkheid om  in deze 
levendige urologische kliniek van het U M C  St Radboud m et een stimulerend onder- 
zoeksklim aat m ijn prom otieonderzoek te verrichten.
M ijn  co-prom otor, Jean de la Rosette, bedankt voor het houden van je beloftes. Je kon 
me op de juiste m om enten opnieuw  enthousiasmeren door negatieve resultaten uit te 
leggen alsof het wereldnieuws is.
M ijn  co-prom otor, Hessel W ijkstra, bedankt voor je kritische en gedetailleerde com ­
mentaar. N a  jo u w  uitleg begreep ik het urodynam isch onderzoek pas echt.
G abe Sonke, ik vond het ook erg gezellig m et jou! Reuze bedankt voor ál je hulp van A  
tot Z  (o f beter: van alfa tot omega).
M ijn  collega’s, Frank d ’Ancona, Elmer Francisca, Diam andis Floratos, M ichel de 
W ild t, Christina Rossi, en M ichiel Sedelaar, bedankt voor jullie hulp bij de dataver­
zameling, wat a f en toe m onnikenw erk was, en voor de vele gezellige m om enten in en 
buiten het ziekenhuis.
Bart Kiem eney, bedankt voor je snelle en onbaatzuchtige hulp bij de data-analyses. Er 
zijn weinig mensen die zoveel w erk voor ’n ander verrichten zonder een co-auteurschap 
te verwachten.
Frank Smedts, bedankt voor je enorme inzet bij en bijdrage aan de ‘bioptenstudie’. Jij’ 
straalt uit dat onderzoeken ontzettend leuk is!
N in a H olm , Thom as H orn, J0rgen N ord ling and Tage Hald, th an kyo u  for the pleas­
ant co-operation and your hospitality in Denm ark.
Lieve A nke (Cooijm ans-Gerrits), bedankt voor je praktische hulp, het meedenken en je 
luisterend oor ten alle tijd.
13 1
Benny Hendriks, bedankt. Ik had je hulp vaak nodig, w ant ik snap nog steeds w einig 
van computers.
Laboranten van het steencentrum, U D O -  en poliverpleegkundigen, bedankt voor de 
prettige samenwerking en voor het extra w erk dat jullie in het kader van het onderzoek 
verrichtten.
Schoonvader D ré Karthaus, bedankt voor het vrolijk en treffend weergeven van mijn 
wetenschappelijk w erk op de om slag van dit boekje.
M ijn  ouders, bedankt voor jullie steun toen ik de keuze moest maken om  al o fn ie t aan 
dit onderzoek te beginnen en jullie oprechte interesse in de voortgang én de inhoud 
van m ijn prom otieonderzoek. M am , nu jij nog!
M ijn  broers, zussen en vriendinnen, bedankt voor jullie interesse en vertrouwen dat 
m ijn prom otieonderzoek daadwerkelijk tot een proefschrift zou leiden.
M ijn  paranimfen, Saskia Plom pen en Constantijn Kortm ann, bedankt voor het op ju l­
lie nem en van deze gewichtige functie. M oge het een stimulans zijn voor een eigen 
doctoraat!
Verder w il ik iedereen bedanken, van wie ik rechtstreeks o f  via via hoorde dat hij/zij 
niet geloofde in het voltooien van dit proefschrift. D at was de beste stimulans om  het 
a f  te maken.
Als laatste dank aan m ijn gezinnetje. T oen  ik na m ijn zwangerschapsverlof weer aan 
het w erk moest, werkte ik harder dan ooit tevoren om  m ijn proefschrift a f te krijgen, 
want alle uren die ik niet bij jo u  kan zijn, Katrien, m oeten zo nuttig m ogelijk besteed 
worden.
Fré, W o u t en Suus, sorry dat ik vaak w einig tijd had en bedankt voor jullie aanpass­
ingsvermogen.
Lieve Herbie, bedankt dat je om trent dit proefschrift je aan m ijn grillen hebt 
aangepast: ’t Is niet m akkelijk je er op het juiste m om ent wél o f  juist niet mee te be­
moeien. Jouw onvoorwaardelijke steun was en is onontbeerlijk.
1 3 2
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Barbara Kortm ann werd geboren op 28 april 1972 te N ijm egen. In 1990 behaalde zij 
het V W O -d ip lo m a  aan het Stedelijk G ym nasium  te N ijm egen. Daarna begon zij aan 
de studie Geneeskunde aan de M edische Faculteit van de Rijksuniversiteit Leiden. In 
1995 behaalde zij haar doctoraaldiplom a. Tijdens haar co-schappen lag haar interesse 
m et name op het gebied van de obstetrie. In 1995 verbleef zij een aantal maanden in het 
St. M ary’s hospital te Isingiro, Tanzania, alwaar zij onderzoek deed naar de effectiviteit 
van de training van traditionele vroedvrouwen (Measurement o f  the effectiveness o f  tradi­
tional birth attendant training). T ijdens haar keuze-co-schap schreef zij een studie- 
protocol voor een studie naar de preventie en de gevolgen op lange termijn van de to- 
taalruptuur (Prevention a n d  long-term follow -up o f  obstetric anal sphincter ruptures) 
(Begeleider: D r. J. van Roosmalen). D e  interesse voor de urologie werd gewekt tijdens 
het co-schap urologie, dat slechts twee weken duurde. In augustus 1997 behaalde zij 
haar artsexamen cum  laude.
N a haar artsexamen liep zij een wetenschappelijke stage op het steencentrum urologie 
van het Universitair M edisch Centrum  St Radboud te N ijm egen (H oofd: Dr. 
J .J .M .C .H . de la Rosette), alwaar de eerste bouwstenen van dit proefschrift werden ge­
legd. V an  december 1997 tot novem ber 1998 werkte zij als A G N I O  op de afdeling 
urologie van het Canisius W ilhelm ina Ziekenhuis te N ijm egen (Opleider: D r H .F .M . 
Karthaus). In juni 1998 werd zij aangenomen voor de opleiding urologie in het cluster 
Nijm egen in een A G IK O -constructie, een constructie waarbij prom otie-onderzoek met 
opleiding w ordt gecom bineerd. V an  novem ber 1998 tot en m et december 2000 was zij 
verbonden aan de afdeling urologie van het Universitair M edisch centrum St Radboud 
te N ijm egen (Hoofd: Prof. D r. F.M .J. Debruyne). In deze periode werd het onderzoek 
verricht dat tot dit proefschrift heeft geleid.
In het kader van de opleiding tot uroloog begon zij in januari 2001 aan haar chirurgi­
sche vooropleiding in het Canisius W ilhelm ina Ziekenhuis te Nijm egen (Opleider: Dr. 
E .D .M . Bruggink).
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